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ABSTRACT
CT Perfusion (CTP) provides measurement of perfusion at the capillary level which can
be used to characterize tissue viability, and blood-brain-barrier (BBB) compromise. Using
CTP, the goals of this research are to: 1) select patients that will benefit from acute stroke
treatment, and 2) determine if pre-stroke neuroprotection reduces stroke severity.
Chapter two investigates the cerebral blood volume (CBV) parameter in a small
acute ischemic stroke (AIS) patient set. Overestimation of the acute CBV defect is caused
by incomplete wash-out of the CT contrast due to a shortened CTP acquisition time
(“truncation artifact”).
In chapter three we examine the prognostic reliability of the acute CBV defect to
predict infarct core and penumbra in AIS. We determine that hypervolemia, the
“truncation artifact” and recanalization are all important variables which affect the
relationship between the acute CBV defect volume and the final infarct volume.
Chapter four implements a novel porcine model of ischemic stroke using the
transient vasoconstrictor, endothelin-1. Using this model, we show that the CTP-cerebral
blood flow (CBF) parameter is as good as MR-DWI for acute infarct core delineation,
and the CBF/CBV mismatch may not indicate penumbral tissue in the acute stroke
setting.
In Chapter five, it we show that vascular integrity measured with the CTP-BBB
permeability surface area product (PS) is a strong predictor of sub-acute bleeding in the
brain (hemorrhagic transformation).
Chapter six shows that different rates of CT contrast extravasation exist for
primary intracerebral hemorrhage (ICH) patients with/without the CTA-Spot Sign and/or
ii

post-contrast leakage. Furthermore, early rates of extravasation are correlated with subacute hematoma expansion.
Chapter seven describes the development of an improved, reproducible and
survivable rabbit large clot embolic model (RLCEM) of cerebral ischemia for testing
treatment options for AIS. We demonstrate that pre-stroke treatment with dipyridamole
provides a neurovascular advantage post stroke onset.
In summary, the current uses of CTP imaging in acute stroke include: 1)
quantifying ischemia to define infarct core and penumbra in AIS, 2) predicting
hemorrhagic transformation of AIS, 3) predicting hematoma expansion in primary ICH,
and 4) assessing treatment response in animal models of stroke to facilitate new drug
development.

Keywords:
Stroke, CT Perfusion, cerebral ischemia, primary cerebral hemorrhage, secondary
hemorrhagic transformation, cerebral blood flow, cerebral blood volume, infarction,
hematoma expansion, animal stroke model, primary stroke treatment, tPA
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CHAPTER 1

1.1 INTRODUCTION
According to the World Health Organization (WHO), stroke is the world leading cause of
long-term morbidity, and the third leading cause of death in developed countries1. Over
the past two decades, there has been an overall reduction in stroke-related deaths in North
America; however, within certain racial groups and gender cohorts, stroke incidence and
severity has worsened during this time2-6. Over the next 40 years, the number of incident
strokes will more than double, with the majority of the increase occurring in individuals
age 75 and older7. Although prevention is the most effective method for mitigating stroke
burden, acute treatment and long-term care remains the current focus for improving
stroke outcome. The expected number of stroke survivors living with permanent disability
will rise dramatically if acute treatment strategies are not improved; the degree of
disability is linked to early treatment response. Further, as long term care remains the
dominant cost for all stroke patients, effective acute treatment could minimize the social
and economic burden of cerebrovascular disease in the future8.

1.2 STROKE PATHOPHYSIOLOGY
Stroke is caused by variable disturbances in blood flow to intracranial brain tissue due to
blockage of supplying vessels and/or leakage of blood from damaged vessels. These
cerebrovascular accidents can result in transient or long term neurological deficit,
depending on the ictus duration and the area of affected brain. The WHO determined that
the global incidence of stroke is ~200 per 100,000 people9. Ischemic stroke accounts for
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~87% of strokes in North American, while primary intracerebral hemorrhage (ICH)
accounts for ~13%10. Of the people who suffer an ischemic stroke, approximately 20%
will die, and 55% will be left with some form of disability that does not permit
independent living11. For patients with primary ICH, the 30 day mortality rate ranges
from 40% to 50%, with some form of

long term morbidity present in almost all

survivors12.

1.2.1 Cerebral ischemia
Cerebral ischemia is a sudden decrease in brain blood flow, resulting in the alteration of
cellular function. With interruption of oxygen and glucose rich arterial flow, electrically
active neurons and supporting glial cells are unable to maintain basal functions needed to
stay alive13.
Cerebral ischemia has various arterial etiologies. The most common of which is
thrombosis, the formation of a blood clot secondary to general endothelial injury or
rupture of an atherosclerotic plaque14. Occasionally breaking away from the site of
thrombosis, single or multiple thromboemboli can travel to the brain causing focal
ischemia; clot consistency (variations of fibrin-platelet bridging and red blood cell
adherence) will affect response to acute treatment and overall stroke severity15. The heart
is also a major source of cerebral emboli, produced by the left atrium in patients with
atrial-fibrillation (blood becomes static due to weak, irregular heartbeats) or recent
cardiac surgery (clots may form via the external coagulation cascade around the surgical
site). Moreover, systemic hypoperfusion, as a result of a general decrease in mean arterial
pressure caused by any myocardial dysfunction, can lead to ischemia in the distal
territories of the cerebral arterial tree, known as watershed stroke16. The Trial of Org

3
10172 in Acute Stroke Treatment (TOAST) criteria allows investigators to report
responses to treatment among important sub-groups of patients with ischemic stroke. The
TOAST classification denotes four subtypes of ischemic stroke: large-artery
atherosclerosis,

cardio-embolism,

small-vessel

occlusion,

and

stroke

of

other

determined/undetermined etiology17. Regardless of the cause, a reduction in blood supply
to the brain creates a homeostatic imbalance in pH, temperature, overall nutrition, and
waste removal, the first steps towards cellular dysfunction18.
More than 70% of all energy use in the brain is to maintain the neuronal
membrane voltage gradient via active, facilitated transport of Na+/K+. This gradient is
fundamental for electrical and chemical signaling via action potential propagation. During
ischemia, if cellular respiration is no longer capable of adequate ATP production,
intracellular ATP is depleted within minutes due to this energy-consuming process. This
first stage of the “ischemic cascade” causes neuronal depolarization, due to the influx of
Ca2+ and Na+ ions, and the efflux of K+ ions19. The increase in intracellular Ca2+ triggers
the release of glutamate, an excitatory neurotransmitter, which activates several enzymes
involved in the lysis of proteins, lipids and nucleic acids. Moreover, sustained
depolarization of neighbouring neurons, called spreading depression, is enhanced with the
failure of glutamate re-uptake, and further Ca2+ influx20. This state of cellular excitation
leads to neuronal apoptosis or necrosis, which depends on the damage intensity caused by
an onslaught of increasing inflammatory, oxidative and nitrative stressors21.
The understanding of the ischemic cascade brought forth distinct definitions of
tissue status during hyper-acute cerebral ischemia. Within the most hypoperfused
territory, called the ischemic or infarct core, cells are irreversibly damaged; even upon
reperfusion, these cells are no longer viable22. Across species, the threshold for
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irreversible neuronal death has been identified as a CBF value of approximately 8-10
ml·min-1·(100g)-1

23-27

. The infarct core, consisting of apoptotic/necrotic tissue, is

surrounded by a variably sized tissue region with blood flow above the threshold to
induce immediate infarction – the ischemic penumbra. The original definition of this
tissue state is based on the absence of electroencephalography (EEG) signals and sensory
evoked potentials with maintenance of membrane pump function and ionic gradients
retained at near normal levels28, 29. Due to this electrical silence (neurons are unable to
transmit signals), clinical symptoms relating to the affected tissue region are apparent;
therefore, it is impossible to discern the amount of viable penumbral tissue based on
clinical symptoms alone. The survival of penumbral tissue on the border zone of
infarction is largely dependent on leptomeningeal collateral supply, as well the degree of
peri-infarct depolarization30. If blood flow is not restored promptly, the viable ischemic
penumbra invariably progresses to infarction; however, with reperfusion in a timely
manner, this tissue will fully recover, along with clinical function – the so-called “time is
brain” paradigm31. Depending on the technique for measuring CBF, the upper threshold
for electrical silence and neuronal dysfunction occurs at a CBF of 22-25 ml·min-1·(100g)1 26

. The duration of ischemia will determine tissue fate below this threshold32. A third

tissue state is described as having a CBF above the upper threshold for neuronal
dysfunction, but lower than normal CBF values, called benign oligemia. Regardless of the
duration of ischemia, this tissue does not progress to infarction and maintains normal
cellular function, in spite of slight hypoperfusion33.
The cerebrum is composed of two distinct tissue types, gray and white matter34.
Gray matter predominates in the cortex and deep nuclei of the brain, composed of
unmyelinated axons, neuronal cell bodies, dendrites and glial cells35. White matter
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consists of mainly of glial cells and myelinated axonal tracts, which allow neural signals
to travel quickly between the cerebrum and other brain regions34. In resting gray matter,
average CBF values are approximately 50-60 ml·min-1·(100g)-1, whereas white matter
values are closer to 20-25 ml·min-1·(100g)-1

36

. This substantial discrepancy in flow

values is mainly because white matter synapse activity consumes ≤ 0.5% of the energy of
gray matter synapses34. It follows that white matter may be more tolerant to ischemia than
gray matter, as there is a greater relative decrease in CBF from normal in gray matter than
in white matter37. Further, since gray matter has a higher metabolic demand, it can be
expected that the damage would occur earlier and be more severe than white matter for a
given CBF. At the cellular level, the ischemic cascade also differs between gray and
white matter. Gray matter infarction is facilitated primarily through glutamate
excitotoxicity, as described in the previous section. White matter is deficient in glutamate
receptors, and Ca2+ enters the cell through a reversal of the Ca2+ -Na+ ion exchanger25, 38.
This disparity could affect the efficacy of therapeutic strategies targeting the ischemic
cascade, depending on what region of the brain is affected. A recent study has shown that
ischemic vulnerability is location-specific; a 60% reduction in rCBF within highly
vulnerable locations (the putamen, frontal gyri, and insular ribbon) distinguishes infarct
core, whereas an 85% reduction in rCBF distinguishes infarct core in the remainder of the
brain39.
The first perfusion thresholds to define infarct and penumbral tissue focused
mainly on gray matter because animal stroke models were used; lower rodents, typical of
many stroke studies, have a much lower white/gray matter ratio compared to humans and
higher primates40. Further, thresholds originating from humans frequently use regions
with combined gray and white matter, which could lead to under/overestimation of
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infarcted tissue in subsequent prospective studies. Since gray and white matter have very
different basal perfusion and thresholds for damage to occur, both pre-clinical and clinical
studies on ischemic damage should define separate thresholds for gray and white matter.

1.2.2 Hemorrhagic transformation of cerebral ischemia
Hemorrhage occurs when blood is abnormally present in brain parenchyma or cerebral
spinal fluid. This may occur due to a number of vasculopathies associated with trauma,
vascular abnormalities, tumours or impaired coagulation; however, several studies have
demonstrated the tendency of embolic ischemia to undergo hemorrhagic transformation4144

. Hemorrhage in an area of ischemia occurs when blood extravasates through vessel

walls with compromised integrity and increased permeability, commonly caused by the
restoration of perfusion to the site of ischemic injury. The risk of hemorrhage secondary
to acute ischemic stroke (AIS) occurs in 2.2%–44.0% of patients, and is the single most
important risk factor to consider in deciding whether thrombolytic therapy should be
given11, 45-47. AIS-related hemorrhage is divided into parenchymal hemorrhage (PH) and
hemorrhagic infarction (HI), the former increasing mortality risk by 10-fold48. While
more severe hemorrhage is undoubtedly associated with worse outcome, there is
controversy whether less severe forms of hemorrhage are clinically important, indicative
of successful reperfusion48-52. Some investigators believe non-PH hemorrhagic
transformation may represent a clinically irrelevant epiphenomenon, with different
pathogenesis53. If this is the case, the ability to predict PH, the symptomatic hemorrhage
sub-type, at the acute stroke phase is critical to guide early treatment. Several groups have
explored the use of biomarkers, as well as CT and MRI imaging in an attempt to predict
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secondary hemorrhage; however, low sensitivity and specificity have limited their use in
acute triage43, 54-59.

1.2.3 Primary intra-cerebral hemorrhage
ICH is an extravasation of blood into the brain parenchyma originating from the
spontaneous rupture of small vessels damaged by chronic hypertension, amyloid
angiopathy, or iatrogenic causes. The primary injury occurs within minutes of bleeding
and is largely the result of mechanical damage associated with edema and subsequent
mass effect. After the initial rupture, the hematoma can continue to expand over several
hours through the primary arterial leakage or mechanically injured surrounding vessels;
there is an exponential increase in mortality when the hematoma volume exceeds 30
milliliters60. The cause of early hematoma expansion is unknown, but secondary vessel
injury and peri-hematomal ischemia have been implicated61. The degree of expansion is
related to both acute hypertension and the innate coagulation efficiency62. Pro-thrombin
cleavage, an essential step in the coagulation cascade, evokes a local inflammatory
reaction responsible for brain swelling and clinical deterioration63. Thrombin has been
shown to be neurotoxic via glutamate-mediated excitotoxicity, causing spreading
depression and overall disruption of the blood–brain barrier and neuronal death64. Further,
red blood cell breakdown products, hemoglobin and the iron constituent, are cytotoxic via
the generation of free radicals causing oxidative damage to enzymes, nucleic acids, and
lipids within cells of the neurovascular unit65. During the sub-acute stage, these
mechanisms may also contribute to secondary ischemic injury, leading to the
development of a peri-hematomal ischemic penumbra, especially in patients with
therapeutically reduced blood pressure to treat the initial ICH episode66. Investigators
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have confirmed the existence of this penumbra after ICH; however, contrary to the
definition of penumbral tissue, recent imaging studies have shown that this delayed
hypoperfusion is accompanied by a decrease in metabolic demand and lowered, not
elevated, oxygen extraction fraction67, 68. Nonetheless, peri-hematomal ischemia may still
represent a therapeutic target for patients with ICH.

1.3 STROKE TREATMENT
Only in the last couple of decades, treatment of stroke has progressed from basic life
support at the time of onset, to administration of advanced neuroprotective therapies. For
both thromboembolic cerebral ischemia and ICH, protecting and salvaging brain tissue
during the acute stroke setting is vital to regulate stroke severity. The acute imaging
assessment, typically a CT scan, informs clinicians on the appropriate treatment course,
depending on stroke etiology (ischemic or hemorrhagic) and whether prior stroke has
occurred. Identical treatment regimens may be beneficial for one stroke sub-type, while
detrimental for another. Even individuals with similar stroke etiologies may also respond
differently to the same treatment. Therefore, establishing individualized approaches to
acute stroke management will improve outcome.

1.3.1 Ischemic stroke
The identification of reversibly damaged tissue during the acute stroke setting has led to
several early treatment strategies aimed to slow the progression of compromised tissue
towards infarction. Although prompt treatment is beneficial, it is currently known that the
penumbra can remain viable for up to 12 hours or more in some patients69. Therefore,
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strategies to return blood flow during the first few hours of onset, as well as to preserve
neuronal integrity during the sub-acute stroke setting are imperative.
Early restoration of blood flow using thrombolytic therapy is an effective way to
reverse ischemic stroke. Thrombolytic agents (mainly fibrinolytic enzymes) activate the
endogenous protein plasminogen to breakdown fibrin, the structural scaffold of most
blood clots. However, the negative pleiotropic effects of these agents may increase the
probability of hemorrhage through the degradation of important clotting factors, and
disruption of the blood-brain barrier70. Nonetheless, evidence from the National Institute
of Neurological Disorders and Stroke (NINDS) tissue plasminogen activator (tPA) study,
showed that tPA administered within the first three hours after stroke

significantly

improved the average neurological outcomes in a large cohort of patients; this result was
sufficient for the Food and Drug Administration (FDA) of the United States to approval
tPA in 199611. Patients treated with intravenous (IV) tPA up to 3 hours post ictus were
30% more likely to have minimal or no disability compared to those receiving placebo.
However, this strict time constraint has limited the use of tPA in less than 7% of AIS
patients, as the risk of hemorrhagic transformation outweighed the clinical benefit beyond
the 3-hour treatment window71, 72. Several important studies have investigated the use of
tPA beyond the 3 hour treatment window, namely: the 2008 European Cooperative Acute
Stroke Study (ECASS) III, followed by a similar study in 2009 examining a broad range
of sub-groups of patients, both comparing groups given alteplase or placebo 3 hours post
ictus73; observational studies investigating the Safe Implementation of Treatments in
Stroke (SITS) through an internet-based audit of the International Stroke Thrombolysis
Registry (ISTR), and the Canadian Alteplase for Stroke Effectiveness Study (CASES),
both comparing patients receiving alteplase before and after the 3 hour window

44, 73-75

.
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Consensus was that IV-tPA has proven benefits if administered up to 4.5 hours from
stroke onset. Only recently, the IV- tPA therapeutic window was extended to 4.5 hours
from stroke onset45,

76

. Nonetheless, the ECASS III study did report a significant

difference in intracranial hemorrhage for patients given alteplase, yet mortality did not
differ between the treated and the placebo group75. The Simplified Management of Acute
Stroke Using Revised Treatment (SMART) criteria study is ongoing, including all stroke
patients for thrombolysis in a time window up to 4.5 hours, with hemorrhage being the
only exclusion criterion77.
Intra-arterial (IA) delivery of tPA to the site of occlusion (as opposed to a
systemic IV delivery) has also been shown to be beneficial78. An advantage of IA-tPA
treatment is the reduced systemic exposure, which allows for a higher concentration of
tPA at the site of occlusion. Early studies showed that IA-tPA may be beneficial up to six
hours after stroke onset, resulting in increased recanalization rates, and no increase in
mortality, compared with controls79. Combining IV and IA-tPA has also been tested, with
moderate improvement in clinical outcome79.
Current alternatives to thrombolysis are the Mechanical Embolus Removal in
Cerebral Ischemia (MERCI) device and Penumbra clot retrieval device, which are
approved to be used up to 8 hours post stroke onset, and are the only treatments available
after the 4.5 hour IV-tPA treatment window80, 81. These devices mechanically remove the
thrombus/embolus from the involved vessel, a process known as thrombectomy or
embolectomy. Both devices have high reperfusion rates and low rates of secondary
intracranial hemorrhage; however, sample sizes of those trials were small82.
A second approach for improving neurological outcome following ischemic stroke
is to use agents which interfere with the ischemic cascade, with the goal of slowing, or
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even stopping the progression of penumbra to infarction. Many of these drugs were
successful when applied to animal models, but failed in the clinical arena, resulting in
skepticism to further research and development in this domain83. Pre-clinical studies
assessing possible neuroprotectants often used young, healthy animals, whereas clinical
subjects are typically over the age of 60 and may present with a number of confounding
conditions such as atherosclerosis, hypertension, small vessel disease, diabetes and other
neurovascular disorders. Further, different proportions of gray and white matter between
humans and animals may further contribute to the lack of efficacy in humans trials, as
both tissue types have different responses to ischemia, as described in a previous section.
One drug which actually showed promise in the clinical setting came out of the
SAINT-1 trial, which investigated the free-radical trapping agent NXY-05984. A 72-hour
infusion of NXY-059 significantly reduced disability 3 months later, and showed a
reduction in the rate of secondary intracerebral hemorrhage when compared to patients
given placebo. However, an attempt to repeat these promising results in a phase III trial
indicated no significant benefit in neurological outcome. Another recent neuroprotectant
tested in the Evaluating Neuroprotection in Aneurysm Coiling Therapy (ENACT) trial,
NA-1, has been successful for reducing the volume of strokes after middle cerebral artery
occlusion in non-human primates85. In a randomized control trial of 197 patients, NA-1
reduced the number of peri-procedural ischemic strokes, as detected by MR imaging, in
patients undergoing endovascular repair of intracranial aneurysms86.
Pre-morbid use of antiplatelet drugs may also offer a neuroprotective benefit via
antithrombotic and anti-inflammatory pleiotropic mechanisms during the acute stroke
setting87. Well-established in their ability to prevent impending stroke, the effectiveness
of pre-morbid administration to reduce stroke severity is still debated88. Discrepancies
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between studies can be attributed to inadequate outcome measurements, small sample
sizes, and variable baseline characteristics between patients, including inconsistent dosing
regimens89. Therefore, controlled experiments are needed to determine the relationship of
anti-platelet drugs on stroke outcome.
Without the need to administer therapeutic agents, cooling the body by ~3-5
degrees Celsius after stroke onset has been shown to be beneficial in animal models and
clinical studies90, 91. Hypothermia decreases the cellular metabolic rate in both gray and
white matter, which coincides in a reduction in free radical formation and suppression of
elevated intracellular calcium – these mechanisms slow the cytotoxic cascade90.
Nonetheless, hypothermia in the acute stroke setting is logistically difficult to achieve and
sustain. Improvements in cooling techniques continue to be made92.
Regardless of the potential of various ischemic stroke therapies, improved
functional outcome can only be achieved if treated patients have the necessary
prerequisites for improvement. That is, the presence of a substantial volume of reversibly
damaged penumbra. Without a relative abundance of salvageable tissue, acute stroke
treatment is futile, and may at times be more detrimental to patient outcome.

1.3.2 Primary intracerebral hemorrhage
Although the pathologic progression of primary ICH is distinct from thromboembolism
induced ischemia, the “time is brain” paradigm still applies with respect to acute
treatment. Systolic hypertension, greater than 140 mm Hg, and increases in intracranial
pressure (ICP) after ICH may be associated with hematoma expansion and has been
shown to double the risk of dependency and death93. Therefore, aggressive blood pressure
(BP) reduction, via the combination of hyperventilation and mannitol infusion has been
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employed clinically. Hypertension, causing a decrease in blood carbon dioxide tension
initiating vasoconstriction, decreases the volume of blood within the rigid cranial cavity,
while mannitol elevates plasma osmolarity, pulling water (brain edema) into the
vasculature for clearance – both strategies directly decrease ICP94,

95

. Nonetheless,

clinicians are cautious not to be overaggressive with BP treatment as secondary ischemic
injury caused by a global decrease in cerebral perfusion pressure is possible96.
In 2005, a phase II study showed that treatment with a powerful hemostatic agent,
recombinant factor VII, within 4 hours of ICH significantly lessened hematoma
expansion, reducing mortality and improving functional outcome at 3 months; although
there was a small increase in thromboembolic complications with incremental doses97. In
spite of these early positive results, the phase III trial (Factor VII for Acute Hemorrhagic
Stroke) failed to show improvement in severe disability and mortality rates within the
treated cohort98.
Current research on neurosurgical interventions focuses on minimally invasive
surgery and intra-ventricular clot fibrinolysis to mitigate hematoma expansion and
improve clinical symptoms have been promising; however, results from studies
examining the benefit of hematoma evacuation and clot aspiration were contradictory in
terms of functional outcome improvement99-101. The randomized Surgical Trial in Lobar
Intracerebral Hemorrhage (STICH) trial found that early surgery is ineffective
corroborating other reports which suggested craniotomy and clot evacuation lead to
higher re-bleeding rates102,

103

. Consequently, the STICH II-trial set out to establish

whether earlier surgical evacuation of the hematoma in patients with spontaneous lobar
ICH would improve outcome compared to initial conservative treatment – recruitment for
this trial is underway100. Clearly, controlled randomized trials are needed to further
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explore and develop therapies to minimize hematoma expansion, peri-hematomal
edema/ischemia and secondary neuronal damage.

1.4 MEDICAL IMAGING IN STROKE
In the past 40 years, the use of medical imaging to distinguish stroke sub-types has
become a mainstay at almost all medical institutions, revolutionizing acute diagnosis and
treatment, as well as improving prediction of long term patient outcome. For both clinical
and experimental stroke, details of the anatomical structure and function of the brain are
currently possible with multi-modal imaging. Computed tomography (CT), magnetic
resonance imaging (MRI), and positron emission tomography (PET) have helped guide
acute stroke triage and advanced our knowledge of pathophysiological mechanisms
guiding stroke treatment strategies.

1.4.1 Positron emission tomography
PET imaging provides functional, metabolic and molecular information at the cellular
level, and is the current clinical gold standard for measurement of cerebral hemodynamics
and metabolism. As a highly sensitive imaging modality, localization of nanomolar
concentrations of a radioactively labeled biological molecule, called tracers, is achieved
through the coincident detection of gamma rays resulting from positron annihilation.
These tracers can be used to measure various hemodynamic and metabolic processes of
interest to diagnosis of stroke, including cerebral blood flow (CBF), cerebral blood
volume (CBV), and cerebral metabolic rate of oxygen (CMRO2). Acute tissue states
defined by these PET parameters have been well established. A matched decrease in CBF
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and CMRO2, measured with 15O-labeled water and oxygen, respectively, represents nonviable tissue104. Penumbra is tissue with maintained CMRO2, with CBF below the
threshold needed for basal neuronal function, a phenomenon termed ‘misery
perfusion’105. Measuring the cerebral metabolic rate of glucose with
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F-2-fluoro-2-

deoxy-d-glucose (18F-FDG) has been shown to discern between viable and non-viable
tissue during the acute stroke setting106. Moreover, monitoring glucose metabolism yields
information about the degree of glycolysis, discerning between aerobic and anaerobic cell
states. Even with these well-established definitions for tissue status, several drawbacks
exist when using these PET parameters, mainly the need for a PET scanner with a
cyclotron close by (the half-life of

15

O is ~2 minutes), rapid arterial sampling to obtain

accurate quantitative values, and the overall poor resolution which affects infarct volume
measures and tissue segmentation. These requirements make it difficult to compare CBF
and CMRO2 values, derived from PET, with values from other imaging modalities.
More recently, tracers have been developed to target cell surface receptors on
neurons, inflammatory cells, and the blood-brain-barrier allowing for specific pathways
and physiological states to be examined. One such tracer,
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F-labeled Flumazenil (18F-

FMZ), binds to a subunit of the central benzodiazepine GABA receptor on healthy
neurons; however, these receptors are only present in cortical gray matter, limiting its
effectiveness to discriminate white matter lesions. Another tracer,
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F-labeled

fluoromisonidazole (18F-MISO), has been shown to identify hypoxic tissue, and
independently delineate ischemic penumbra107. Inflammation during the sub-acute stroke
setting can also be observed using 11C-PK11195, which binds to activated microglial cells
within the brain108. A possible relationship between neuroinflammatory reaction and
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integrity of white matter tracts has recently been investigated by combining microglia
PET with diffusion tensor imaging109.
PET imaging in acute stroke remains limited to research studies in academic
centers due to its cost, and logistical/technical complexities. PET tracers and scanners will
continue to evolve, but it is unlikely that PET will see widespread clinical use for acute
stroke patients in the near future. Nonetheless, PET will remain instrumental in the
validation of other imaging techniques and the understanding of the pathophysiology of
stroke.

1.4.2 Magnetic resonance imaging
MRI is a multi-faceted imaging modality used frequently for acute stroke diagnosis and
prognosis. Recent studies indicate that MRI, particularly diffusion-weighted imaging
(DWI) and gradient-recalled echo (GRE) sequences are as sensitive as CT for detecting
ICH in the acute setting110. The DWI sequence has also been shown to have a greater
sensitivity for detecting acute ischemic changes, especially in patients with transient
ischemic attack111. Further, magnetic resonance angiography (MRA) can be used to
assess intra- and extra-cranial vessel patency, while perfusion-weighted imaging (PWI)
can describe the cerebral hemodynamics in all stroke sub-types112.
DWI is one of the most sensitive methods for identifying very early ischemic
changes. The hyperintense lesion is caused by reduced brownian motion (diffusion
restriction) of water molecules as a result of swollen, edematous cells caused by
cytotoxicity113. This defect is a downstream effect of hemodynamic dysfunction, and
cellular ion pump failure, one of the final steps towards irreversible tissue damage.
Nonetheless, recent reports have shown complete reversal and recovery of tissue that was
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initially hyperintense on acute DWI114,

115

. Moreover, DWI abnormalities have been

shown to disappear then recur within hours and days following and ischemic episode in
both animal and clinical studies113,

114, 116

. In spite of these inconsistencies, the DWI

sequence remains an important imaging modality to define hyper-acute and sub-acute
ischemic changes.
To complement the DWI sequence, the PWI acquisition requires the intravenous
injection of the paramagnetic contrast agent, gadolinium-DTPA. This dynamic sequence
provides functional maps for relative cerebral blood flow (rCBF), cerebral blood volume
(CBV), and time to peak (TTP)117, 118. PWI cannot provide accurate absolute CBF values
due to the non-linear relationship between signal intensity and contrast concentration and
difficulties in obtaining accurate artery input function119. Thresholds of TTP and rCBF
have been shown to discriminate tissue at risk of infarction, though there is no consensus
on the optimal parameter or threshold27, 37, 117, 120-123. By combining the PWI and DWI
images, the PWI/DWI mismatch is also a commonly used working definition of the
ischemic penumbra by identifying the difference between viable tissue at risk and tissue
that is irreversibly damaged, given by the DWI lesion; however, recent studies have
shown that milder perfusion defects are experiencing benign oligemia, insufficient to
produce infarction124.
MR imaging of blood-brain-barrier permeability has also become an important
tool for prediction of hemorrhagic transformation of ischemic stroke. Several MRpermeability studies have shown that increased permeability at admission is associated
with hemorrhage at later times secondary to ischemia118, 125, 126.
Compared to PET imaging, MRI is more readily available in the setting of acute
stroke and does not require a radioactive substance to be injected. Further, most
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sequences, unlike CT, are able to cover both supra- and infra-tentorial brain regions,
allowing a more robust diagnostic imaging window and increased prognostic sensitivity.
In terms of patient throughput, individuals who are claustrophobic, or have metal
implants and pacemakers are excluded from MR imaging. Further, MRI scanners have
limited availability, primarily accessible at large city hospitals or academic centers.
Nonetheless, the absence of harmful ionizing radiation and the ability to discern very
early ischemic changes makes the MR imaging an important modality in acute stroke
triage.

1.4.3 Computed tomography imaging
CT imaging is a diagnostic tool that is widely available, relatively inexpensive compared
to its MRI counterpart, non-invasive and fast. The acute CT imaging stroke series
generally consists of a non-contrast CT (NCCT), followed by CT angiography (CTA), for
patients with stroke symptoms.

1.4.3.1 Non-contrast CT
Improvements in the quality of the CT images and further experience in NCCT images
currently allow for a number of subtle changes to be appreciated prior to complete
infarction, as well as reliable diagnosis of ICH. Petechial hemorrhage, the loss of graywhite matter differentiation, cortical swelling, and obscuration of the insular ribbon, basal
ganglia, and internal capsule can be seen within a few hours of stroke onset127,

128

.

Hypoattenuation, including loss of gray-white differentiation and delineation of brain
structures on NCCT have also been recognized as specific for irreversible infarction129,
130

. Further, the change in hypoattenuation over time could be used to indicate time of
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stroke onset131. In patients with ICH, a single NCCT scan at onset has been shown to
predict morbidity and mortality at 30 days132.
Currently, the NCCT acquisition is the most common imaging modality used to
make tPA administration decisions for patients with ischemic stroke. Contraindications
for tPA, as observed on NCCT, are: 1) ICH, and 2) any region of hypointensity, which
likely reflects non-viable tissue, greater than 1/3 of the middle cerebral artery (MCA)
territory133, 134. Notwithstanding general acceptance of the above criteria, inter-observer
agreement for the criterion of 1/3 MCA territory involvement is rather poor133. A more
recent scoring system, The Alberta Stroke Program Early CT Score (ASPECTS) is a ten
point rating system for assessing the extent of early ischemic changes on NCCT135. It is
easy to implement, using two representative slices from the admission NCCT, and
provides valuable information for predicting patient outcome after thrombolysis. When
compared with the 1/3 MCA rule, ASPECTS has been shown to have an improved
reliability and inter-observer concurrence in identifying stroke patients unlikely to make
an independent recovery despite thrombolytic treatment134-136.

1.4.3.1 CT angiography
CTA requires the intravenous injection of iodinated contrast agent followed by rapid
helical scanning during the peak intravascular contrast enhancement. Various techniques
can be applied to interpret the acquired images, including direct viewing of source
images, three-dimensional reconstructions, and maximum intensity projections (MIP).
Although all three techniques are utilized, MIPs are the most common, with threedimensional reconstructions requiring extra post-processing time. Source images are
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important for examining the information in detail, and are often used to confirm occlusion
or stenosis seen on the reformatted MIP images.
For patients with ICH, 40-50% has contrast extravasation on acute CTA and postcontrast CT (PCCT), which is associated with hematoma expansion and increased
mortality137-141.
For patients with ischemic stroke, the CTA based Clot Burden Score and the
Boston Acute Stroke Imaging Scale are also used for the successful assessment of EIC,
and can determine radiological and clinical outcomes142, 143.

1.4.4.2 CT Perfusion
In a few added minutes, further assessment of cerebral hemodynamics with CT perfusion
(CTP) can give insight into early ischemic changes (EIC), tissue states, and blood-brain
barrier disturbances, unseen on NCCT/CTA. Moreover, due to optimized scanning
protocols, the added radiation dose is minimized.
Although CTP imaging is rarely used for acute diagnosis of ICH, recent perfusion
studies have attempted to find secondary ischemic changes in surrounding tissue, leading
to edema and possibly worsening clinical outcome96, 144-146. Briefly, Rosand et al. (2002)
revealed a gradient of peri-hematomal hypoperfusion, which may have been associated
with ischemic changes145. Subsequent findings by Fainardi et al. (2008) demonstrated that
this centrifugal CBF distribution around the hematoma was not suggestive of ischemic
penumbra destined to survive, but rather indicative of edema formation, a potential
confounding factor in hematoma growth144. During the first 3 hours of symptom onset,
early hematoma growth is seen in 18-38% of patients with ICH, reducing to 11%
thereafter62, 65. Mitigating secondary bleeding is imperative when dealing with ICH.
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In the setting of ischemic stroke, hemodynamic thresholds from multiple
parameters could be utilized to define the acute infarct core147. Since absolute CTP
parameter values may depend on the details of the processing algorithm, using relative
thresholds have been proposed as an alternative. Schaefer et al. (2006) had success with
defining infarction using normalized (to contralateral hemisphere) CTP-CBF values148. It
is critical that the contralateral region of interest (ROI) contains a similar distribution of
gray and white matter, as both tissue types have different CBF and CBV values149.
Similarly, absolute thresholds obtained from ROIs with a mix of gray and white matter
tissue may present a problem, as both tissue types have different CBF and CBV, as
described in a previous section. To circumvent this issue, efforts to determine individual
gray and white matter threshold values for infarct core and penumbra have been carried
out, with varying results150-154.
Depending on the clinical symptoms, the imaged volume is selected at the level of
the basal ganglia, which includes posterior, anterior, and middle cerebral arteries. CTP
derived CBF and CBV describes hemodynamics within the entire vasculature including
large arteries, arterioles, capillary beds, venules, and veins. As an intravascular contrast
bolus passes through a mass of brain tissue, the signal intensity of each voxel within a CT
image will change over time. The intensity of the CT image, expressed in Hounsfield
Units (HU), is linearly proportional to the efficiency with which x-rays are attenuated.
For each pixel, its time-density (attenuation) curve (TDC) is used to quantify several
perfusion parameters: cerebral blood flow (CBF), the volume rate of blood moving
though the mass of tissue [ml·min-1·(100g)-1]; cerebral blood volume (CBV), the total
volume of moving blood in the mass of tissue [(ml·(100g)-1]; the time-to-peak of the pixel
TDC corrected for the dispersion in the artery TDC (Tmax) or the time-to-maximum of the
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tissue residue function, and a new parameter used in the acute stroke setting, the
permeability surface area product (PS) of the blood-brain-barrier, the rate of contrast
extravasation from intra- to extravascular compartments through a damaged barrier
[ml·min-1·(100g)-1].
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Figure 1.1 – Sample CBF, CBV, Tmax , and PS CTP functional maps for patient with
ischemic stroke

Colour coded functional maps of cerebral blood flow (CBF), cerebral blood volume
(CBV), time-to-peak of tissue-residue-function (Tmax), and permeability surface area
product (PS) calculated using CT Perfusion software (GE Healthcare). CBF is expressed
in units of ml∙(100g)-1∙min-1, CBV in ml∙(100g)-1, Tmax in seconds, and PS in ml∙(100g)1

∙min-1.
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With current CT perfusion software (GE Healthcare), post-processing of
hemodynamic functional maps is practically automated. The operator needs only to select
an arterial input function (AIF-TDC) and a venous output function (VOF-TDC). The AIF
is selected from within a large artery (usually the anterior cerebral artery), preferably at a
location along the artery where it is orthogonal to the scan plane to limit partial volume
averaging (PVA) – this ‘dilution’ effect will become apparent when comparing the peak
enhancement (increase of attenuation above baseline) of arteries of different sizes. The
VOF is selected from a large vein, usually the superior sagittal sinus, to minimize the
effect of PVA on its accurate measurement. As such, the underestimation of the AIF from
PVA can be corrected by normalizing the area of the AIF with that of the VOF155.
Deconvolution and non-deconvolution based models are used to calculate
perfusion parameters. The work contained in this thesis uses the deconvolution process.
Although physiologically more appropriate, deconvolution models involve complex
algorithms and require more time for the calculation, whereas the simplicity of nondeconvolution models stems from their simplified assumptions about hemodynamics in
the brain that may not hold true in general. Deconvolution methods correct for the
inability to deliver a contrast bolus directly into the supplying artery of a tissue of interest
– the bolus introduced at a peripheral vein undergoes ‘delay’ and ‘dispersion’ prior to its
arrival at the artery to become the AIF or the TDC of the artery. Deconvolution corrects
for this by calculating an impulse residue function [IRF or R(t)], which simulates the
tissue TDC obtained under the ideal injection condition (Figure 1.2).
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Figure 1.2 – Sample IRF

R(t)
R(t+t)

The impulse residue function (IRF) can be viewed as the fraction of contrast medium that
remains in the tissue as time evolves following a bolus injection into the arterial input.
Beyond the minimum transit time (the duration of the plateau), the difference of R(t + Δt)
and R(t) is the fraction of contrast medium that has a transit time of t. This difference is
the height of the strip with a transit time of t. Further, the area of each of the horizontal
strips is the product of the transit time and the fraction of contrast medium having that
transit time. It follows that the area of all the horizontal strips, that is, the area under the
curve (AUC) of R(t), is the mean transit time (MTT). Alternatively, as the Central
Volume Principle states that the product of CBF and MTT is CBV, the AUC of CBF∙R(t)
is the CBV. The Tmax parameter is the time to peak of the IRF. For the case when the
IRF has a flat ‘top’ as shown, without loss of generality, Tmax can be taken as the halfway time point of the flat ‘top’.
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Limited axial coverage of the whole brain and use of ionizing radiation are current
limitations of CT perfusion. The volume of brain tissue which can be imaged in one CTP
acquisition is limited in the craniocaudal direction (z-axis for all scanners) by the number
of detector rows in a CT scanner (4-12 cm).Coverage in this direction can be doubled (to
include two adjacent sections of the brain) using shuttle mode or two separate boluses156,
157

. The shuttle technique can have two variations, step and shoot (axial shuttle) between

two sections or continuous table translation back and forth (helical shuttle). Axial shuttle
mode generally has less motion artifact than helical shuttle mode as images are acquired
with the patient table (brain) stationary. Also, the image interval of all slices in axial
shuttle mode is uniform (2-3 seconds), while the helical shuttle mode is non-uniform for
the cranial and caudal slices – the image intervals for slices in the centre of the twosection volume will be roughly uniform at 2-3 seconds, and those for the more cranial and
caudal slices of that volume can vary from 1-2 to 4-5 seconds. The two injections
technique requires double the dosage of iodinated contrast increasing the risk of contrast
induced nephrotoxicity (CIN). However, a recent multicenter study has shown that the
incidence of CIN was low ~2.6% among at-risk patients undergoing contrast enhanced
CT scans in a “real world” clinical setting, where guideline-recommended strategies for
CIN prevention may not be consistently followed158.
Although a 60-70 second imaging protocol is sufficient for a perfusion only study,
acquisitions of 90-180 second durations have been advocated for combined perfusion and
blood-brain barrier permeability studies76, 159-161. To minimize radiation exposure from the
lengthened scan time required for blood-brain permeability measurement, temporal
sampling is decreased to one image every 10-15 seconds after the first phase160. The total
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effective dose from a multimodal CT stroke study, for a 64-row detector CT, is ~7mSv,
which is double the average annual background radiation162. Radiation-dose reduction
strategies, such as the Adaptive Statistical Iterative Reconstruction, can maintain image
quality while reducing effective dose by > 25%163. Also, radiation dose could be reduced
by two thirds, without compromising the accuracy of the CTP functional maps, by
increasing the sampling interval from 1 second to 3 seconds in the first phase of a CTP
study156. Other limitations of perfusion, across all modalities, including MRI, CT and
PET are: the lack of standardized image acquisition protocols; post-processing tools in the
experimental and clinical settings and total perfusion imaging time, which could take up
to 30 minutes from entering the imaging suite to making a treatment decision. Even with
these drawbacks, the role of perfusion imaging in the setting of acute stroke continues to
progress.

1.5 ANIMAL MODELS OF STROKE
Several animal models have been developed over the last four decades to explore global
and focal permanent and transient cerebral ischemia, as well as primary and secondary
hemorrhage. Current stroke models are divided into two categories: 1) non-induced,
spontaneous vascular insults, and 2) artificially induced vascular insults. These models
contribute to our overall understanding of stroke sub-type etiology, while developing
primary treatment and secondary prevention strategies, in a controlled environment.
Furthermore, the development of new imaging techniques and the establishment of
imaging thresholds have become important research goals in the pre-clinical setting, with
obvious clinical translation. Typically, rodent models of stroke have been developed due
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to their cost-effectiveness, high throughput, reproducibility, and their genome is easily
manipulated to form transgenic strains; however, the anatomical, and possible
pathophysiological differences between the rodent and human brain remains a limitation
– rat brains are lissencephalic (smooth brain surface lacking gyri and sulci), and possess
very little white matter compared with humans. Therefore, rabbits, pigs, dogs and even
primates have also been utilized over the years as they more closely resemble humans,
including a gyroencephalic brain structure and similar proportions of gray and white
matter. Disadvantages of using higher animals for stroke research are their higher cost
and ethical concerns.
The use of animal models tends to eliminate confounding factors pertinent in the
clinical setting (vascular cognitive impairment, small vessel disease, diabetes etc.). This is
especially important when determining drug efficacies. However, no animal model
completely recapitulates the complicated processes of ischemic or hemorrhagic stroke in
humans, a factor which should be considered translating animal model results to the
clinical arena.

1.5.1 Global ischemia
Global ischemia is achieved in a four vessel occlusion model where temporary ligation of
two vertebral and two common carotid arteries results in a reduction in blood flow to the
entire brain. These models, primarily developed in rats, are used to study the
hemodynamic changes that occur during cardiac arrest, as well delayed neuronal death of
the pyramidal cells in the CA1 region of the hippocampus164, 165.
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1.5.2 Focal ischemia
The alternative to global ischemia is focal ischemia, which attempts to mimic the
majority of ischemic stroke cases, in which the occlusion of the middle cerebral artery
occurs. A common model of focal ischemia is the intraluminal filament procedure, which
attempts to preserve blood flow through the internal carotid artery (ICA)166. This
technique involves the insertion of a filament of surgical suture anterograde into the ICA,
which is then advanced to block the MCA origin; however, significant mechanical
abrasion may result in endothelial damage and even hemorrhage. If done correctly, this
model is relatively easy to implement, produces consistent results between animals and
removal of the filament can mimic a reperfusion scenario. Other models of focal ischemia
are photothrombosis, endothelin-1, and the Tamura method (transection of the MCA), all
of which create an occlusion of the MCA167-169.
To investigate thrombolysis and tPA therapy, an autologous blood clot can useful.
The rabbit small/large clot embolic stroke model (RCEM), which involves an injection of
autologous blood clots into the internal carotid artery, causing occlusion of the MCA170.
This model was utilized in the original study that showed the beneficial effect of tPA and
also in the development of the first neuroprotectant to show efficacy in clinical trials171,
172

. Advantages of the RCEM include a similar vascular anatomy to humans, formation of

thrombus following occlusion, and the similarity of the embolic material in both the
animal model and human disease. The similarities between human stroke and this
embolic stroke model make it suitable for testing future therapies, especially those being
tested in combination with tPA to achieve reperfusion. Nonetheless, the ligation of the
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external carotid artery, prior to insertion of the clot, makes longitudinal studies difficult as
extra-cranial structures, including mastication muscles, are damaged.
A number of rare forms of stroke occur in humans as a result of single gene
disorders. The most common of these is cerebral autosomal dominant arteriopathy with
subcortical infarcts and leucoencephalopathy, resulting from mutations in the Notch3
gene173. With the introduction of transgenic animals, many spontaneous stroke models
have been developed with small rodents to cause spontaneous vascular pathologies, as
observed in the clinical setting174. Though, due to inter-strain variations of the vascular
territories and incomplete posterior communicating arteries, careful selection is required
to minimize these effects. The spontaneously hypertensive stroke-prone rat is commonly
used to mimic clinical case of hypertension, used for producing large MCA infarcts175.
This model closely resembles older individuals who typically have underlying vascular
pathologies.

1.5.3 Intracerebral hemorrhage
Intracerebral injection of blood or bacterial collagenase, as well as mechanically induced
vessel rupture mimics the pathophysiology of spontaneous primary and secondary forms
of ICH in humans. These models can also be used to determine the effects of hemostatic
agents on edema formation and hematoma expansion. Genetically engineered mice are
valuable in determining the mechanisms of injury following ICH176. Several groups have
recently used transgenic mice to study the role of factors that may contribute to ICHinduced injury, identifying therapeutic targets. Furthermore, they can be used to
corroborate the gene expression profile in peri-hematomal tissue after ICH in humans177.
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Despite the setbacks in translating experimental results to the clinical setting,
animal models provide a necessary step for testing potential strategies to improve
treatment of acute stroke.

1.6 FUTURE STROKE DIAGNOSIS & TREATMENT
Stroke diagnosis, prognosis and treatment planning has come a long way in the last four
decades. Currently, one of the major limiting factors in the acute setting is whether
treatment, either surgical or pharmacological, will improve or worsen outcome.
Neuroimaging is at the forefront of establishing a more individualized approach to stroke
treatment, which emphasizes the physiological condition of the brain tissue, rather than a
strict reliance on time from ictus. Development of this comprehensive diagnostic work-up
makes use of both MRI and CT imaging. MRI and CT can both be used to determine
vessel status (MRA and CTA) while perfusion-weighted imaging (PWI) and CTP
imaging can provide comparable information on the hemodynamic parameters. PWI is
advantageous since it provides greater anatomical coverage than CT and does not involve
ionizing radiation; however, CTP has the benefit of providing quantitative values,
acquisition speed is faster, and is more frequently available at most hospitals. Further,
absolute measurement of vascular integrity in terms of permeability surface area product
during the first few hours of stroke onset is possible. The addition of CTA and CTP to the
standard NCCT adds minimal time to the acute stroke triage, and all studies can be
performed within the same scanner. Using these three CT protocols, development of a
patient-specific treatment plan has the ability to significantly advance stroke treatment by
assessing the relative risks and benefits of early therapy on a patient by patient basis.
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Additionally, these techniques may provide the necessary information to exclude patients
at high risk of hematoma expansion and hemorrhagic transformation in primary and
secondary hemorrhage cases.

1.7 RESEARCH OBJECTIVES
The main objective of the work contained in this thesis is to use the CT perfusion imaging
modality to reduce the average rate of neuronal loss during the acute stroke setting by
guiding acute treatment and determining the efficacy of pre-stroke neuroprotective
strategies.

This work is divided into the following projects:
1) Determine the prognostic reliability of the cerebral blood volume parameter in acute
ischemic stroke.
2) In a porcine model of ischemic stroke, correlate the optimal CT perfusion
parameter/thresholds for acute infarct core delineation in gray and white matter with
the imaging and histological gold standards.
3) Determine whether early blood-brain-barrier integrity, as measured by the CT
perfusion derived permeability surface area product, is associated with both
radiological and clinical outcomes in primary and secondary intracerebral
hemorrhage.
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4) Development of a longitudinal animal model of middle cerebral artery embolic
occlusion (rabbit) to explore the neuroprotective effect of dipyridamole, an antiplatelet drug, in embolic cerebral ischemia.
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CHAPTER 2
The Evolution of the Cerebral Blood Volume Abnormality in Patients
with Ischemic Stroke
The contents of this chapter have been adapted from the paper entitled “The evolution of
the cerebral blood volume abnormality in patients with ischemic stroke: a CT perfusion
study”, published in Acta Radiologica 2012;53(4):461-7 by C.D. d’Esterre, R.I. Aviv, and
T.Y. Lee.

2.1 INTRODUCTION
When a cerebrovascular accident of thromboembolic origin occurs, the primary objective
is to salvage tissue at-risk (penumbra) by limiting infarct expansion. Treatment with
tissue plasminogen activator (tPA) up to 4.5 hours post stroke onset has shown to be
clinically effective in this regard1. Yet, the triggering of clinically adverse events, such as
hemorrhagic transformation, remains a concern anytime thrombolysis treatment is given2.
Recent studies have shown that hemorrhage risk post revascularization and clinical
outcome are highly correlated with final infarct volume and acute (< 6 hours post ictus)
infarct volume, respectively3, 4. In conjunction with the admission National Institutes of
Health Stroke Scale (NIHSS) score, the acute infarct core could be used to indicate the
amount of tissue at-risk – presumably, a small infarct core at onset combined with a high
NIHSS score suggests there is a substantial amount of electrically silent but viable tissue.
Therefore, acute infarct core quantification during the acute stroke setting bears high
clinical significance, potentially guiding acute stroke treatment.
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Numerous attempts to identify admission imaging thresholds for delineation of non-viable
cerebral tissue have been extensive, resulting in a wide range of values5-10. One modality,
magnetic resonance (MR) diffusion weighted imaging (DWI), has the capability to detect
cerebral infarction within hours of stroke onset with high sensitivity, and is correlated
with clinical outcome days later11-13. Nonetheless, there are instances where DWI
hyperintensities have been shown to reverse following successful thrombolysis14-17. This
overestimation of acute infarct volume may falsely exclude patients from receiving
thrombolytic therapy17,

18

. Further, the limited availability of MR imaging during the

acute stroke setting promotes the use of other imaging modalities.
Due to its accessibility and simplicity, computed tomography (CT) is suitable for
diagnosis ischemic stroke. Although the Alberta Stroke Program Early CT Score
(ASPECTS) has proven to be a reliable indicator of early ischemic change using only a
standard CT examination, irreversibly damaged tissue and/or tissue at risk of progression
to infarction may still exist within normal appearing regions on hyper-acute non-contrast
CT (NCCT)19,

20

. CT perfusion (CTP) ASPECTS has been shown to provide some

advantage over NCCT for clinical outcome prediction, and detecting reversible
ischemia21. Specifically, the CBV-ASPECTS emerged as the best predictor of fatal stroke
in the hyperacute state22; however, due to high correlation between predicted infarct
volumes defined by DWI- and CBV-defects, speculation concerning the evolution of
CBV within critically hypoperfused tissue is vindicated

23, 24

. Therefore, we sought to

examine: (1) the temporal profile of CTP-derived CBV within tissue that progresses to
infarction (CBVI) at admission, 24 hours and 5-7 days post stroke onset to determine if
CBVI, like DWI defects, can normalize, and (2) the possible overestimation of predicted
infarct volume as defined by the CBV abnormality.
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2.2 MATERIALS & METHODS
2.2.1 Participants and study design
Ethics approval was obtained from both participating institutions+. Informed consent was
obtained from patients and family members. Patients were eligible for inclusion in the
study if they: showed signs and symptoms of middle cerebral artery occlusion, had CTA
confirmed recanalization, presented at the hospital < 6 hours post symptom onset, had no
previous stroke, NIHSS > 4, had a CT perfusion (CTP) scan at admission, 24 hour and 57 post ictus, and had a delayed non-contrast CT (NCCT) to quantify final infarct size.
Exclusion criteria were as follows: evidence of brain stem infarct, prior stroke with
residual deficit intracranial hemorrhage, minor stroke symptoms (NIHSS score < 4),
clinically significant hyperglycemia, impaired renal function and/or known allergy to
contrast media; pregnancy, and age less than 18 years. Patients were enrolled regardless
of therapy, and results of the CT perfusion study performed at admission did not
influence treatment decisions (patients and family members providing informed consent
were aware of this).

_______________________________
+

Appendix A – Human Ethics Approval Form
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2.2.2 CT imaging procedures
Imaging was performed on a Lightspeed CT scanner (GE Healthcare, Milwaukee, WI,
USA) at Sunnybrook Health Sciences Center, Toronto Canada. Thirteen patients had a
non-contrast CT (NCCT), CT angiography (CTA), and CT perfusion (CTP) scan at
admission and 24 hours, and NCCT and CTP 5-7 days post admission. Thirty-two
patients had a NCCT, CTA, and CTP scan at admission, and NCCT/CTA and 5-7 days
post admission. NCCT scans were performed using the following parameters: 120 kVp,
340 mA, 4 x 5 mm collimation, 1 second/rotation. CTA scan covered from the carotid
bifurcation through to the vertex and was acquired using 0.7 ml/kg contrast agent, at 120
kVp and 270 mA, 1 sec/rotation, 1.25 mm thick slices, and pitch of 0.75. Recanalization
was characterized as no visible narrowing of the vessel, while occlusion was
characterized by the absence of contrast material distal to the thrombus on the CTA,
based on an adaptation of the thrombolysis in myocardial infarction criteria25. CTP
images were collected from the basal ganglia to the lateral ventricles, with 4 x 5 mm thick
slices acquired at 80 kVp and 190 mAs for 60 seconds. Iodinated contrast agent,
Omnipaque (300 mg iodine per milliliter; Iohexol; GE Healthcare, Mississauga, Ontario,
Canada) was injected (0.5 ml/kg) at a rate of 4 ml/sec.
An overview of the CTP image processing was provided in Chapter 1. Briefly,
each CTP imaging study was analyzed using commercially available CT perfusion, delayinsensitive software (version 4, GE Healthcare, Milwaukee, WI, USA). For each CTP
scan, time-density curves (TDC) for the arterial input function (AIF) and venous output
functions (VOF) were obtained from the anterior cerebral artery and superior sagittal
sinus, respectively. The AIF was corrected for partial volume averaging by scaling its
area relative to that of the VOF-TDC; partial volume averaging effects are minimal in the
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sagittal sinus26. Parametric maps of cerebral blood flow [CBF; ml·min-1·(100g)-1] and
cerebral blood volume [CBV; ml·(100g)-1] were calculated by deconvolution of tissue
TDCs and the AIF; these values have been validated by using microspheres in animal
studies and positron emission tomography (PET) in humans27,

28

. Perfusion weighted

maps were created by averaging the cine CTP images over the duration of the first pass of
contrast.

2.2.3 CTP image analysis
Custom software (IDL, version 6.2, RSI, Boulder, Colorado) was used for all post
processing analysis. Analysis was performed while blinded to results from imaging at
each time point, as well as to clinical outcomes.

2.2.3.1 The 5-7 day evolution of CBV within tissue destined to infarct
Group A was used for this analysis (Table 2.1). Delayed NCCT images were registered
with admission, 24 hour and 5-7 post admission parametric maps by adjusting for inplane rotational changes. Final infarct regions of interest (ROI), as defined by areas of
hypoattenuation, were traced onto the delayed NCCT images by an experienced
neuroradiologist of 5 years. These ROIs were superimposed onto CBF and CBV
parametric maps at each time point, avoiding cerebrospinal fluid, and skull bones.
Perfusion weighted maps were used to produce a gray and white matter anatomical mask
based on the Hounsfield Unit differences between the two tissue types. CBV values from
within superimposed infarct ROIs (CBVI) for gray and white matter were calculated from
all ROIs for each patient, at each time point. These values were weighted according to the
size of the ROI for each slice. Further, patients were dichotomized based on whether the
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TDC, taken from the ischemic defect (TDCi), was truncated or non-truncated; truncation
was defined as the absence of the lower 50% of the TDC trailing slope (contrast wash out
phase). An overall average CBVI using all patients was calculated at each time point.
Pixels with a CBF > 100 ml·min-1·(100g)-1 or CBV > 8 ml·(100g)-1 were excluded from
the average calculation, a technique used to eliminate large vessel hemodynamic values,
focusing on parenchymal perfusion28.
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Table 2.1 Demographics for Group A, N = 13 ischemic stroke patients.

Patient

Age

1
2
3
4
5
6
7
8
9
10
11
12
13

54
60
62
56
78
72
64
90
72
67
53
92
57

Onset to
Admission
Recanalization
TDCi
Gender Imaging
tPA
NIHSS
@ 24 hours
truncation
(minutes)
M
73
18
IV
Partial
No
M
135
8
IV+IA
Partial
No
F
78
21
IV+IA
Partial
Yes
IA
F
75
8
IV
Partial
Yes
IA
M
286
25
None
No
No
M
126
13
IV
No
No
M
175
19
IV
No
No
F
427
19
None
No
No
F
394
19
None
No
No
M
169
12
IV
No
Yes
M
300
22
None
No
Yes
F
107
24
None
No
No
M
225
17
IV+IA
No
No

67±13 8M,5F

197±120

17.3±5.5

8/13

4/13

tPA
NIHSS = National Institutes of Health Stroke Scale, M = Male, F = Female, tPA = tissue
plasminogen activator, IA = intra-arterial, TDCi = time density curve from tissue destined
to infarct. Data presented as mean ± standard deviation.
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2.2.3.2 Determining CBV defect overestimation
In part 1 of this analysis, Group B was used to obtain admission CBV thresholds for
infarction in gray and white matter, respectively. Patients were included if they had full
recanalization and were classified as ITDC truncation negative. Of the 32 patients with
imaging, 13 contributed data for this analysis (Table 2.2). This was carried out as follows:
the perfusion weighted map was used to segment gray and white matter on the basis of
Hounsfield unit thresholds to produce a gray/white matter mask. This ROI mask was then
applied to the admission CBF and CBV maps. The admission perfusion-weighted, CBF,
and CBV maps were automatically co-registered as they came from the same CT
perfusion study. Delayed NCCT images were registered to the admission images using
custom software (IDL, version 6.0, RSI, Boulder, Colorado). The final infarct was outlined
by an experienced neuroradiologist of 5 years. The final infarct ROI was then
superimposed onto the admission CBF and CBV functional maps, and the gray/white
matter ROI mask was applied within the infarct ROI. CBV values from within the
superimposed ROI were obtained for gray and white matter, respectively. These values
represent the acute infarction thresholds. To be certain penumbral tissue pixels were not
incorporated, we set an upper threshold for CBV for each patient using the mirror
contralateral hemisphere ROI – this upper threshold was defined as the mean CBV
subtract one standard deviation.

59
Table 2.2 Demographics for Group B, N = 13 ischemic stroke patients.

Patient

Age

Gender

14
15
16
17
18
19
20
21
22
23
24
25
26

44
77
81
75
82
89
54
77
78
60
67
57
82

F
F
F
M
F
F
F
F
M
F
F
F
M

Onset to
Imaging
(minutes)
280
163
147
168
178
133
129
82
157
64
130
137
122

71±

3M,10F

145±51

Admission
NIHSS

tPA

10
6
26
4
23
18
9
10
9
11
13
14
11

IA
IA
None
None
None
None
IV
IV
None
IV+IA
IV+IA
IA
None
IV

12.3±6.3

7/13

Recanalization @ 24
hours
Complete
Complete
Complete
Complete
Complete
Complete
Complete
Complete
Complete
Complete
Complete
Complete
Complete

TDCi
Trunc
-ation
No
No
No
No
No
No
No
No
No
No
No
No
No
0/13

13
tPA
NIHSS = National Institutes of Health Stroke Scale, M = Male, F = Female, tPA = tissue
plasminogen activator, IA = intra-arterial, TDCi = time density curve from tissue destined
to infarct. Data presented as mean ± standard deviation.
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In part 2 of this analysis, the CBV values obtained in part 1 were applied to all
CTP time points for patients in Group A. This was carried out as follows: peri-infarct
hypoperfusion was outlined at CBF < 25 ml·min-1·(100g)-1

29

. Within this hypoperfused

region, gray and white matter tissue was flooded with their respective CBV infarct
thresholds obtained in part 1. Patients with peri-infarct tissue regions with a CBV below
these determined thresholds were classified as having an overestimation of the CBV
defect (ie. the final infarct volume at 5-7 days, defined on NCCT, was smaller than the
admission and/or 24 hour infarct volume predicted by the CBV infarct thresholds).
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Figure 2.1 - Study design flow chart

Number of patients assigned to each of the study groups (solid boxes), and analysis
procedure performed on each group (dashed boxes).

62
2.2.4 Statistical analysis
Results are reported as mean ± standard deviation, unless stated otherwise. An unpaired ttest was used to examine significant differences in overall average CBV I between time
points, for both cerebral tissue types. Within truncated and non-truncated TDCi groups,
CBVI values were analyzed by repeated measures ANOVA to identify significance over
time. All statistical analyses were performed by using software (SPSS, version 16 for
Windows; SPSS, Chicago, IL, USA).

2.3 RESULTS
2.3.1 The 5-7 day evolution of CBV within tissue destined to infarct
Gray matter infarct regions were present in 11 patients, while white matter infarct regions
were present in 9 patients. Three patients did not have CTP data at 24 hours. CBV I
[ml·(100g)-1 ; mean ± stdev] values for gray and white matter at admission, 24 hours and
5-7 days were 1.82 ± 0.56, 1.56 ± 0.42, 1.75 ± 0.31 and 1.38 ± 0.65, 1.13 ± 0.31, 1.32 ±
0.44, respectively when averaged over all patients (Figure 2.2). There were no significant
differences in mean CBVI between time points for both brain tissue types (p > 0.05).
TDCi truncation was present in 4/13 (30%): Two patients had TDCi truncation at
admission only, while two others had TDCi truncation at admission and 24 hours. For
these four patients, mean CBVI [ml·(100g)-1; mean ± stdev] values for gray and white
matter at admission, 24 hours and 5-7 days were 1.24 ± 0.17, 1.22 ± 0.20, 1.70 ± 0.9, and
1.05 ± 0.36, 1.13 ± 0.37, 1.51 ± 0.32, respectively. Significant CBVI increases occurred at
the 5-7 day time point within gray matter only (p < 0.05); white matter values were not
significant, but showed a similar trend. For patients without TDCi truncation, 9/13 (70%),
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mean CBVI [ml·(100g)-1; mean ± stdev] values for gray and white matter at admission, 24
hours and 5-7 days were 2.15 ± 0.41, 1.90 ± 0.21, 1.79 ± 0.38, and 1.64 ± 0.75, 1.13 ±
0.28, 1.18 ± 0.32, respectively. There were no significant CBV I increases at 24 hours or
5-7 days compared to admission for this group.
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Figure 2.2 Cerebral blood volume within tissue destined to infarct

Mean ± stdev CBVI [ml·(100g)-1] for gray matter (A) and white matter (B) at admission,
24 hours and 5-7 days post stroke onset for all patients (open circles). Box plots represent
patients with and without TDCi. In each box, median (solid line), mean (dotted line), first
and third quartile values are illustrated. A significant increase in gray matter CBV I was
observed at 5-7 days for the truncated group (*p < 0.05).
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2.3.2 Determining acute CBV defect overestimation
In part 1, CBV [ml·(100g)-1; mean ± stdev] values to define infarction, obtained from 13
patients (group B) with confirmed recanalization/reperfusion and no ITDC truncation,
were 1.10 and 0.75 for gray and white matter, respectively. In part 2, overestimation of
the final infarct volume, as defined by the CBV thresholds in part 1, was present at
admission in 3/4 (75%) and 1/9 (11%) of patients who were TDCi truncation positive and
negative, respectively. Final infarct volume overestimation was absent at both 24 hour
and 5-7 day CTP imaging time points (Figure 2.3).
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Figure 2.3 Example of truncation artifact and CBV defect overestimation

Patient 10, CTP-derived contrast enhanced image, CBF [scale 0-150 ml·min-1·(100g)-1]
and CBV [scale 0-8 ml·(100g)-1] functional maps (i-iii) at admission, 24 hours, and 7
days post stroke onset (A-C). NCCT from 7 days post stroke shows outlined infarct
region (iv). Corresponding time-density curves (Hounsfield units versus time) were taken
at each time point. Confluent areas outside of superimposed infarct ROI showing CBV
defect overestimation (dashed arrows); at this time, TDCi truncation is apparent. CBVI
reversibility is observed at 24 hours and 7 days, compared to admission, for this patient.
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2.4 DISCUSSION
To our knowledge, progression of CTP-derived CBV defect has never been realized
beyond the acute stroke stage. This study examines CBV changes within gray and white
matter cerebral tissue destined to infarct, as well as determines the final infarct volume
overestimation as defined by the CBV abnormality. Previous studies have shown the
ability of acute CTP-derived CBV defects (ie. CBV close to zero) to predict non-viable
ischemic tissue9, 30. Briefly, a decrease in cerebral perfusion pressure leads to the eventual
loss of cerebrovascular autoregulation in very hypoperfused tissue, followed by a
permanent, focal decrease in CBV; however, this mechanism is not yet fully understood3133

. We observe CBVI reversibility out to 7 days post admission in several patients;

however, this reversal is more common in patients with an incomplete (truncated) tissue
TDCi at admission and/or 24 hours post stroke ictus. We also observe CBV defect
overestimation (very low CBV outside of superimposed final infarct volume) at
admission in 75% and 11% of patients with and without TDCi truncation, respectively.
Figure 2.3 illustrates CBV overestimation in a patient with TDCi truncation at admission.
These findings highlight the importance of acquiring a complete tissue TDC for the
accurate calculation of the impulse residue function, H(t), by the CT perfusion software
(GE Healthcare). This function describes the amount of contrast remaining in the tissue
over time. In short, the adiabatic approximation to the Johnson and Wilson model
describes the impulse residue function as34:

1

H (t )    EF t T 
c
 Ee  Vc  


0  t  Tc
t  Tc



 (1)
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where Tc is the capillary mean transit time and F is CBF. Therefore, according to the
central volume principle, CBV is F · Tc. E is the contrast extraction fraction, and Vc is the
contrast agent distribution volume in the extra-vascular space (EVS). The measured tissue
TDC, Q(t), can be calculated by the convolution of the arterial input, Ca(t) and H(t):

Q(t) = F ∙ [Ca(t) * H (t –To)]

(2)

where * is the convolution operator and T0 is the tracer arrival time relative to the arterial
input. After measuring Q(t) and Ca(t) using the CTP study, CBV and CBF are calculated
by iteratively changing their values until an optimum fit to Q(t) is achieved by means of
Equations (1)-(2). The initial height of the function H(t) is equal to CBF in ml·min1

·(100g)-1 and the area under this function gives CBV in ml·(100g)-1. Therefore, when the

tissue TDC is truncated, CBV is underestimated as a consequence.
In the present study, there were four instances where the admission CTP-CBV
defined defect volumes extended beyond the superimposed final infarct ROI. One of
these patients did not have TDCi truncation, and was therefore considered to have ‘true
CBV reversibility’. This reversibility may be caused by a failure of contrast to access the
ischemic tissue even though blood filled capillaries may still be present before and/or
after the short imaging time window35. Endothelial swelling (cytotoxic edema) and
inflammatory mechanisms, such as platelet aggregation and leukocyte adhesion in
capillaries of ischemic tissue, known as capillary plugging, may play a role36. Moreover,
early reperfusion could allow recovery of cellular membrane ion pumps, instigating
metabolic resurgence in clusters of cells within the periphery of CBV-predicted infarction
– this is especially true during instances when spontaneous partial/full reperfusion occurs
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around the time of image acquisition37. In similar work by Silvennoinen et al., 4/45(9%)
of tPA treated patients had CBV defect volumes that were larger than final infarct
volumes. However, the CTP software (CTP version 3, GE Healthcare) used to produce
these hemodynamic parametric maps uses a singular value decomposition algorithm
which does not have delay correction optimization. To help compensate for the late tracer
bolus to the affected area, the newest version of CT perfusion (CTP version 4, GE
Healthcare) “delay optimized” algorithm shifts the tissue TDC baseline to match the
arterial input function. Making use if this optimized delay correction CTP software (CTP
version 4, GE Healthcare), Schaefer et al. observed CBV defect reversibility in 2/11
(18%) patients post endovascular induced recanalization38. The small decreases in initial
defect size were also considered ‘true CBV reversibility’ as TDCi truncation was reported
not to affect CBV computation.
The use of CTP imaging to define non-viable tissue during the acute stroke setting
is possible if technical aspects are considered. Several institutes continue to use a CTP
acquisition less than 50 seconds when examining acute stroke39-42. By incorporating a
two-phase CTP imaging protocol, TDCi truncation can be prevented. Following the initial
50-60 second cine scan, sampling every 15 seconds for an additional 90 seconds can
minimize radiation dose while obtaining the data required for an accurate CBV
calculation43. The second phase data can also be used to evaluate blood brain barrier
permeability, further guiding thrombolysis treatment43. In addition to the lengthened scan
time, newest versions of the CT Perfusion functional map processing software (GE
Healthcare), with the delay correction algorithm, should always be utilized; however, this
correction may not always be sufficient, especially when the peak contrast enhancement
of the TDC is never reached during the CTP acquisition. Endogenous characteristics
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which may contribute to the late arrival time of the CT contrast include: atrial fibrillation,
internal carotid stenosis, inadequate blood supply from collaterals and congestive heart
failure. To improve arrival time of contrast, a higher injection rate (6-8 ml/sec) is needed.
In the study by Silvennoinen et al. a rate of 7 ml/sec was used which would shorten the
contrast bolus, and thus the width of the measured TDC. They reported a much lower
incidence of TDC truncation, in contrary to the results herein.
This study is not without its limitations. First, improvement on the small sample
size of 13 patients with CTP imaging out to 5-7 days or more is needed. Second, defining
infarcted tissue at 5-7 days post stroke could result in over/underestimation of final infarct
volume as penumbral tissue remains in a transient state of viability past one week8. An
NCCT with a DWI scan several weeks after stroke onset would be more suitable. Third,
since slice location varied slightly between time points, image registration was not always
exact. Accordingly, an ROI analysis comparing the entire 20 mm slab was performed
(weighted average of 4 slices), instead of a pixel-by-pixel analysis. Fourth, only a 2 cm
slab of tissue was imaged during the CTP acquisition, which could have missed part of
the infarct volume. Also of note, the validation of CTP-CBV has yet to be demonstrated
in any clinical study, and only CTP-CBF has been formally validated44.

2.5 CONCLUSION
This study describes changes in the CBV abnormality from the first few hours of
ischemic stroke onset. The acute CBV abnormality is shown to be a reliable indicator of
impending infarction when the CT contrast wash out phase within ischemic tissue is
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completed within the CTP imaging time frame. Further investigation is needed to
determine the effects of this truncation artifact on other CTP parameters.
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CHAPTER 3
Reliability of the CT Perfusion Cerebral Blood Volume Parameter in
Ischemic Stroke
The contents of this chapter have been adapted from the paper entitled “Reliability of the
cerebral blood volume parameter in ischemic stroke”, has been reviewed and re-submitted
to the journal Neuroradiology, by C.D. d’Esterre, T.Y. Lee, S. Ceruti, G. Roversi, A.
Saletti, E. Fainardi.

3.1 INTRODUCTION
Thromboembolic cerebral ischemia makes up 87% of all stroke sub-types1. Early
restoration of blood flow using thrombolytic therapy is the most effective way to reverse
stroke symptoms, improving clinical outcome2. The intravenous (IV) tissue plasminogen
activator (tPA) therapeutic window is limited to 4.5 hours post stroke onset3, 4. This time
constraint has limited its use in less than 7% of acute ischemic stroke (AIS) patients as the
risk of hemorrhagic transformation outweighed the clinical benefit beyond the treatment
window5, 6. A major goal of acute neuroimaging in AIS is to eliminate this rigid temporal
criterion used to decide if thrombolytic therapy is appropriate. Instead, a patient specific
approach, based on tissue viability at the time of onset, is currently being explored by
many investigators, using both computed tomography (CT) and magnetic resonance (MR)
imaging7-14.
CT imaging remains the modality of choice for AIS for its widespread
availability, acquisition speed and limited invasiveness. The initial non-contrast CT
(NCCT) scan is used for detection of stroke mimics, intracranial hemorrhage, infarct
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delineation, and remains the imaging modality needed to administer tissue plasminogen
activator (tPA)15. Nonetheless, a current widespread method to detect early ischemic
changes (EIC), the Alberta Stroke Program Early CT Score (ASPECTS), provides only
subtle indication of EIS along with broad inter-subject variability, especially during the
first few hours from ictus16,

17

. Consequently, there have been many attempts to

standardize perfusion parameters to determine cerebral tissue viability during the acute
stroke setting18-24. A complete reduction in CBV was suggested as the hemodynamic
indicator to discriminate between viable and non-viable tissue states25, 26. The rationale is
that a decrease in cerebral perfusion pressure in severely hypoperfused tissue leads to
cerebrovascular autoregulatory failure followed by a supposedly permanent, focal
decrease in CBV27. Conversely, an acute increase in cerebral blood volume (CBV) was
proposed to have a protective effect on perfusion compromised, yet viable tissue; the socalled “penumbral hypothesis”

10, 28

. Recently, when comparing perfusion parameters to

the AIS imaging gold standard, the MR-diffusion weighted (DWI) sequence, several
studies suggest that the CBV parameter is unreliable in the accurate delineation of the
acute infarct core22, 23, 29. Specifically, Campbell et al. (2011) and Kamalian et al. (2011)
both demonstrated that absolute and relative (to contralateral hemisphere) CBF parameter
approximate better the DWI-defined infarct core than CBV and MTT parameters

22, 23

;

however, both studies used shortened CT Perfusion (CTP) scan times, which may underand overestimate CBV and MTT, respectively30. Further, acute DWI defects may not be
truly representative of non-viable tissue, as partial/full reversal has been shown in 7%85% of patients31,

32

. Therefore, the CBV parameter may still have its place in AIS

imaging triage. Accordingly, using the newest CTP software from GE Healthcare, which
incorporates a delay-insensitive deconvolution algorithm, we address the physiological
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and technical variables which affect the CBV parameter during the acute and sub-acute
stroke period by comparing the acute CBV defect (CBVD) with the fully evolved infarct,
defined on the 3 month NCCT, and examining perfusion values, CBV and CBF, within
tissue destined to infarct at admission, 24 hours, 7 days and 3 months.

3.2 MATERIALS & METHODS
3.2.1 Patient selection
The study was approved by the research ethics board of the institution+. Informed
consents were obtained from patient and/or their legal representative. Sixty-four
consecutively screened acute ischemic stroke patients were enrolled over a two year
period (between February 2009 and July 2011). Patients were included if they: presented
at the hospital < 6 hours post symptom onset, had no previous stroke and showed signs
and symptoms of middle cerebral artery occlusion, had a CT angiography (CTA) at
baseline and 24 hours for recanalization status, and were able to complete CTP studies at
all four time points. Exclusion criteria included: evidence of brain stem infarct, prior
stroke with residual deficit, intracranial hemorrhage, minor stroke symptoms [onset
National Institutes of Health Stroke Scale (NIHSS) score < 4], clinically significant
hyperglycemia, impaired renal function and/or known allergy to contrast media;
pregnancy, and age less than 18 years. Of the 64 patients enrolled, 55 contributed data for
this study, while 9 were excluded for the following reasons: onset NIHSS score < 4 (n=5),
no perfusion deficit at onset (n=4). Results of the CTP study performed at admission did

____________________________________
+
Appendix B – Human Ethics Approval form
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not influence treatment decisions (patients and/or legal representatives providing
informed consent were aware of this). Patients were enrolled regardless of therapy. An
experienced neurologist (G.R.) assessed clinical outcome for all patients using the NIHSS
and at admission, 24 hour, one week, and 3 months, as well as modified Rankin Scoring
(mRS) 3 months post stroke onset.

3.2.2 Imaging protocol
Imaging was performed at four time points post stroke onset. Patients underwent a
NCCT, CTA and CTP at admission (< 6 hours post ictus), 24 hours, 7 days and at 3
months. Imaging was conducted on a 64–slice Lightspeed VCT scanner (GE Healthcare,
Waukesha, WI, USA). The CTP scanning protocol consisted of a continuous 50 second
scan using 80 kV, 100 mA and 1 second rotation time while the couch remained
stationary. Seven-hundred ninety two 512 × 512 images were reconstructed with a 25 cm
field-of-view at 0.5 second intervals for each of the eight 5 mm thick slice locations. Five
seconds before the start of scanning, a 40 ml bolus of iodinated contrast agent (Iomeron
300 mg/ml, Bracco Imaging SpA, Milan, Italy) was injected at a rate of 4 ml/second into
an antecubital vein with an automatic injector (Medrad, Indianola, PA). The gantry was
tilted to parallel the supraorbito-meatal line to avoid irradiation of eye lenses. NCCT
helical scans were performed from the skull base to the vertex using the following
imaging parameters: 120 kV, 340 mA, 4x5-mm collimation, 1 second/rotation, and table
speed of 15 mm/rotation. CTA was performed as follows: 0.7 mL/kg contrast (maximum
90 mL), 5- to 10-second delay from injection to scanning, 120 kV, 270 mA, 1

80
second/rotation, 1.25-mm thick slices, and table speed 3.75 mm/rotation. CTA covered
from the carotid bifurcation to vertex.

3.2.3 CTP functional maps
For consistency, each CTP imaging study was analyzed using a commercially available
delay-insensitive deconvolution software (CT Perfusion 4D, GE Healthcare, Waukesha,
WI). For each CTP scan, time-density curves (TDC) for the arterial input function (AIF)
and venous output functions (VOF) were obtained from the anterior cerebral artery and
superior sagittal sinus, respectively. The AIF was corrected for partial volume averaging
using the VOF-TDC. Functional maps of cerebral blood flow [CBF; ml·min-1·(100g)-1]
and cerebral blood volume [CBV; ml·(100g)-1] were calculated by deconvolution of tissue
TDCs and the AIF. Perfusion weighted maps were created by averaging the cine CTP
images over the duration of the first pass of contrast. A functional map was also created
representing the percentage of TDC truncation (incomplete imaging of the contrast washout phase) for each tissue voxel, defined as: the ratio of the increase in Hounsfield Unit
(HU) value at the end of the CTP acquisition relative to that of the peak HU above
baseline.

3.2.4 CTP, CTA, and NCCT image analysis
One author performed all analysis on CTP maps using custom software (IDL, version 6.2,
RSI, Boulder, Colorado). For all perfusion studies, perfusion weighted maps were used to
exclude cerebrospinal fluid (CSF) and cranium from analysis as well as to produce a gray
and white matter anatomical mask based on the HU differences between the two tissue
types. All CTP and NCCT scans were co-registered. The admission CBVD volumes were
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outlined on all CBV functional maps (8 x 5mm) using previously established gray and
white matter CBV thresholds for infarct core, derived from maps generated by delayinsensitive deconvolution software (GE Healthcare)30. This was performed separately by
two observers with the final result arrived at by consensus. For each patient, the total
CBVD size (gray plus white matter volumes) was determined and compared with
corresponding 3 month post ictus NCCT images. Two neuroradiologist, traced a region of
interest (ROI) around the hypodense area of the 3 month NCCT (NCCTD) as the final
infarct ROI. All CBVD and NCCTD areas from each involved slice were multiplied by the
section thickness and summed to obtain the final defect volume in cubic centimeters.
To examine perfusion states within the tissue destined to infarct over time, the
final infarct ROI, from the 3 month NCCT, was superimposed onto the CBV and CBF
functional maps at all four time points. This ROI was mirrored in the contralateral
hemisphere. Large vessels within the infarct and contralateral ROIs were excluded from
the calculation of the mean tissue perfusion parameters33.
Recanalization was classified using CTA at 24 hours post as complete, partial, or
absent by an experienced neuroradiologist based on an adaptation of the thrombolysis in
myocardial infarction (TIMI) criteria34. Complete occlusion was characterized by the
absence of CT contrast distal to the thrombus, while full recanalization was characterized
by no visible narrowing of the involved vessel seen at baseline CTA. Partial
recanalization was defined as a narrowing of the vessel at the site of occlusion with
contrast distal to the thrombus.
The 24 hour and 7 day NCCT was used to categorize hemorrhagic transformation
(HT), if present, according to the European Cooperative Acute Stroke Study II criteria35:
hemorrhagic infarction (HI-1,2) or parenchymal hematoma (PH-1,2). Symptomatic
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intracerebral hemorrhage (sICH) was identified as PH with worsening of neurological
deficit ≥ 4 points on the NIHSS between admission and 24 hours.

3.2.5 Patient groupings and statistical analysis
One author performed all statistical analysis (SPSS, version 16 for Windows; SPSS,
Chicago, IL, USA) and results were verified by all co-authors. All data sets were checked
for normality with the Shapiro-Wilk test prior to analysis with the appropriate parametric
or non-parameteric tests.
In some CTP studies, the 50 second acquisition led to truncation of ischemic
tissue time density curves (TDCi) before the washout phase was completed
underestimating the area under the TDCi. Therefore, patients were divided into TDCi
truncation positive (n=24) and negative (n=31) sets, based on the average (values from
both gray and white matter tissue) TDCi truncation. An TDCi with an average truncation
value of 50% or greater was deemed truncation positive (Table 3.1 and 3.2). For both
sets, the mean and standard deviation for age, time from ictus, treatment status with tPA,
recanalization status at 24-hours, NIHSS (admission, 24 hours, 7 days and 3 months), 3
month modified Rankin Score (mRS) and severity of HT were listed .
The agreement between the admission CBVD volume and NCCTD volume was
assessed with Bland-Altman analysis for recanalization positive (n=32) and negative
groups (n=23), and sub-groups based on TDCi truncation and hypervolemia status at
admission (Table 3.3). Agreement between CBVD and NCCTD volume was evaluated by
95% limits of agreement, defined as the bias ± 1.96 times the standard deviation of the
differences36. As a secondary analysis, all CBVD volumes were plotted against NCCTD
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volumes for linear regression analysis. The Pearson correlation coefficient and slope of
the regression line was calculated for both groups and sub-groups as listed in table 3.3.
To examine perfusion states within gray and white matter destined to infarct over
time, admission CBF and CBV were compared with 24 hour, 7 day, and 3 month
perfusion values using Mann-Whitney Rank Sum Tests for all patients, recanalization
positive and negative groups. Significant differences were defined as p < 0.05.
For this study, we define hypervolemia and hyperperfusion as CBV and CBF,
from within the superimposed final infarct ROI, greater than the average plus one
standard deviation of the CBV and CBF values obtained from the contralateral mirrored
ROI, respectively, for each patient. The fractions of patients with hypervolemia and
hyperperfusion along with the clinical improvement, as given by the average ± standard
deviation of the difference of the NIHSS from admission for all patients, were determined
at admission, 24 hours, 7 days and 3 months post stroke. At each of the four time points,
Fisher Exact Tests were used to investigate: 1) whether the fractions of patients with
hypervolemia or hyperperfusion between the recanalization positive and negative groups
and 2) the difference in clinical improvement from admission, as defined by a decrease in
the NIHSS of ≥4 points, between the recanalization positive and negative groups were
significantly different.
Patients were also dichotomized into hypervolemia positive (n=25) and
hypervolemia unknown (n=30). Comparing both groups, Fisher Exact Tests were used to
investigate: 1) the difference in clinical improvement from admission, as defined by a
decrease in the NIHSS of ≥ 4 points and 2) the fraction of patients with HT.
Average gray and white matter admission CBV and CBF values from within
tissue destined to infarct were determined for each HT type and compared with Student-t
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tests. Also, for patients with a CBVD at admission (n=30) average CBVD volume (cm3)
for patients with HI, PH and non-HT were compared using student t-tests, to examine the
effect of admission infarct core size on HT severity.

3.3 RESULTS
Fifty-five patients (23 females, 32 males) were included in this study, and their
demographics are shown in tables 3.1 and 3.2. A summary for all patients is as follows
[mean (range; SD)]: Age was 67 (42 to 82; 11 years), stroke onset to CTP time 155 (50 to
345; 90 minutes), NIHSS 12 (4 to 25; 6), 24 hour NIHSS 9 (1 to 22; 6), 7 day NIHSS 6 (1
to 22; 6), 3 month NIHSS 5 (1 to 21; 6), 3 month modified Rankin Score 2 (1 to 5; 1).
Twenty-seven patients were treated with intra-venous (IV) tPA, 7 with intra-arterial (IA)
tPA, 1 with both IV and IA tPA, and 20 were not treated with thrombolytic agents.
Locations of occlusions were as follows: 27 M1 only occlusions, 6 proximal ICA + M1
occlusions, 16 M2 only occlusions, 6 M3 only occlusions.
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Table 3.1 Demographics for patients with truncation of the ischemic time-density
curve at admission.

Patient

Age

Gender

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
N=24

65
78
67
50
72
73
43
73
56
51
57
74
69
69
65
50
69
42
76
66
78
77
76
82
65±11

F
M
F
F
F
F
F
F
M
M
M
F
F
M
M
F
M
M
M
M
M
F
M
F
12F,12M

Recan. at
24 hrs

Onset
NIHSS

24hrs
NIHSS

7day
NIHSS

3month
NIHSS

3month
mRS

No
No
Yes
No
Yes
No
No
Yes
Yes
Yes
No
Yes
No
No
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

12
13
5
10
4
22
4
20
8
9
9
14
24
13
4
13
16
13
4
7
7
4
4
12

6
4
10
4
3
8
4
9
3
9
6
9
22
13
1
13
11
3
4
3
6
4
8
2
6.9±4.7

1
4
5
3
2
3
2
4
2
7
4
9
22
10
1
2
4
1
4
3
3
4
2
2
4.3±4.4

1
1
1
1
1
2
2
3
2
5
2
5
20
15
1
1
3
0
6
3
2
2
2
4
3.5±4.6

1
1
2
1
1
1
1
1
1
2
1
2
4
4
1
1
1
0
1
1
1
1
1
2
1.5±1.2

10.7±5.7

HT
None
None
None
HI-1
None
None
None
HI-2
None
HI-1
None
None
None
HI-1
None
None
HI-1
None
None
PH-2
None
None
None
None

NIHSS = National institute of health stroke scale, tPA = tissue plasminogen activator, i.v.
= intra-venous, i.a. = intra-arterial, M = male, F = female, mRS = modified Rankin Score,
HT = hemorrhagic, HI = hemorrhagic infarction, PH = parenchymal hematoma.
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Table 3.2 Demographics for patients without truncation of the ischemic time-density
curve at admission.

Patient

Age

Gender

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

70
61
55
55
47
56
56
80
69
67
69
80
67
42
65
81
77
65
80
67
76
76
82
78
59
78
81
58
70
79
80

M
M
M
M
F
M
M
F
M
F
M
F
M
M
M
M
F
M
F
M
F
M
F
F
M
M
M
F
M
F
M

N=31

68±11

11F,20M

Recan. at
24 hrs
No
Yes
No
Yes
Yes
Yes
No
No
No
No
Yes
No
Yes
No
Yes
No
No
Yes
Yes
Yes
No
No
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
No

Onset
NIHSS

24hrs
NIHSS

7day
NIHSS

3month
NIHSS

3month
mRS

17
12
22
9
14
20
8
16
25
9
16
6
8
12
13
4
18
9
11
5
18
8
8
8
7
10
10
4
19
20
21

17
10
16
6
7
15
3
13
21
9
11
6
6
17
15
18
17
7
3
1
18
6
0
1
13
3
5
1
17
16
21

17
6
9
3
2
15
2
10
19
4
4
1
3
14
8
18
17
3
1
1
17
5
0
1
13
1
2
1
9
11
18

3
6
18
2
1
12
2
14
12
3
3
1
2
11
3
15
5
1
0
1
17
4
0
1
6
1
1
1
4
3
21

1
3
3
1
1
4
1
3
4
1
1
1
1
3
2
3
1
1
0
1
5
2
0
1
3
1
1
1
2
1
5

12.5±5.7

10.0±6.6

7.6±6.5

5.6±6.0

1.9±1.3

HT
HI-1
PH-1
None
None
None
PH-1
None
HI-1
HI-1
HI-1
HI-1
None
None
HI-2
None
PH-1
None
None
None
None
PH-2
PH-1
None
None
PH-1
None
None
None
HI-1
PH-2
HI-2

NIHSS = National institute of health stroke scale, tPA = tissue plasminogen activator, i.v.
= intra-venous, i.a. = intra-arterial, M = male, F = female, mRS = modified Rankin Score,
HT = hemorrhagic, HI = hemorrhagic infarction, PH = parenchymal hematoma.
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Table 3.3 contains the results for the Bland-Altman analysis, as well as the
Pearson correlation for the CBVD volume versus final infarct volume, measured on the 3month NCCT. The 95% limits of agreement from the Bland-Altman analysis were widest
for the recanalization negative group and its sub-groups, compared with the
recanalization positive group and its sub-groups. The recanalization positive and
truncation negative group had the highest Pearson correlation coefficient (R = 0.81) and
slope of the regression line closest to unity (slope = 0.80). The regression line slopes for
both hypervolemia positive sub-groups were negative and closest to zero.
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Table 3.3 Bland-Altman and linear regression results for the admission CBV defect
volume versus the final infarct volume at 3 months

Recanalization Positive (n=32)
Truncation negative (n=17)
Truncation positive (n=15)
Hypervolemia unknown (n=17)
Hypervolemia positive (n=15)

95% Limits of
Agreement
(mean difference
± 2*SD)
[-48.3,29.1]
[-8.4,16.0]
[-40.5,30.3]
[-51.9,38.2]
[-37.6,16.1]

Pearson
Correlation
Coefficient,
R (P value)
0.78 ( 0.08)
0.81 (0.19)
0.61 (0.11)
0.80 (0.04)
0.22 (0.79)

Recanalization Negative (n=23)
Truncation negative (n=14)
Truncation positive (n=9)
Hypervolemia unknown (n=13)
Hypervolemia positive (n=10)

[-86.2,51.1]
[-85.9,68.3]
[-69.9,36.9]
[-96.9,61.3]
[-56.9,19.2]

0.57 (0.03)
0.15 (0.74)
0.71 (0.04)
0.68 (0.10)
0.39 (0.22)

Slope of
Regression
Line
0.64
0.80
0.46
0.57
-0.04
0.42
0.14
0.62
0.37
-0.13
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Tables 3.4, 3.5 and 3.6 give CBF [ml·min-1·(100g)-1] and CBV [ml·(100g)-1]
values from within the superimposed final infarct volume for all patients, the
recanalization positive group and negative group, respectively, at each time point. CBF
and CBV were highest at day 7 for both tissue types; gray matter CBF was significantly
higher than the admission CBF value (p < 0.05). For both gray and white matter, there
were no significant differences between admission and 3 month CBF and CBV values (p
> 0.05). Also shown are the fractions of patients with hypervolemia or hyperperfusion at
each time point, and the NIHSS improvement relative to the admission NIHSS. The
recanalization positive group had a higher fraction of patients with hypervolemia at
admission, 24 hours, 7 days, and hyperperfusion at 24 hours and 7 days than the
recanalization negative group (p = 0.054 to 0.067). There were trends in clinical
improvement from admission in patients who recanalized, but the changes in NIHSS
scores were not significantly different from the non-recanalized group (p > 0.05).
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Table 3.4 All patients (n=55): CBF and CBV values at four time points from within
superimposed final infarct volumes. Also shown are the fractions of patients with
hypervolemia and hyperperfusion, along with change in NIHSS.

Table 3.5 Recanalization positive group (n=32): CBF and CBV values at four time
points from within superimposed final infarct volumes. Also shown are the fractions
of patients with hypervolemia and hyperperfusion, along with change in NIHSS.

γ

Significantly different (p < 0.05) from admission gray matter CBF.

Table 3.6 Recanalization negative group (n=23): CBF and CBV values at four time
points from within superimposed final infarct volumes. Also shown are the fractions
of patients with hypervolemia and hyperperfusion, along with change in NIHSS.
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Table 3.7 shows the NIHSS improvement from admission throughout the 3
months in patients with/without hypervolemia at admission, and the HT percentage for
both groups. Comparing the NIHSS improvement among the three time points, there were
no significant differences (p > 0.05). However, admission hypervolemia was associated
with a significantly higher incidence of HT (p = 0.048), but this group also had a nonsignificantly higher incidence of recanalization relative to hypervolemia negative
patients.
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Table 3.7 Clinical outcome and hemorrhage rates for patients with/without
admission hypervolemia.
Improvement in NIHSS from admission
Hypervolemia at
admission
Positive (n=25)
Unknown (n=30)

24 hours

7 days

3 months

2.2±4.5
2.6±4.5

4.8±5.1
5.2±5.4

6.4±5.5
6.7±5.7

HT

52%*
26%

* Percentage of patients with hemorrhagic transformation (HT) was significantly higher
(p = 0.0478) when hypervolemia was confirmed at admission.
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The relationship between admission CBVD and final infarct size is affected by the
following technical and physiological conditions: truncation of TDCi, recanalization
status within 24 hours of the admission CTP study and hypervolemia during the
admission CTP study. Using the scores 1, 0 and -1 to denote admission CBV defect is
larger than, equal to and smaller than final infarct size, respectively, table 3.8 evaluates
the effect of the presence or absence of each of the confounding factors on the size of
admission CBV defect size relative to the final infarct size. While TDCi truncation and
recanalization can be determined by analysis of the TDCi and CTA/CTP-CBF images,
respectively, hypervolemia cannot be determined with certainty, except for the case when
the admission CBV is higher than contralateral normal brain. In cases where ipsilateral
CBV is equal to or lower than contralateral CBV, hypervolemia status is unknown
because of one or more of the following reasons: the TDCi is truncated, hypervolemia is
heterogeneous and does not happen uniformly throughout the CBVD, or it may have
occurred before or after the admission CTP study. In these instances, if we assume the
proportion of hypervolemia positive and negative cases are equal, table 3.8 contracts to
table 3.9. Therefore, this heuristic model predicts that the admission CBVD will
overestimate the final infarct size for truncation positive/recanalization positive cases, and
underestimate the final infarct size for all other cases (Table 3.9). Table 3.10 shows the
measured admission CBVD as a percentage of the final infarct volume, under different
conditions of TDCi truncation and recanalization. The proposed heuristic model was able
to demonstrate the trend in the dis/agreement between admission CBVD and the final
infarct size, though no significance of the dis/agreement was observed in any of the
groups (p > 0.05).
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Table 3.8 Model to describe the relationship between admission CBVD and final
infarct size from 3 month NCCT.
Hyper (-)
0
Truncat (+) 1
Recan(+)
0
Sum
1
Hyper (+) -1
Truncat (+) 1
Recan(+)
0
Sum
0

Hyper (-)
Truncat (+)
Recan(-)
Sum
Hyper (+)
Truncat (+)
Recan(-)
Sum

0
1
-1
0
-1
1
-1
-1

Hyper (-)
Truncat (-)
Recan(+)
Sum
Hyper (+)
Truncat (-)
Recan(+)
Sum

0
0
0
0
-1
0
0
-1

Hyper (-)
Truncat (-)
Recan(-)
Sum
Hyper (+)
Truncat (-)
Recan(-)
Sum

0
0
-1
-1
-1
0
-1
-2

Table 3.9. Predicted baseline CBVD size relative to final infarct size among the four
cases of TDCi truncation and recanalization status when prevalence of hypervolemia
is 50%.
Truncation (+)
Truncation (-)

Recanalization (+)
0.5
-0.5

Recanalization (-)
-0.5
-1.5

Table 3.10 Measured baseline CBV defect size as a percentage of the final infarct size
among the four cases of TDCi truncation and recanalization status when prevalence
of hypervolemia is 50%.
Truncation (+)
Truncation (-)

Recanalization (+)
111.1 ± 94.1
83.4 ± 78.2

Recanalization (-)
64.9 ± 50.2
74.4 ± 99.2
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Hemorrhagic transformation (HT) was observed in 21/55 patients: 13 HI, 8 PH
(Tables 3.1 and 3.2). HT was present in 10/32 and 11/23 patients in the recanalization
positive and negative groups, respectively. Figure 3.1 and 3.2 depict box plots for
admission gray and white matter CBV and CBF values for patients with PH, HI and
without HT. For both cerebral tissue types, mean CBV and CBF values, from within
tissue destined to infarct, in non-HT patients were significantly different than values from
patients with PH (p < 0.05). Average CBVD volumes (cm3) for non-HT, HI, and PH and
groups were 39.9 ± 32.3, 53.1 ± 28.9 and 102.3 ± 43.0, respectively (Figure 3.3). Average
admission CBVD volume for patients with PH was significantly higher than the CBVD
volume for patients without HT (p < 0.05).
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Figure 3.1 Admission gray matter CBV and CBF from within the superimposed
final infarct ROI
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Box plots for admission gray matter CBV [ml·(100g)-1; blue boxes] and CBF [ml·min-1·
(100g)-1; gray boxes] from within the superimposed final infarct ROI. Patients were
separated into non-hemorrhagic transformation (HT), hemorrhagic infarction (HI), and
parenchymal hematoma (PH). Median and mean are given as solid and dashed lines,
respectively. Mean CBV (*) and CBF (#) values for the non-HT group were both
significantly different (p < 0.05) than the mean CBV and CBF values for the PH group.
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Figure 3.2 Admission white matter CBV and CBF from within the superimposed
final infarct ROI
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Box plots for admission white matter CBV [ml·(100g)-1; blue boxes] and CBF [ml·min-1·
(100g)-1; gray boxes] from within the superimposed final infarct. Patients were separated
into

non-hemorrhagic

transformation

(HT),

hemorrhagic

infarction

(HI),

and

parenchymal hematoma (PH). Median and mean are given as solid and dashed lines,
respectively. Mean CBV (*) and CBF (#) values for the non-HT group were both
significantly different (p < 0.05) than the mean CBV and CBF values for the PH group.
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Figure 3.3 CBV defect volume for non-HT and HT sub-groups

Average ± standard deviation admission CBVD volume (cm3) for patients with a CBV
defect present at admission for patients with no hemorrhagic transformation (n=17),
hemorrhagic infarction (HI; n=9) and parenchymal hematoma (PH; n=5). Median and
mean are given as solid and dashed lines, respectively (*) denotes significantly different
from non-HT patients (p < 0.05)
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3.4 DISCUSSION
This AIS study explores technical and physiological processes which affect the CBV
parameter: 1) TDCi truncation, 2) nutritive and non-nutritive hypervolemia, and 3)
recanalization status. As a secondary analysis, we describe acute and sub-acute perfusion
states (CBV and CBF values) within gray and white matter that progresses to infarction,
and association with hemorrhagic transformation (HT). The volume of infarct core, as
defined by the CBV parameter, is associated with the severity of HT. Further, very low
CBF and CBV values, within tissue that progresses to infarction, were also indicative of
HT severity. A three month NCCT was used to define the final infarct volume to allow
for edema reduction and infarct maturation.
The CBV parameter continues to be an important parameter to distinguish tissue
viability states in the setting of ischemic stroke. A substantial reduction in CBV during
the acute stroke setting is presumed to be a physiological surrogate for infarction, due to
the irreversible loss of vascular smooth muscle autoregulatory capacity37. Conversely, an
increase in CBV in an area of hypoperfusion has been suggested to represent electrically
silent, yet viable tissue38. Still, there remains a lack of standardization for CBV thresholds
to define tissue viability, and with its poor correlation with the acute DWI hyperintensity,
the reliability of the CBV parameter are increasingly being questioned29. Although
diffusion-weighted imaging (DWI) hyperintensities are commonly described as nonviable tissue, a recent study showed that reversal can occur in > 50% of patients 31. PET
imaging of the central benzodiazepine receptor with 18F-flumazenil, is the only method to
truly define infarct core, but this technique is not practicable within the setting of acute
stroke39. The results herein show that the best correlation between CBVD versus the final
infarct volume occurs in patients who recanalize within 24 hours. This makes intuitive
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sense, as the infarct core will minimally expand into the surrounding penumbra once
recanalization is achieved. Moreover, TDCi truncation has a differing effect on
recanalization positive and negative groups, as shown in table 3.3. In patients who do not
recanalize and have truncation of the TDCi, the acute CBVD volume closely matches the
final infarct volume because truncation at admission artificially lowers CBV,
overestimating the predicted infarct core. This could lead to an inaccurate estimate of the
CBV threshold for infarction in retrospective studies.

Conversely, in patients who

recanalize, the overestimation of the infarct core at admission, caused by truncation of the
TDCi, could lead to the paradoxical phenomenon of reversal of infarct define with CBV
threshold30, 40.
In determining whether truncation of the TDCi is present, it is important to note
that complete wash-in and wash-out of the arterial input function and/or venous output
function do not mean the ischemic tissue TDC is free of the artifact. Conditions which
may lead to the late arrival time of the CT contrast and truncation of the TDCi include
internal carotid artery stenosis, atrial fibrillation, insufficient blood supply from
collaterals and congestive heart failure. An effective way to prevent truncation of TDCi
from late arrival of contrast is to use an extended second phase perfusion imaging
protocol. Following the initial 45-50 second cine scan, sampling every 15 seconds for an
additional 90 seconds can minimize radiation dose while obtaining the data required for
an accurate CBV calculation 41. The second phase data can also be used to evaluate blood
brain barrier permeability, further guiding thrombolysis administration decisions41. The
total effective dose from a multimodal CT stroke study, for a 64-row detector CT, is
~7mSv, double the annual background radiation dose42. Radiation-dose reduction
strategies, such as the Adaptive Statistical Iterative Reconstruction (ASIR) (GE
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Healthcare), can maintain image quality while reducing effective dose by > 25%43. Also,
radiation dose could be reduced by two thirds, without compromising the accuracy of the
CTP functional maps, by increasing the sampling interval from 1 s to 3 seconds in the
first phase of a CTP study44.
The physiological state of hypervolemia, defined as an increase in CBV, or the
increase in the amount of blood in tissue, relative to the mirror region of the contralateral
hemisphere, may also impact both prospective clinical decisions as well as characterizing
perfusion thresholds experimentally. Irrespective of recanalization, the CBVD volume had
the poorest correlation with final infarct volume in patients with admission hypervolemia.
This transient perfusion state is observed in regions with increased, decreased or normal
CBF at any time during infarct maturation45. The hypervolemic response can be promoted
by embolic migration, therapeutic dissolution, and/or release of vasolidatory- and
inflammatory-mediators45.
Chronic, non-nutritive hypervolemia and hyperperfusion can induce blood-brain
barrier breakdown, enhancing the risk of HT, edema formation and release of
inflammatory-related mediators (reperfusion injury) potentially worsening clinical
outcome, as shown in figure 3.445,

46

. Here, a matched decrease in CBF and CBV is

apparent at onset within the hypodense region, indicative of cortical swelling, on the
corresponding admission NCCT. After CTA confirmed recanalization, hyperperfusion
and hypervolemia are seen at 24 hours and 7 days post stroke onset, the so-called “luxury
perfusion syndrome”47. Nonetheless, this non-nutritive hypervolemic/hyperperfusion
response was associated with only a short-term decline in clinical outcome. When
examining all patients at 24 hours, 7 days and 3 months, an increase in CBV was present
in 33%, 40% and 0% of patients, respectively, which was not associated with an average
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overall worsening of the NIHSS score at any time point, compared to the patients without
hypervolemia at onset. This finding is consistent with a study by Kidwell et al. (2001)
who found that hyperperfusion occurred in 50% of AIS patients by day 7; correlating
perfusion images with diffusion weighted MR images, this hyperperfusion occurred
mainly in regions that went on to infarction and was not associated with clinical outcome
48

. Examining 9 patients with AIS, Hatazawa et al. (2011) demonstrated that variable

states of hypervolemia, as shown by increased, decreased and unchanged CBV, depended
on the severity of hypoperfusion. The results herein showed that early hypervolemia was
associated with low CBF, and late hypervolemia was associated with low, normal or high
CBF within tissue progressing to infarction.
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Figure 3.4 Example of acute matched decrease in CBF and CBV, and sub-acute
hypervolemia and hyperperfusion

Onset

24 hours

7 days

3 months

CT perfusion studies at admission, 24 hours, 7 days, and 3 months post ictus for AIS
patient 3, with confirmed recanalization at 24 hours. NCCT, CBV and CBF maps are
shown in rows 1, 2 and 3, respectively. A matched decrease in CBV and CBF is visible at
onset, corresponding to the slightly hypodense area on the NCCT. At 24 hours and 7
days, a matched increase in CBV and CBF, within the tissue destined to infarct, is
indicative of hyperperfusion and hypervolemia responses, respectively. NIHSS scores for
this patient were 5, 10, 5, 1 for onset, 24 hours, 7 days and 3 months, respectively, with
modified Rankin score of 2, at 3 months
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Overall, incidences of hypervolemia and hyperperfusion were highest at 7 days in both
gray and white matter tissue and more pronounced in patients who recanalized. During
this sub-acute stroke stage, the occurrence could mask late, evolving infarction, but does
not seem to have a long term effect on clinical outcome. During the hyper-acute stroke
stage (< 6 hours), increased CBV within hypoperfused tissue has been used to detect
potentially salvageable tissue, the so called “penumbral hypothesis”. Contrary to subacute hypervolemia, the hyper-acute (< 6 hours) increase in pooled blood may offer
improved nutrition and act as a buffer for acid metabolites, protecting against pH
changes; however these hypervolemic regions may not be distinguished from potentially
malignant, non-nutritional hypervolemia within already evolving infarction. Figure 3.5
shows a patient with a CBF/CBV mismatch at admission with little evidence of early
ischemic

change

on

the

corresponding

NCCT.

Even

with

confirmed

recanalization/reperfusion at 24 hours, portions of the supposedly viable hypervolemic
tissue at admission still progressed to infarction. For the entire patient cohort, this
admission CBF/CBV mismatch within areas of little or no early ischemic change
discerned on contemporaneous NCCT images was observed in 38% (12/32) of patients
with confirmed recanalization at 24 hours. Of this sub-group, 83% (10/12) of patients had
hypervolemic tissue at admission (the CBF/CBV mismatch) and 24 hours (either a
matched increase, or mismatch in CBF/CBV), that went on to infarction. Also, the same
10/12 patients had full or partial hyperperfusion at 24 hours within areas of NCCT
hypoattenuation at 3 months. Moreover, incidence of HT was higher in patients with
admission hypervolemia, but this group also had a higher incidence of recanalization;
however, just 17% of patients with HT had hypervolemia out to 7 days.
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Figure 3.5 Example of acute mismatch CBF/CBV, and sub-acute hypervolemia and
hyperperfusion

Onset

24 hours

7 days

3 months

CT perfusion studies at admission, 24 hours, 7 days, and 3 months post ictus for AIS
patient 29, with confirmed recanalization at 24 hours. NCCT, CBV and CBF maps are
shown in rows 1, 2 and 3, respectively. A mismatch between CBF and CBV is apparent at
onset. At 24 hours, CBF returns to normal, while a slight decrease in CBV was visible. At
7 days, the CBF defect matched the area of hypoattenuation on the NCCT, while CBV
remained high within the region of hypoperfusion. At 3 months, both the CBV and CBF
defects matched the final infarct volume. NIHSS scores for this patient were 14, 7, 2, 1
for onset, 24 hours, 7 days and 3 months, respectively, with modified Rankin score of 1 at
3 months.
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We speculate that acute and sub-acute collateral recruitment and vasodilatory
effort of relatively (compared to neurons) ischemic resistant endothelial cells is one of
futility, as neurons have already begun their slow progression towards apoptotic/necrotic
cell death, a process which could last out to 7 days post ictus; neurons are more
vulnerable to ischemic injury than any other type of cell in the brain (except immature
oligodendrocytes)49-51. Hypervolemia and hyperperfusion during the acute and sub-acute
stages can also result from the opening of arteriovenous shunts (anastomoses) and
subsequent increase in venous volume, a feature independent of the particular injury
process, within the infarct zone52. Figure 3.6 depicts a scanning electron micrograph of
the gerbil microvascular architecture in a control animal and papaverine pre-treated
animal, injected with acrylic resin causing parenchymal herniation from brain swelling. In
response to the increased intra-cranial pressure, development of direct arteriovenous
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Figure 3.6 Example of arteriovenous shunting

A

B

Scanning electron micrograph of the gerbil microvascular architecture in a control animal
(A) and papaverine pre-treated animal (B), injected with acrylic resin causing
parenchymal herniation from brain swelling. Arteriovenous shunting, venous filling, and
capillary compression are evident. Adapted from Cererbral Hyperemia and Ischemia:
From the Standpoint of Cerebral Blood Volume (p. 19), by M. Tomita et. al., 1987,
Osaka, Japan: Elsevier Science Publishers. Adapted and Reprinted with permission
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shunting via thoroughfare channels, venous distension, and compressed capillaries is
evident. In stroke, similar pathological mechanisms, as shown in Figure 3.6, likely
characterize the transition from nutritive to non-nutritive hypervolemia as cytotoxic
and/or vasogenic edema increases in conjunction with the loss of endothelial cell smooth
muscle regulation, and capillary compression. Therefore, we hypothesize that a hyperacute CBF/CBV mismatch is not always indicative of viable tissue (penumbra), an
important consideration when defining the infarct core. This is further validated by the
fact that the degree of clinical improvement was not higher in patients with an acute
CBF/CBV mismatch, compared to patients with a matched decrease in CBF/CBV (Table
3.7). Nonetheless, the transition from nutritive to malignant hypervolemia is time
dependent and differs between individuals.
When implementing brain perfusion thresholds it’s also important to separate gray
and white matter. In resting gray matter, average CBF values are approximately 50-60
ml·min-1·(100g)-1, whereas white matter values are closer to 20-25 ml·min-1·(100g)-1.
This substantial discrepancy in flow values is mainly because white matter synapses
consume ≤ 0.5% of the energy of gray matter synapses53. It follows that white matter may
be more tolerant to ischemia than gray matter, as there is a greater relative decrease in
CBF from normal in gray matter than in white matter54. Further, since gray matter has a
greater metabolic demand for maintenance of cell structure integrity, it can be expected
that the damage would occur earlier and be more severe than white matter for a given
CBF. Thresholds originating from human studies frequently use regions with combined
gray and white matter, which could lead to under/overestimation of infarcted tissue in
follow-up prospective studies. Since we know gray and white matter have very different
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basal and pathological perfusion thresholds, current studies need to define separate
thresholds for gray and white matter.
This study is not without its limitations. First, use of the 3 month NCCT to
determine final infarction volume could be affected by infarct shrinkage and secondary
vascular injury, potentially causing under- and overestimation of final infarct volume,
respectively. Second, only a 2cm slab of tissue was imaged during the CTP acquisition,
which could have missed part of the infarct volume and hypervolemic states. Further,
recanalization and reperfusion are defined using the 24 hour CTA and CTP-CBF images,
respectively.
In summary, the reliability of the admission CBV defect to define infarct is
affected by the physiological factors of recanalization and hypervolemia, and the
technical factor of TDCi truncation. When determining an optimal threshold to define
acute tissue viability, patients should be dichotomized into recanalization positive and
negative groups, due to potential differences in infarct expansion. The truncation artifact
can cause varying degrees of artificial CBV reduction, potentially overestimating the
acute infarct core. We observed varying perfusion states within evolving infarction, both
acutely and sub-acutely. Late hypervolemia and hyperperfusion measures were not
associated with clinical decline or HT, but could mask late evolving infarction if CBV
thresholds were used to define infarct size. We speculate that early hypervolemia, as seen
in the CBF/CBV mismatch, could contain ‘hidden infarction’ due to opening of nonnutritive arteriovenous shunts, causing venous filling. This could affect both thrombolytic
treatment decisions as well as the validity of CBV thresholds obtained from retrospective
studies. At admission, the size of the CBVD volume in patients without admission
hypervolemia, and lower CBF and CBV values were associated with HT development.
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Although use of CBV thresholds may miss infarction present in ~80% of
CBF/CBV mismatch,

we conclude that very low CBV, or a matched decrease in

CBF/CBV, is a valuable predictor of infarct core, and potentially HT when the acquisition
of TDCi data is complete and recanalization does not occur. Therefore, CBV thresholds
for acute infarct core should be obtained from this sub-set of patients, and may be used to
guide thrombolysis treatment.
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CHAPTER 4
Multi-modality Neuroimaging in a Porcine Model of Endothelin-1
Induced Cerebral Ischemia: Defining the Acute Infarct Core

The contents of this chapter have been adapted from the paper entitled “Multi-modality
neuroimaging in a porcine model of endothelin-1 induced cerebral ischemia: defining the
acute infarct core”, was submitted to Stroke in April, 2013 by: C.D. d’Esterre, U.
Anazodo, K. St. Lawrence, L. Morrison, T.Y. Lee, E. Fainardi.

4.1 INTRODUCTION
As discussed in Chapters 2 and 3, delineation of irreversibly injured tissue that cannot be
salvaged, even with reperfusion, in patients with anterior large vessel occlusion has
important implications for recanalization decisions, hemorrhagic transformation
prognosis, and long-term clinical outcome. Patients with a small infarct core volume,
confirmed with neuroimaging techniques, and a high NIHSS will likely benefit from
reperfusion therapy, less than 4.5 hours post ictus; however, consensus on the optimal
imaging parameter to delineate hyper-acute infarct core remains uncertain1-4.
There remains conflicting evidence concerning the reliability of the acute MRdiffusion weighted imaging (DWI) defect, as permanent hyperintensity reversal is
prevalent in both temporary artery occlusion models, and human stroke; however, the
causal relationship between DWI defect reversal and improved clinical outcome remains
uncertain5, 6. Due to the impracticality of the MRI modality during the acute stroke
setting, much effort has been put forth to determine CT perfusion (CTP)-derived

117
hemodynamic thresholds to define acute tissue states - CT imaging is fast, non-invasive,
and with new dose-saving techniques, relatively safe7, 8. Taking into account certain
caveats which affect the prognostic ability of the cerebral blood volume (CBV)
parameter, namely reactive hypervolemia, truncation of the ischemic time density curve,
and recanalization status, reversibility of very low CBV is uncommon, as loss of vascular
autoregulation likely represents non-viable tissue9, 10. In contrast, normal or elevated CBV
is suspected to represent either nutritive or non-nutritive hypervolemia, within electrically
silent yet viable tissue (penumbra) and infarct core, respectively, as discussed in Chapter
3. As such, recent reports suggest a cerebral blood flow (CBF) threshold is optimal to
separate infarct from penumbra, prior to reperfusion efforts1, 2, 11. It has been shown in
animal stroke studies that the threshold for pan-necrosis is between 0.17 and 0.24 ml·min1

·g-1 with persistent occlusion12. This threshold decreases to 0.12 ml·min-1·g-1 when

ischemia is limited to a few hours13. However, the threshold of infarction (pan-necrosis)
for ischemia lasting less than an hour, which is becoming more relevant in the era of rapid
revascularization, is unknown.
Due to the assortment of different perfusion post-processing algorithms, and
consequent lack of standardized perfusion thresholds, CTP has yet to fully breakthrough
into the clinical setting4, 11, 14. Further, many CTP thresholds are commonly compared to
the final infarct volume derived from delayed imaging at 24 hours or 5-7 days post ictus,
which may under/overestimate the final infarct volume, depending on time of
recanalization15,

16

. PET imaging with

18

F-flumazenil, the imaging gold standard for

infarction, or histology are not feasible in the clinical setting17,

18

. Therefore, stroke

models continue to be valuable for defining and assessing perfusion thresholds for acute
tissue status. The use of endothelin-1 (ET-1) to cause transient cerebral ischemia has been
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well established in rodents and lower primates19,

20

. As a potent vasoconstrictor, ET-1

causes a dose-dependent focal CBF decrease through G-protein coupled contraction of
smooth muscle, adjacent to endothelium21. Appearance of infarction, with minimal tissue
edema, occurs within an hour of ET-1 administration, mimicking ischemic progression
similar to that of humans22. This characteristic makes the ET-1 stroke model useful for
tracking changes in vascular/tissue pathophysiology during the early stages of stroke
onset23.
This hyper-acute ischemic stroke study sought to determine: 1) whether the
predicted infarct volume (PIV) described by CTP parameters and contemporaneous DWI
imaging correlates with true infarct volume (TIV) defined by 2,3,5-tetrazolium chloride
(TTC) histology; 2) the distribution of 18F-FDG uptake (glucose metabolism) within the
TIV and peri-TIV; 3) CTP-CBF and CBV values within superimposed TIV regions of
interest.

4.2 MATERIALS & METHODS
4.2.1 Study design
Animal experiments were conducted following the guidelines of the Canadian Council
on Animal Care and approved by the Animal Use Subcommittee at the University of
Western Ontario+. Duroc-cross pigs (n = 10) were obtained from a local supplier, housed
and allowed to grow to a desired weight of 45 ± 10 kg. Anesthesia was induced with an
intra-muscular injection of telazol (100 mg/ml, 1 ml/20 kg). A 22 gauge catheter was

_____________________________________
+
Appendix C – Human Ethics Approval form
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placed in the ear vein for single bolus of propofol (10 mg/ml, 2-5 mg/kg) to maintain
anaesthesia during intubation.

Animals were mechanically ventilated with an

oxygen/medical air mixture and surgical anesthesia was maintained with inhaled
isoflurane at 2-4%. A 22 gauge catheter was placed in the cephalic vein for imaging
contrast injections. A femoral artery was also catheterized (24 or 22 gauge) to monitor
heart rate and mean arterial blood pressure as well as to intermittently collect arterial
blood samples for blood gas measurements. Heart rate, end tidal CO 2, arterial O₂
saturation, respiration rate, blood pressure and temperature were monitored continuously.
Rectal temperature was maintained between 37.5 and 39.5 ◦C at all times throughout
surgery and imaging, using a whole-body water blanket. The animals were placed in a
prone position, an incision was made above the parietal bone, mid-way between the left
ear and eye, and the skin and periosteum were separated from the skull bone. A 2 mm
diameter hole was drilled into the parietal bone through the incision site, using a dremel
rotary hand tool. A 27 gauge, 1 ¼ inch needle and PE20 polyethylene tubing was used to
inject 25µg of ET-1 (human/porcine, Sigma Chemical Company, St. Louis, MO, USA) in
150 µL of sterile water, at a rate of 50µL/minute (NE-100 single syringe pump, New Era
Pump Systems Inc., Farmingdale, NY). Careful placement of the needle into the left
striatum, avoiding ventricles, was confirmed with a non-contrast CT (NCCT) scan prior
to ET-1 infusion. Two equal doses of ET-1 were given 2 hours apart with monitoring of
ischemic progression using CT perfusion imaging after each infusion. An experimental
timeline is shown in figure 1. Throughout all imaging anesthesia was maintained with 23% isoflurane.
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Figure 4.1 Timeline for the experimental protocol

Mean ± standard deviation acquisition time for post 3 hour contemporaneous MR, CTP
and PET imaging was 2hrs21min ± 18min. CTP = CT perfusion, ET-1 = endothelin-1,
18

FDG = glucose analog radiotracer, MR-DWI = magnetic resonance diffusion weighted

imaging, PET = positron emission tomography, TTC = tetrazolium chloride stain
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4.2.2 Computed tomography perfusion imaging
Each CT acquisition was performed with a Discovery LS PET/CT hybrid scanner (GE
Healthcare, Waukesha, WI). A preliminary axial CT scan was used to localize 16 x 2.5
mm-thick slices in the territory of the ET-1 injection. For CT perfusion (CTP) imaging, a
contrast-enhanced cine continuous scan was performed where the couch remained
stationary while the gantry rotated continuously, acquiring images simultaneously from
sixteen different (contiguous) slice locations. A 40 ml bolus of 370 mg·ml-1 non-ionic,
iodinated contrast (Isovue®-300, Bracco Diagnostics, Princeton, NJ) was injected (1.5
ml•s-1) into a saphenous vein 5 seconds after the start of the CTP acquisition. The head
was continuously scanned at 120 kVp, 200 mA and 1second rotation period for 120
seconds, to avoid any truncation artifact. From the acquired data, 512 x 512 images were
reconstructed at 0.5 second intervals and 15 cm FOV. CTP scans were performed at
baseline (pre-ET-1) and every 30 minutes post-ET-1 to monitor its effect on tissue
perfusion. A second dose of ET-1 was given around 2 hours after the first dose – the
second dose was given when the CBF defect started to normalize, as observed on the
CTP-CBF functional maps (ie. any shrinkage of the initial CBF defect observed after the
first ET-1 infusion). ‘Severe’ ischemia (adequate to cause infarction) was confirmed with
CTP imaging immediately following the infusion. The final CTP acquisition was
performed within 10 minutes of the completion of MR imaging (see below).

4.2.3 Magnetic resonance imaging
MR imaging was performed on a Siemens 3T BIOGRAPH mMR (Erlangen, Germany)
with software syngo VB 18P. Heart rate and O2 saturation were monitored by an MR
compatible pulse oximeter (8604F0 Pulse Oximeter, Nonin Medical, Plymouth, MN).
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Animals were imaged supine using a 15 channel phase array transmit/receive extremity
coil. Diffusion imaging was performed parallel to collosal line as determined from
acquisition of 3D high resolution anatomical scan (MPRAGE T1, 1 mm x 1 mm x 1 mm
resolution).

Echo Planar DWI was acquired with the following parameters:

TR

(repetition time) 3500 ms, TE (echo time) 95 ms, FOV (field of view) 220 mm, spectral
fat saturation, 16 interleaved slices 5 mm thick with no gap, matrix 128 x 128, in-plane
resolution 1.7 mm x 1.7 mm, acceleration GRAPPA 2, b-values 0 and 1000 s/mm2, 20
diffusion gradient directions, 6 signal averages and bandwidth 1446 Hz/pixel. Time for
DWI acquisition 7:46 min. 20 diffusion directions were applied to avoid anisotropy
effects and allow signal averaging to generate high quality apparent diffusion coefficient
(ADC) maps from the DWI data. Median (range) time (minutes) of MR imaging relative
to the second ET-1 infusion was 57 (49-68).

4.2.4 18F-FDG Positron emission tomography imaging
Thirty minutes after the second injection of ET-1, a dose of the glucose analog, fluorine18 labeled fluorodeoxyglucose (18F-FDG, 300-380MBq), was administered via ear vein.
PET imaging commenced within 15 minutes of completing the MR imaging (3 minutes
after completion of the last CTP scan), 40-60 minutes after

18

F-FDG injection. Prior to

acquisition of the PET raw data, a CT-based attenuation correction was performed. PET
emission data was collected on a Discovery LS PET/CT hybrid scanner (GE Healthcare)
in 2D mode, with a photopeak window of 280-700keV for 20 minutes. Data were
acquired in a 128 × 128 matrix with pixel widths of 0.478 mm and slice thickness of 3.3
mm. Image sets were reconstructed, using the iterative reconstruction software available
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on the commercial system (GE Medical Systems software) including attenuation and
random correction.

4.2.5 Histology
Following imaging, the whole brain was carefully excised and cut into coronal sections
corresponding to the CT-perfusion weighted images (PWI) scan slice locations. To
identify infarcted tissue, each slice was stained with TTC to quantify the extent of dead
tissue, and fixed in 10% formalin. TTC, which is colorless in solution, is reduced to a
deep red formazan by dehydrogenase enzymes of functioning mitochondria, while
infarcted brain regions do not convert TTC and remain unstained. Digital images were
acquired with a desktop colour scanner (Brother DCP-7040, Bridgewater, NJ). Image J
(Image J, Bethesda, MD) software was used to determine the TIV (cm3) as described
previously24. Briefly, to determine infarct volume by manual measurement, a calibration
factor was derived by scanning a ruler alongside the brain slices, and determining the
number of pixels per mm. For each animal, this calibration factor was entered into ImageJ
to convert pixel area measures to mm2. The outlined infarct area for each slice was
multiplied by 5 mm (thickness of each section) and the volumes summed to get the true
infarct volume (cm3).

4.2.6 Image analysis
For consistency, functional maps of cerebral blood flow [CBF; ml·min-1·(100g)-1]
cerebral blood volume [CBV; ml·(100g)-1] and time-to-maximum (Tmax; seconds) were
calculated by one author using a commercially available delay-insensitive deconvolution
software (CT Perfusion 4D, GE Healthcare, Waukesha, WI). A 2 × 2 pixel region of
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interest was placed in the right common carotid artery to obtain the arterial input function
(AIF). The AIF was deconvolved with each tissue time density curve using a method
described previously25, 26. After functional map processing, a CBF•CBV product map was
also calculated by multiplying matching voxels from the CBF and CBV functional maps.
PWIs were created by averaging the cine CTP images over the duration of the first pass of
CT contrast.
Custom software (IDL, version 6.2, RSI, Boulder, Colorado) was used for all
image post processing analysis. The ~3 hour post (final CTP acquisition) CTP-PWIs were
matched up with the histological slices to establish the reference slab. Using anatomical
features, the MR-DWI/ADC maps, and

18

FDG-PET images were registered with the

CTP-PWI image set and hence the CTP functional maps as well.
The PWIs were used to exclude cerebrospinal fluid and cranium from analysis as
well as to produce a gray and white matter anatomical mask based on the Hounsfield Unit
differences between the two tissue types. The critically hypoperfused area was defined as
relative Tmax > 2 2. Gray and white matter CTP thresholds, derived from human studies
(see Appendix D), were used to delineate the PIV volume on CBF, CBV and CBF•CBV
functional maps, while blinded to MRI, PET, and histological results. CBF, CBV and
CBF•CBV product infarct thresholds were 10.1 ml·min-1·(100g)-1, 1.9 ml·(100g)-1, and
26.0, respectively, for gray matter and 7.4 ml·min-1·(100g)-1, 1.25 ml·(100g)-1, and 9.9,
respectively, for white matter (Appendix D). The volume of each voxel was determined
as (120 mm/512 pixels)2 x 5 mm. For each animal, total infarct volume (cm3) was
calculated by multiplying the number of infarct positive voxels (gray plus white matter)
with the voxel volume.
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As a secondary analysis, the histologically defined TIV was superimposed onto
CTP-CBF and CBV functional maps to determine perfusion values within gray and white,
and mirrored contralateral regions. Pixels with a CBF > 100 ml·min-1·(100g)-1 or CBV >
8 ml·(100g)-1 were excluded from the region of interest to remove influence of large
vessels on parenchymal perfusion27. Animals were classified as having CBF/CBV
mismatch (complete or partial) or CBF/CBV matched decrease (Table 4.2). We define
mismatch as an increase in CBV, from within the superimposed TIV, greater than the
average plus one standard deviation of the CBV value obtained from the contralateral
mirrored region of interest (ROI) for each animal.
MR-derived PIV was defined as the abnormal hyperintense (exceeding the DWI
signal intensity of the contralateral hemisphere by more than three standard deviations)
and hypointense (ADC signal < 85% of contralateral hemisphere) areas on DWI and
ADC maps, respectively, while blinded to CTP, PET and histological results, as described
previously28, 29. The volume of each voxel was determined as (220 mm/128 pixels)2 x 5
mm slice thickness. Total number of voxels in all slices were determined and scaled by
the voxel volume to obtain the total infarct volume (cm3).
We visually assessed uptake of the

18

F-FDG semi-quantitatively within

superimposed TIV as defined by TTC staining by categorizing the regional uptake as
increased, decreased, or similar to uptake in the contralateral hemisphere. Core, periphery
and peri-infarct uptake were assessed (Figure 4.2). Core was defined as very low uptake
[Standard uptake value (SUV) < 50% of contralateral hemisphere SUV] within the
superimposed TIV. Periphery-TIV is the total TIV less the core-TIV area. All ROIs were
mirrored into contralateral hemisphere.
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Figure 4.2 Assesement of glucose metabolism with 18FDG-PET

TTC-stained excised brain with TIV delineated and corresponding

18

FDG uptake with

superimposed TIV (solid black lines), core ROI (solid white), peri-TIV (dashed white).
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4.2.6 Statistical analysis
The statistical package, SPSS 15.0 (SPSS Inc., Chicago, IL), was used for all analyses.
Differences were considered significant at p < 0.05. All data sets were checked for
normality with the Shapiro-Wilk test prior to analysis with the appropriate parametric or
non-parametric tests.
The relationship between the PIV as defined by CTP and MRI parameters and
TIV from TTC-histology was evaluated for agreement with: 1) percent difference, 2)
linear regression and 3) Bland-Altman analysis between PIV and TIV. The last analysis
determined the systematic error (bias) and the 95% limits of agreement, defined as the
mean and ± 1.96 times standard deviation of the individual differences respectively.
Pearson correlation was applied to 2), while pairwise multiple comparisons using
ANOVA with Tukey correction was applied to 1). Also, a paired student t-test was used
to compare average CBF and CBV values from within superimposed TIV and mirrored
contralateral TIV. Differences were considered significant at p < 0.05.

4.3 RESULTS
For all imaging parameters, a significant correlation (p < 0.05) was observed between the
PIV and TIV (Figure 4.3). The CTP-CBF parameter had the highest R2 value and slope
closest to unity, while the CTP-CBV had the lowest R2 value and slope furthest away
from unity. The CTP-CBF•CBV parameter had a higher R2 value, but lower slope than
both MR parameters.
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Figure 4.3 Regression of imaging defined PIV versus TTC defined TIV

Scatterplots for predicted infarct volumes (PIVs) as defined by A) MR-DWI, B) MRADC, C) CTP-CBF, D) CTP-CBV, E) CTP- CBF•CBV versus the true infarct volume
(TIV), defined on TTC-stained excised brain (n=10). Graphs are plotted with linear
regression fit (solid line) and 95% confidence intervals (dashed lines). Adjusted R2
values, p-values and slopes of regression lines are also shown. Significance was classified
as p < 0.05.
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The 95% limits of agreement from the Bland-Altman analysis were as follows:
MR-DWI = [8.7, -11.5], MR-ADC = [11.1, -12.7], CTP-CBF = [4.7, -6.8], CTP-CBV =
[23.0, -9.1], CTP-CBF•CBV = [14.4, -5.6]. The best agreement was observed with CTPCBF. The limits of agreement for MR-DWI and CTP- CBF•CBV were closely matched
(Figure 4.4).

130
Figure 4.4 Bland-Altman plots

Bland-Altman plots for predicted infarct volumes (PIVs), as defined by A) MR-DWI, B)
MR-ADC, C) CTP-CBF, D) CTP-CBV, E) CTP- CBF•CBV, and the true infarct volume
(TIV), defined on TTC-stained excised brain (n=10). For all plots, the y-axis depicts the
difference between the PIV and TIV, while the x-axis depicts the mean of both PIV and
TIV values. Also shown are the mean differences (dotted line) ± 95% limits of agreement
(solid lines).
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PIV from MR-DWI, ADC and CTP-CBF overestimated the TIV defined with
histology (Table 4.1). The percent difference between CTP-CBF defined PIV and TIV
was significantly lower than those for CTP-CBV and CTP-CBF•CBV defined PIVs (p <
0.05). Significant differences were not observed between CTP-CBF, MR-DWI or MRADC defined PIVs

or their percent differences from TIV (p > 0.05). For all animals,

mean CBF within superimposed TIV was decreased relative to the contralateral side (p <
0.05), while CBV was not (p > 0.05). Median (range) values for CBF [ml·min-1·(100g)-1]
and CBV [ml·min-1·(100g)-1] within mirror contralateral TIV ROIs were 42.3 (31.5-64.1)
and 2.1 (1.9-2.7) for gray matter, respectively, and 28.9 (19.4-38.0) and 1.5 (1.2-2.1) for
white matter, respectively. A complete CBF/CBV mismatch (hypervolemia without a
CBV defect), partial mismatch (hypervolemia with a CBV defect) and absent mismatch
(no hypervolemia) was observed in 3/10 (30%), 3/10 (30%), and 4/10 (40%) of animals,
respectively (Table 4.2).
A decrease in glucose metabolism (reduced uptake of

18

FDG) was observed

within the core TIV, peripheral TIV, and peri-TIV in 8/10 (80%), 1/10 (10%) and 0/10
(0%) of animals (Table 4.2).
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Table 4.1 Infarct volumes from MR imaging, CTP imaging and histology.

Parameter
MR-DWI
MR-ADC
CTP-CBF
CTP-CBV
CTP-CBF·CBV
Histology (TTC)

Infarct volume
Median [range]
(cm3)
13.9 [3.1-27.1]
14.1 [2.3-24.3]
13.3 [3.8-30.9]
3.2 [0.4-19.6]
6.2 [1.2-21.4]
10.6 [0.7-32.3]

% change between PIV &
TIV
Mean ± SD (cm3)
-31.4 ± 98.5
-31.6 ± 115.4
-23.3 ± 31.7*
42.3 ± 44.1
28.5 ± 31.5
N/A

*Significantly different from the CTP-CBV and CTP-CBF•CBV parameters (p < 0.05).
TTC = tetrazolium chloride, PIV = predicted infarct volume, TIV = true infarct
volume, N/A = not applicable
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Table 4.2 CT perfusion values from within superimposed true infarct volume and
corresponding glucose metabolism.

Animal
1
2
3
4
5
6
7
8
9
10
Mean
Stdev

Perfusion values within TIV
ROI
Gray matter
White matter
CBF
CBV
CBF
CBV
6.5
1.8
4.3
1.5
11.6
2.3
7.4
1.9
7.6
2.0
6.9
1.1
8.5
1.9
7.5
1.3
9.1
1.7
5.7
1.2
12.6
1.1
5.3
1.0
4.87
1.8
7.2
0.9
9.1
1.2
5.8
1.1
5.9
1.4
6.7
0.7
13.7
2.3
14.7
1.8
8.9
1.8
7.2
1.3
2.9
0.4
2.8
0.4

18

CBF/CBV Core
mismatch TIV
Complete
↓
Complete
↓
Absent
↓
Complete
↓
Partial
↓
Partial
↓
Partial
→
Absent
↓
Absent
↓
Absent
→

FDG-uptake
Peripheral
TIV
↑
↑
↑
↑
→
↓
→
↑
↑
↑

PeriTIV
→
↑
↑
→
↑
↑
↑
↑
↑
↑

TIV = true infarct volume, ROI = region of interest, Complete mismatch = hypervolemia
without CBV defect, Partial mismatch = hypervolemia with CBV defect, Absent mismatch
= no hypervolemia.

18

F-FDG was categorized as increased (↑), decreased (↓), or similar

(→) to the uptake in the contralateral hemisphere. Units for CBF is ml·min-1·(100g)-1 and
CBV is ml·(100g)-1
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4.4 DISCUSSION
This study used a porcine model of enndothelin-1 (ET-1) induced focal cerebral ischemia
to compare predicted infarct volume (PIV) with true infarct volume (TIV), defined with
acute neuroimaging and histology, respectively. We showed that the PIV defined with
absolute gray and white matter CT-CBF thresholds correlated best with the TIV, and was
similar to both MR-DWI and ADC defined PIVs. This is contrary to previous results
which showed that the CBF•CBV product was the optimal parameter for infarct
delineation in gray and white matter15, 16. These studies by Murphy et al. used a shortened
CTP acquisition of 45 seconds, delay-sensitive CTP software, and defined the final
infarct volume with a 7 day NCCT, which could be larger than the acute infarct volume
due to maturation and edema. Herein, we used a 2-phase 120 second CTP acquisition to
eliminate data truncation, followed by functional map calculation using the newest delayinsensitive CTP software (GE Healthcare, CT Perfuison 4D), and compared our CTPPIVs with both the imaging and histological gold standards30.
Our result is consistent with the current literature which confirms that CBF is
superior to CBV and CBF•CBV in defining infarct volume; although consensus on the
use of relative or absolute CBF thresholds has not been established31. Applying an
absolute CBF threshold can be problematic if CTP image acquisition protocol and
processing algorithms are not optimized to calculate accurate CBF values. In this study,
the average CBF gray and white matter (9.9 and 7.2 ml·min-1·(100g)-1, respectively),
from within superimposed TIV, varied only ~8% and ~2%, respectively, from the
described clinical CBF thresholds, obtained using similar scanning parameters with the
same post-processing algorithm and image analysis. These CBF values are similar to
those obtained by Jones et al. (1981) who demonstrated in a primate stroke model, that
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the CBF threshold for infarction was 10–12 ml·min-1·(100g)-1 for 2–3 hours of occlusion
which was similar to the time of ischemia in this study 12. Conversely, CBV values from
both gray and white matter were ~17% and ~27% higher, respectively, than human
thresholds, which is likely due to the varying incidence of hypervolemia at the time of
CTP imaging.
As discussed in chapter 3, the prognostic reliability of the CBV parameter is
affected by reactive hypervolemia, truncation of ischemic time density curve, and
recanalization status, all of which will vary between study cohorts. Drawbacks for the use
of relative to contralateral ‘normal’ region perfusion thresholds include variation in
gray/white matter tissue distributions, potential underlying vascular pathologies, and
variable/unstable central hemodynamic status of acute stroke patients at admission.
Many investigators define the penumbra as hypoperfused (low CBF) tissue with
hypervolemia (high CBV, relative to the contralateral hemisphere) - the so called
CBF/CBV mismatch hypothesis33,

34

. Complete or partial CBF/CBV mismatch was

observed in 60% of animals, and in all of these cases, a portion of the mismatched area
occurred within infarcted tissue, defined with histology (Figure 4.5 B & C). As described
in chapter 3, we speculate that acute increases in CBV may be nutritive or non-nutritive,
the latter caused by the opening of arteriovenous shunts within areas of considerable
neuronal death35. These mismatched regions were accompanied by varying degrees of
glucose metabolism, which may indicate whether the CBV increase is futile or not;
however, increased

18

F-FDG accumulation could also be due enhanced anaerobic

glycolysis, activated repair processes (inflammatory phagocytosis and gliosis), and
neuronal excitation from spreading depolarization36,
others (see below) of this study.

37

. This is one limitation besides
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Both the DWI and ADC defined PIV overestimated the TIV in 60% of animals, by as
much as 350%. Nonetheless, brain tissue that stains positively for TTC may not
necessarily be healthy and may yet succumb hours later. TTC staining relies on the
ability of mitochondrial dehydrogenase enzyme to react with the tetrazolium salt to form
the red formazan pigment18. Therefore, with mitochondrial breakdown, and subsequent
dehydrogenase enzyme denaturation, the pro-apoptotic/necrotic factors are released into
the cell38. The DWI and ADC parameters are related to bioenergetic failure in neurons,
causing cytotoxic edema and reduced water diffusion39. Therefore, for tissue with a DWI
-PIV/TIV mismatch, mitochondria are not producing enough ATP to maintain neuronal
ionic gradients, but their structural integrity is likely maintained – a borderzone between
infarct core and penumbra40. Timely reperfusion of this tissue region is potential cause for
the high incidence of DWI reversal in both clinical and experimental studies5,
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.

Similarly, CBF defined PIV overestimate the TIV in 60% of animals by as much as
~70%. One possible explanation is that CBF threshold for infarction was derived from a
prior clinical study in which the infarct size was determined from a 5-7 days post ictus
NCCT scan. The expansion of infarct between admission and follow-up imaging could
contribute to a higher CBF threshold for infarct evaluated at admission.
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Figure 4.5 Examples of imaging and TTC stained brains
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Coronal sections of (i) TTC stained excised brain, with infarct outlined in white, (ii) MRDWI, (iii) MR-ADC, (iv) CTP-CBF, (v) CTP-CBV, (vi)

18

FDG uptake. Colour maps of

CBF and CBV are 0-100 ml·min-1·(100g)-1 and 0-8 ml·(100g)-1, respectively. (A) Animal
3 shows matched infarct volume defects in all imaging modalities, with a decrease and
increase in

18

FDG uptake within core TIV and peri-TIV, respectively, relative to

contralateral uptake; (B) Animal 4 shows a complete CBF/CBV mismatch in the
corresponding TTC- and MR-defined infarct volumes, along with a decrease and same
18

FDG uptake in the core-TIV and peri-TIV areas, respectively, relative to contralateral

uptake. (C) Animal 6 shows a partial CBF/CBV mismatch, which corresponds to TTCand MR-defined infarct volumes, with a decrease in 18FDG uptake within the entire TIV
and peri-TIV, relative to contralateral uptake. (D) Animal 10, shows MR-defined DWI
and ADC infarct volumes without corresponding TTC- and CTP-defined infarction, with
the same and increased

18

FDG uptake within the core-TIV and peri-TIV, respectively,

relative to contralateral uptake.
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Besides the limitation of the

18

FDG-PET study, this study has several other

limitations. First, ET-1 receptors are found on vascular smooth muscle cells (pericytes)
and, endothelial cells. When ET-1 binds to endothelial receptors, the formation of nitric
oxide (NO) is stimulated, and in the absence of smooth muscle endothelin receptor
stimulation, this NO causes vasodilation42, 43. Therefore, the hypervolemia, observed in
the CBF/CBV mismatch of this study, may be mechanistically different than that
observed in thromboembolic stroke models where presence of arteriovenous shunts
causing venous filling and capillary compression are expected and can be confirmed with
scanning electron microscopy. Second, false-negative errors may be caused by partial
volume effects of neighbouring large blood vessels, masking regions of infarction; this
may contribute to the high incidence of CBF/CBV mismatch within DWI and TTC
defects. Third, as mentioned previously, glucose is used for all processes requiring
energy, including acute inflammation and excitotoxic events, which may mask the
reduced glucose uptake within infarcted tissue. The use of

18

F-flumazennil, a central

benzodiazepine receptor antagonist, would be specific for neuronal death44. Fourth, we
qualitatively assessed and outlined DWI and ADC defects, which has a high level of
subjectivity; applying diffusion thresholds may be an objective way to delineate
infarction, and could improve accuracy in delineating infarct volume. Fifth, PIV can
underestimate TIV as TTC staining occurred 20-30 minutes after the animal was
euthanized as time was required to excise the brain; moreover, TIV may also be
underestimated as the apoptotic cascade may already be initiated within peri-infarct
tissue. Lastly, differentiation between gray and white matter is challenging due to limited
resolution of the CT scanner coupled with the smaller porcine brain compared to humans.
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4.5 CONCLUSION
This study determined that the CBF parameter is as good as MR diffusion imaging for
acute infarct delineation, when CTP functional map calculation and image postprocessing was standardized. We also show that the CBF/CBV mismatch may not
indicate penumbral tissue in the acute stroke setting. These observations could have
implications on patient selection for thrombolytic therapy.
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CHAPTER 5
Hemorrhagic Transformation of Ischemic Stroke:
Prediction with CT Perfusion

The contents of this chapter have been adapted from the paper entitled “Hemorrhagic
transformation of ischemic stroke: prediction with CT perfusion” published in Radiology
2009;250(3):867-77 by R.I Aviv, C.D. d’Esterre, B.D. Murphy, J.J. Hopyan B. Buck, G.
Mallia, V. Li, L. Zhang, S.P. Symons, T.Y. Lee.

5.1 INTRODUCTION
Hemorrhagic transformation (extravasation of red blood cells through a damaged BBB;
HT) of acute ischemic stroke is an undesirable complication that occurs with rates
between 2.2% and 44% in clinical studies and increasing to 70% in pathological studies 15

. Several radiological and clinical parameters including baseline stroke severity, time to

reperfusion, thrombolytic protocol violations, tissue plasminogen activator (tPA), white
matter disease burden, aspirin, and heparin use are associated with HT6-12. While more
severe hemorrhage is undisputedly associated with worse outcome, there is controversy
whether less severe forms of hemorrhage are important8, 10, 13-17. Considering that even
small amounts of hemorrhage may be detrimental, it may be desirable to detect patients
who are more likely to undergo HT prior to tPA administration. Disruption of blood-brain
barrier (BBB) integrity, considered focal to the development of HT has been
demonstrated in animal models as increases in PS, but has not yet been fully elucidated in
humans18, 19. Recently, a small study using dynamic contrast-enhanced MRI with kinetic
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modeling demonstrated the feasibility of measuring BBB disruption20. However, the
availability, speed, and accessibility of CT are key reasons that it remains the diagnostic
procedure of choice in initiating thrombolysis. CT is also able to provide physiological
information regarding the infarct core and tissue at risk, as described in Chapter 121-23.
This is achieved with a dynamic contrast enhanced CT, or CT perfusion study with a
duration of 70-90 seconds. By extending the acquisition time window, further information
relating to the BBB integrity can be calculated24. Techniques for the measurement of the
CTP-permeability surface area product (PS) have been shown to be achievable with CTP
in animal tumor models and a small human case series, but until recently has not been
applied to stroke imaging25-28.
The aim of this study was to determine whether admission CT perfusion–derived PS
maps differ between patients with HT secondary to ischemic stroke and those without
HT. We hypothesize that patients with HT will have an increased BBB-PS compared to
those without HT.

5.2 MATERIALS & METHODS
5.2.1 Study design and patient cohort
Patients were prospectively recruited at a regional stroke centre (Sunnybrook Health
Sciences Center, Toronto, Canada) between January 2006 and October 2007. All study
procedures and medical chart review were approved by the institutional research ethics
board+. All recruited patients gave signed consent for the study. Inclusion criteria were:
less than 3 hours of stroke symptoms, full clinical assessment by the on-call neurology
____________________________________
+
Appendix E – Human Ethics Approval form
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stroke team, completed CT stroke imaging protocol at admission, as described below;
completed follow up CT and MRI study (including MR-diffusion weighted and gradientecho T2 weighted imaging) 5-7 days after stroke onset to determine final infarct size and
detect HT. All patients were included, regardless of whether they underwent
thrombolysis. One of two dedicated stroke neurologists, each with more than 5 years
stroke experience and certified in National Institutes of Health Stroke Scale (NIHSS)
score and modified Rankin score assessments, collected baseline patient data (age;
sex;blood pressure; clotting status; NIHSS score; tPA treatment status, dose, route, and
administration time; and stroke onset) at presentation and determined the modified
Rankin score at the 90-day follow-up stroke clinic visit. Intravenous tPA therapy was
administered up to 3 hours after symptom onset, following the admission CT perfusion
examination, according to standard clinical practice based on American Heart
Association–American Stroke Association guidelines29. TPA treatment was administered
in patients with an Alberta Stroke Program Early CT (ASPECT) score of 5 or higher30. A
modified Rankin score of 2 or lower was considered a good clinical outcome. The data
were maintained in a database. Patients were excluded if they had contraindications to
iodinated contrast material injection or MR imaging. Patients who repatriated to a local
hospital before completing the CT stroke imaging protocol were also excluded. Seventyfour patients met the study entry criteria. Thirty-three patients were excluded owing to
repatriation to another hospital before completion of the imaging protocol (n=26),
intraventricular hemorrhage (n=1), or excessive movement during imaging (n=6). Fourtyone patients were included in this study.
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5.2.2 CT and MR imaging protocols
A CT stroke series was performed at admission using a 64-section scanner (VCT GE
Healthcare) which included a non-contrast CT (NCCT), contrast-enhanced CT
angiography (CTA) and CT perfusion (CTP). The NCCT was taken at 120 kVp, 300 mA,
a 1-second rotation, a 5 mm section thickness. The CTA, from the aortic arch to the
vertex, was performed with the administration of iodinated contrast material (300 mg of
iodine per kilogram of body weight; iohexol [Omnipaque], GE Healthcare, Piscataway,
NJ) to a maximum of 90 mL, a 5–10 second scanning delay, 120 kVp, 270 mA, a gantry
speed of 1 second per rotation, a 1.25-mm section thickness, and a table speed of 20.62
mm per rotation. After the CT angiography series, a two-phase CTP examination was
performed. The first phase involved a 45-second continuous (cine) acquisition
reconstructed at 0.5-second intervals to produce a series of 90 sequential images of eight
sections each, encompassing a total of 40 mm from the basal ganglia to the lateral
ventricles. In the second phase of the CTP exam, images encompassing the same eight
sections were collected at 15-second intervals for an additional 90 seconds immediately
after the first phase. The scanning parameters for both phases were 80 kVp, 190 mA, 8x5
mm collimation, and a gantry speed of 1 second per rotation. A 0.5 mL/kg dose (maximal
dose, 50 mL) of iohexol was injected at a rate of 4 mL/sec 3–5 seconds before the start of
the first phase. Follow-up CT and MR examinations were performed for all patients 5–7
days after stroke onset. NCCT scanning was performed as described above. MR
sequences were performed as follows: diffusion-weighted imaging (DWI) parameters
were 8125/minimum (repetition time msec/echo time msec), 26-cm field of view, image
matrix of 128 x 128 pixels, 5 mm section thickness with no intersection gap; fast lowangle inversion-recovery imaging with scanning parameters of 8000/120/200 (repetition
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time msec/echo time msec/inversion time msec), 22-cm field of view, image matrix of
320 x 224 pixels, 5-mm section thickness with 1-mm intersection gap); and gradient-echo
T2-weighted (1100/35, 20° flip angle, 24 cm field of view, image matrix of 320 x 224
pixels, 5 mm section thickness with 1-mm intersection gap)

5.2.3 Image analysis
Two neuroradiologists with more than 5 years stroke experience and blinded to previous
examination results used follow-up NCCT and gradient-echo T2-weighted MR images to
determine HT severity in consensus. Any susceptibility effect–induced area of low signal
intensity in the ischemic region on a gradient-echo T2-weighted MR image was
considered HT, even in the absence of a corresponding area of high attenuation on the
NCCT image. The neuroradiologists did not record the size and location of these areas,
but they graded the extent of hemorrhage by using an established grading system (6). HT
was categorized as hemorrhagic infarction (HI) or parenchymal hematoma (PH)
according to the ECASS criteria2. HI was defined as blood petechiae within the infarcted
area, without space-occupying effect, while PH was defined as blood clot with spaceoccupying effect. ASPECT scores were assigned by one experienced neuroradiologist
with 5 years of experience. One operator with 2 years of experience used commercially
available software (CT Perfusion 4; GE Healthcare Waukesha, Wis) to calculate
parametric maps of cerebral blood flow (CBF), cerebral blood volume (CBV), mean
transit time (MTT), and PS from the first- and second-phase CT perfusion data (Appendix
F). Arterial input and venous output functions were derived from the ipsilateral anterior
cerebral artery and the superior sagittal sinus, respectively. We corrected partial volume
averaging of the arterial input curve by scaling the curve with the ratio of the area under
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the venous output curve to the area under the arterial input curved. Maps were calculated
by means of deconvolution of the arterial input curve and the tissue curves from 3 x 3
pixel blocks of CT images with use of the Johnson-Wilson model31. In addition to CBF,
CBV, and mean transit time maps, perfusion-weighted and PS maps were calculated.
Although we calculated the perfusion-weighted maps by averaging the images acquired
over the duration of the first phase, calculation of the PS maps required use of the data
from the second phase of the two-phase CT perfusion examination. The PS is used to
assess the rate of contrast material extravasation from the intravascular to the
extravascular space through a disrupted BBB26. Extravasation of contrast material leads to
prolonged enhancement of the tissue beyond the intravascular (first) phase, which can
only be properly characterized with a two-phase CTP acquisition. One author with 2 years
of experience analyzed the parametric maps by using custom software (IDL v6.1;
Research Systems, Boulder, Colorado). To reduce bias, all components of the analysis
were performed with the author blinded to the other study data - the HT status in
particular. As depicted in figures 5.1 and 5.2, imaging data for all patients was analyzed
by: 1) a CBF threshold of 25 ml·min-1·(100g)-1 was applied to delineate an ischemic
region of interest (ROI) on the admission CBF map, 2) this ROI was superimposed onto
the admission PS and CBV functional maps, 3) a mirror ROI was created by reflecting
the ischemic ROI across the hemispheric midline. To minimize the contribution of large
vessels, any pixel with CBF > 100 ml·min-1·(100g)-1 or a CBV > 8 ml·(100g)-1 was
excluded from the mean ROI value calculations23. Finally, CBF and CBV defect volumes
were calculated by using a CBF threshold of 25 ml·min-1·(100g)-1 and a CBV threshold of
2 ml·(100g)-1 on the corresponding maps22, 23.
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Figure 5.1 CT images for patient with small leakage in ischemic region

(A) Admission CT perfusion– derived CBF map of 5 mm thick brain section displayed
with color scale from 0 (dark blue) to 150 (red) ml·min-1·(100g)-1. (B) Corresponding
CBF map shows ischemic ROI outlined with help of a yellow overlay of pixels with CBF
of less than 25 ml·min-1·(100g)-1. (C) PS map corresponding to (A) shows superimposed
ischemic ROI and mirrored ROI in contralateral hemisphere. PS values in ischemic and
mirrored ROIs are 0.17 and 0.038 ml·min-1·(100g)-1, respectively. (D) Corresponding
delayed (7 day) NCCT scan of same section shows infarct and HT (arrow).
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Figure 5.2 CT images for patient with large leakage in ischemic defect

(A) Admission CT perfusion– derived CBF map of 5 mm thick brain section displayed
with color scale from 0 (dark blue) to 150 (red) ml·min-1·(100g)-1. (B) Corresponding
CBF map shows ischemic ROI outlined with help of a yellow overlay of pixels with CBF
of less than 25 ml·min-1·(100g)-1. (C) PS map corresponding to (A) shows superimposed
ischemic ROI and mirrored ROI in contralateral hemisphere. PS values in ischemic and
mirrored ROIs are 0.40 and 0.122 ml·min-1·(100g)-1, respectively. (D) Corresponding
delayed (5 day) NCCT scan of same section shows infarct (hypoattenuation) and HT
(arrows).
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5.2.4 Statistical analysis
Quantitative variable results were expressed as mean ± standard deviation or median with
corresponding interquartile ranges, and categorical results were expressed as proportions.
All data was checked for normality to determine if parametric or non-parametric tests
should be performed. An unpaired Wilcoxon rank sum, or Fisher exact test was used to
compare differences in demographic data and CTP variables between the HT and non-HT
groups, and between the tPA and non-tPA groups. Age, NIHSS score, time to treatment,
HT type were compared between these groups. PS, CBF and CBV values from within
ipsilateral and contralateral ROIs, as well as CBF and CBV defect size were compared
between groups. Associations between PS and both demographic and CTP parameters
were tested at univariate and multivariate logistic regression analyses. The odds ratio for
PS-based prediction of hemorrhage extent and the corresponding 95% confidence interval
(CI) were estimated at logistic regression analysis. Receiver operating characteristic curve
analysis of the PS values for prediction of hemorrhage extent was then performed, and the
area under the receiver operating characteristic curve, sensitivity, specificity accuracy,
positive and negative predictive values, and positive likelihood ratio were determined.
Results were considered significant at p < 0.05.

5.3 RESULTS
The 41 patients (26 men, 15 women) included in the study had a mean ± standard
deviation age of 70.3 years ± 15.4. The median NIHSS score at presentation was 15
(interquartile range, 7–20). The mean ± standard deviation time from stroke symptom
onset to CT scanning was 125 ± 46 minutes. The MR and CT follow-up examinations
were performed a median of 3 days (interquartile range, 2–6 days) after the initial CT
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examination. Twenty-two (54%) patients received tPA, which was administered both
intravenously (IV) and intra-arterially (IA) in two patients and IV only in 20. The mean ±
standard deviation tPA dose was 61 ± 12mg. Twenty three (56%) patients had a HT: 15
(37%) with HI and eight (20%) with PH. The data obtained at both baseline and discharge
was dichotomized according to presence of HT (Table 5.1). Patients with hemorrhage
were more likely to have a higher NIHSS score at presentation (p < 0.01), receive tPA (p
< 0.01), have a lower baseline ASPECT score (p < 0.05), and have a worse outcome (p <
0.01)) compared with patients without HT. There was no significant difference in time to
tPA treatment between the two groups (p = 0.65). At presentation, defect volumes
obtained with CBF and CBV ischemic thresholds were larger for the HT group, but not
significant (p > 0.05; Table 5.1).
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Table 5.1 Baseline and follow-up patient data dichotomized according to presence of
HT
Characteristic
Female patients
Age (y)*
Mean arterial blood pressure > 120mm Hg
International normalized ratio†
NIHSS at presentation
Time to imaging (min) †
ASPECT score*
Volume with CBF defect (cm3)†
Volume with CBVdefect (cm3)†
TPA given number (%)
Time to TPA (mins)
TPA dose (mg)
90 day modified Rankin score mRS

HT
(n = 23)
10 (44)
74 (58-83)
7 (30%)
1.04 ± (0.10)
19 (13-20)
124 ± 765
6 (5-7)
63±31
48±24
17 (74%)
143 (27)
62±13
4 (2-6)

No HT
(n = 18)
5 (28)
72 (64-81)
2 (11)
1.02 ± (0.07)
10 (7-15)
125 ± 118
10 (8-10)
52±21
31±13
5 (28%)
135 (31)
57±10
1 (0-2)

Pvalue
0.30
0.67
0.25
0.99
0.005
0.37
0.02
0.17
0.11
0.005
0.65
0.43
0.001

Unless otherwise noted, data are numbers of patients, with percentages in parentheses. P
values were obtained with unpaired t, Wilcoxon rank sum, or Fisher exact testing. P <
0.05 was considered to indicate a significant difference.
* Data are median values, with the interquartile range in parentheses.
† Data are mean values ± the standard deviation.
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The mean ± standard deviation PS within superimposed ischemic ROIs for patients with
and without HT was 0.49 ± 0.3 ml·min-1·(100g)-1 and 0.09 ± 0.10 ml·min-1·(100g)-1.
These were significantly different (p < 0.01; Figure 3A). No significant differences in
CBF within the ischemic ROI were observed between the HT [15.6 ± 6.8 ml·min 1

·(100g)-1] and non-HT [18.0 ± 5.9 ml·min-1·(100g)-1 (p > 0.05). Similarly, no significant

differences in mean CBV were observed between patients with HT [1.0 ± 0.38 ml·(100g)1

] and patients without [1.0 ± 0.40 ml·(100g)-1] (p > 0.05). For patients with HT, mean ±

standard deviation PS values within the contralateral ROI [0.17 ± 0.15 ml·min-1·(100g)-1]
was significantly different than ipsilateral values [0.49 ± 0.3 ml·min-1·(100g)-1] (p <
0.05). For patients without HT, no significant difference was observed between ipsilateral
[0.09 ± 0.10 ml·min-1·(100g)-1] and contralateral ROIs [0.06 ± 0.04 ml·min-1·(100g)-1] (p
> 0.05). The mean PS for the contralateral ischemic ROI was significantly different for
patients with and without HT (p < 0.05). Subgroup analysis revealed no significant
differences in PS, CBF, or CBV between the patients with HI and those with PH;
however, significant differences in PS, but not in CBF or CBV, were observed between
patients with HI, PH, and non-HT groups (p > 0.05; Table 5.2, Figure 5.3b).
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Table 5.2 Mean PS, CBF and CBV values for ischemic ROIs in patients
dichotomized according to HT type and presence

-1

-1

PS [ml•min •(100g) ]
CBF [ml•min-1•(100g)-1
CBV ml•(100g)-1

PH (n=8)
0.51 ± 0.39
15.67 ± 5.6
1.00 ± 0.38

HI (n=15)
0.48 ± 0.27
15.6 ± 7.6
0.98 ± 0.39

Any HT (n=23)
0. 49 ± 0.3
15.62 ± 6.8
1.00 ± 0.38

No HT(n=18)
0.09 ± 0.10
18.01 ± 5.9
1.00 ± 0.40

Data are mean values ± the standard deviation. P < 0.0001 for difference between PS and
CBF in parenchymal hematoma (PH), hemorrhagic infarction (HI), and any HT groups
compared with those in no HT group. P = 0.97 to P = 0 .99 for PS, CBF, and CBV in PH
group compared with those in HI group.
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Compared with the patients who were treated with tPA, non-tPA treated patients
were older (p = 0.03), tended to have a higher baseline NIHSS (p = 0.06), arrived at the
hospital later (p = 0.04), and were less likely to have HT (p = 0.005). The patients treated
with tPA had smaller CBF and CBV defect volumes, although neither parameter was
significantly different between the two groups. Among the patients treated with tPA, PS
values were higher in those with HT [0.47 ± 0.33 ml·min-1·(100g)-1] than in those without
HT [0.13 ± 0.13 ml·min-1·(100g)-1] (p < 0.05). A similar finding was seen for non-tPA
patients with and without HT [0.56 ± 0.24 vs. 0.07 ± 0.07 ml•min-1•(100g)-1; p < 0.05].
No PS difference was found between tPA and non tPA patients with HT (0.47 ± 0.33 vs.
0.56 ± 0.24 ml•min-1•(100g)-1; p=0.49) and without HT (0.13 ± 0.13 vs. 0.07 ± 0.07
ml•min-1•(100g)-1; p > 0.05). The PS value of tPA treated patients with HT was not
different from that of all hemorrhage patients (p > 0.05; Table 5.3).
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Table 5.3 Baseline and follow-up patient data dichotomized according to tPA
treatment status
Characteristic
Age (y)
Baseline NIHSS score*
Baseline ASPECT score*
Time to treatment (min)
CBF volume (cm3)
CBV volume (cm3)
PS [ml•min-1•(100g)-1]
CBF [ml•min-1•(100g)-1]
CBV[ ml•(100g)-1]
HT†
PH†

tPA (n=22)
66.86 ± 14.98
15.8 (13-21)
6 (6-9)
97 ± 49
59.32 ± 33.02
40.52 ± 16.14
0.28 ± 0.28
16.0 ± 6.48
0.98 ± 0.32
17 (77)
5 (23)

No tPA (n=19)
76.56 ±11.85
8.3 (5.25-16.25)
9 (6-19)
159 ± 116
54.66 ± 20.96
45.20 ± 25.75
0.39 ± 0.33
17.39 ± 6.62
1.03 ± 0.45
6 (31.6)
2 (10)

P-value
0.03
0.06
0.13
0.04
0.90
0.77
0.10
0.77
0.77
0.005
0.42

Unless otherwise noted, data are mean values ± the standard deviation. P values were
obtained with unpaired t, Wilcoxon rank sum, or Fisher exact testing. P < 0.05 was
considered to indicate a significant difference.
* Data are median values, with the interquartile range in parentheses.
† Data are numbers of patients, with the percentage of patients in parentheses.
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The patients were subdivided according to hemorrhage status in addition to tPA
treatment status (Figure 5.4). Although there were overlapping mean PS values within the
ipsilateral ischemic ROI between the HT and non-HT groups among the patients treated
with tPA, there was no such overlap in values among the patients who were not treated
with tPA.
Univariate logistic regression analysis demonstrated significance for HT with PS
(OR 3.5; 95% CI 1.69-7.06, p = 0.001), baseline NIHSS (OR 1.2; 95% CI 1.0-1.3
p=0.001), baseline ASPECTS (OR 0.5; 95% CI 0.3-0.7; p=0.0007) and tPA
administration (OR 6.8; 95% CI 1.7-27.5, p=0.007). PS (OR 3.5; 95% CI 1.69-7.06;
p=0.0007) and baseline ASPECTS (OR 0.4; 95% CI 0.2-0.7, p = 0.002) were the only
independent variable associated with HT following a stepwise multivariate analysis.
Receiver operator curve (ROC) analysis demonstrated an optimum PS cutoff value of
0.23 ml-1•min-1•(100g)-1, with an AUC of 0.92±0.05 (Figure 5.4). Sensitivity, specificity,
positive and negative predictive value and positive likelihood ratio was 77% (CI 5592%), 93.8% (CI 70-100%), 94% (CI 84-100%), 75% (CI 60-90%) and 4.1 respectively.
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Figure 5.3 PS values for patients with/without HT, and HT sub-types

Box plots of PS [ml-1•min-1•(100g)-1 ] within ischemic ROIS for (A) patients with HT and
those without HT, and (B) patients with either of two hemorrhage subtypes (HI or PH)
and those without HT. In each box, median, 95% CI, and first and third quartile values
are illustrated.

163

Figure 5.4 Distribution of PS values for tPA treated/non-treated

Graph illustrates distribution of mean PS values for ischemic ROIs in patients grouped
according to tPA treatment status and HT status.
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Figure 5.5 Receiver Operator Characteristic Curve for the PS parameter

Receiver operator characteristic curve (true positive rate versus false positive rate) of PS
thresholds to determine HT. Area under the curve (AUC) is shown.
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5.4 DISCUSSION
Our study results demonstrate the feasibility of a two-phase protocol for measuring
hemodynamic parameters and the PS during one CT perfusion examination. The patients
with HT had a significantly higher PS than did those without hemorrhage. A PS threshold
of 0.23 ml-1•min-1•(100g)-1 also enabled the differentiation of patients with HT from those
without.
It is important that we identify no significant difference in CBF between the patients with
and those without hemorrhage. The patients treated with tPA were more likely to have
HT. However, we observed no significant differences in PS between the tPA-treated and
non-treated patients. Patients with HT were more likely to have higher admission NIHSS
scores and poorer clinical outcomes compared with patients without HT. There were no
significant differences between the patients with HI and those with PH. The limited
number of patients precluded further stratification of the HT sub-types into HI-1, 2 and
PH-1,2.
MR imaging has also been used to study BBB breakdown in patients with acute
stroke32-34. In particular, Warach et al. (2004) found the hyperintense acute reperfusion
marker (HARM) to be a useful early marker of BBB breakdown in their MR-based
natural history examination of acute stroke patients35. HARM is the hyperintense signal
observed on fast low-angle inversion-recovery images hours to days after gadopentetate
dimeglumine administration and is believed to be caused by the accumulation of MR
contrast material in the cerebrospinal fluid space or ventricles before BBB breakdown. In
some cases, the HARM signal was not just localized to the ischemic hemisphere; rather, it
was generalized throughout the brain on the fast low-angle inversion-recovery images,
signifying more widespread and remote BBB permeability, including that in the
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contralateral hemisphere. Given that HARM was found to be associated with HT and
stroke severity, their finding may help to explain our observation that the PS in the
contralateral mirror ROI in patients with HT was higher than that in patients without HT.
HT is common in stroke patients, especially following thrombolytic therapy9, 36, 37.
In our study, HT was associated with PS, NIHSS score, baseline ASPECT score, and tPA
therapy at univariate analysis; however, the association with tPA was weaker. The
absence of an independent association between tPA and HT likely reflects the fact that the
patients were selected for treatment on the basis of their ASPECT and NIHSS scores,
both of which were independently used to predict HT. Therefore, no additional influence
of tPA on this outcome could be detected. Our results, like those in most stroke studies,
could have been affected by the specific inclusion and exclusion criteria that we adopted
for this study, and by whether the studied cohorts had matched clinical data. Nonetheless,
our results show that besides the PS parameter and ASPECT score, no other factors (age,
sex, or baseline NIHSS score) were associated with HT.
The prevalence of PH in this study is higher than that of previously published
randomized studies of thrombolysis10,

38

. This may have been due in part to the

classification of hemorrhage at 5–7-day post symptom onset, rather than within the 36hour time window used in many other studies14, 39. Vasogenic edema and mass effect are
expected to peak at 3–4 days, which may contribute to the increased number of cases with
mass effect in our series. An experienced team of stroke neurologists administered tPA by
following standard thrombolysis guidelines. No tPA dosing errors or protocol violations
occurred. All patients in this series were classified into hemorrhage and nonhemorrhage
groups by using gradient-echo T2-weighted MR imaging rather than CT. The superiority
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of this MR sequence for hemorrhage detection may also account for the higher reported
prevalence of HT 40, 41.
Our sample size was too small for us to make any definitive conclusions about the
effect of tPA treatment on HT; however, tPA may act in concert with ischemic effects to
render the brain more susceptible to HT as the minimal PS in patients with HT who were
treated with tPA [0.047 ml-1•min-1•(100g)-1] was lower than that of patients with
hemorrhage who were not treated with tPA [0.23 ml-1•min-1•(100g)-1]. A lower pretreatment PS with tPA treatment may be as likely to cause HT as a higher PS without tPA
treatment.
CT is the modality of choice for the initial investigation of acute stroke for
patients that may require lytic treatment29. CT scanners are widely available, accessible,
and less expensive to operate compared with MR units. Occlusion site and perfusion
defect size are important considerations in determining the outcome of revascularization
procedures and defining a target population for treatment42-44. Surrogate radiological
markers of BBB breakdown, including intra-procedural early venous filling and postprocedural contrast enhancement and extravasation, have been described previously45, 46.
These markers are usually associated with larger volumes of contrast material injected
over a prolonged period. Until recently, leakage of contrast material volumes used in
current acute stroke protocols were not detectable with CT47, 48. The two-phase perfusion
CT protocol, described herein, is designed to depict contrast material leakage owing to
the extension of the acquisition time window of a conventional perfusion CT examination
by 90 seconds, with six additional acquisitions at 15-second intervals. In this study, CT
angiography was performed before PS measurement in the two-phase perfusion CT
protocol. This particular design raises the question of whether residual contrast material
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from the prior CT angiography examination affects the accuracy of the subsequent PS
measurement, which itself requires another contrast agent injection. Both the arterial
input curve and the tissue curve used to calculate the PS with the Johnson-Wilson model
were generated by subtracting the attenuation of the artery and the tissue before the
arrival of contrast material from the attenuation after the contrast material arrival. The
residual contrast material from prior CT angiography would cause the same increase in
attenuation in the artery and the tissue before and after the arrival of contrast material, and
the effect of this increase would be eliminated by the subtraction during the generation of
the arterial input and tissue curves. Therefore, the residual contrast material from prior
CT angiography would not affect the accuracy of the PS parameter.
Our study had several limitations. First, comparisons among the small number of
patients with HT did not reveal significant differences in PS between the HI and PH
groups. However, the importance of the HT subtypes is being debated15, 17-19. Results of a
recent study demonstrated that HI is not necessarily benign and is associated with a worse
clinical outcome compared with that of patients without hemorrhage18. Second, six
patients in our study were excluded because of excessive motion during imaging. This
number represents 15% (6/41) of the current patient data set, and the exclusion may have
resulted in an overestimation of the diagnostic accuracy of the technique. Third, the
sensitivity and specificity of our optimal PS threshold for predicting HT needs to be
tested prospectively in a larger data set. Fourth, as quantitative permeability
measurements are uniquely tracer dependent, our specific quantitative results may not be
generalizable to other contrast agents or other acquisition timing protocols - every
contrast agent has a different permeability constant, depending on its charge and
molecular weight. Fifth, we used one threshold value to delineate ischemia, which may
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have led under/overestimation of the ischemic ROI depending on gray/white matter
distribution. Sixth, although blood products are easily identified on gradient-echo T2weighted MR imaging, this sequence is hindered by susceptibility artifacts that can make
the area of hemorrhage appear larger than it really is. However, since the PS was
evaluated within the entire ischemic ROI, defined on CBF maps, overestimation of the
hemorrhage region volume likely had no substantial effect on the PS calculation. Last,
although CT perfusion is widely used, it is limited by ionizing radiation, contrast material
nephrotoxicity, and limited coverage in the z-direction.

5.5 CONCLUSION
In conclusion, the BBB PS parameter can be measured accurately during the acute stroke
CT protocol. PS elevation appears to be a promising marker for predicting the risk of HT
in acute stroke patients.
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CHAPTER 6
Early Rate of Contrast Extravasation in ICH Patients

The contents of this chapter have been adapted from the paper entitled “Early rate of
contrast extravasation in patients with intracerebral hemorrhage” published in the
American Journal of Neuroradiology, 2011;32(10):1879-84, by: C.D. d'Esterre, T. Chia,
A. Jairath, T.Y. Lee, S.P. Symons, R.I. Aviv.

6.1 INTRODUCTION
As discussed in Chapter 1, primary intracerebral hemorrhage (ICH) accounts for ~23% of
all strokes, and leads to rapid clinical deterioration1. During the first 3 hours of symptom
onset, early hematoma growth is seen in 18% to 38% of intracerebral hemorrhage
patients, reducing to 11% thereafter2-4. Early hematoma expansion is associated with
poorer neurological outcome and increased mortality5. The cause of early hematoma
expansion is unknown, but secondary vessel injury and perihematomal ischemia have
been implicated. Prevention or reduction of secondary bleeding is important when dealing
with ICH6. Recently, administration of recombinant Factor VIIa resulted in the reduction
of hematoma expansion, without improvement in clinical outcome7; however, post hoc
analysis has suggested benefit in a small sub-group of patients8.
CT imaging is considered the modality of choice for the acute investigation of
ICH. Extravasation is demonstrated on CT angiography (CTA) and post contrast CT
(PCCT) in approximately 40-50% of patients9,

10

. Several imaging studies have

demonstrated an association between early contrast extravasation and hematoma
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expansion10-13. A recent study demonstrated that foci of contrast-leakage not discernable
during the arterial phase of a CTA may be detected on PCCT (PCL)14. A further study
demonstrated that delayed CTA detected other areas of contrast extravasation not seen on
an early CTA15. In both studies, sensitivity to hematoma expansion improved when
delayed images were considered - it is reasonable to assume that a slower rate of contrast
extravasation in PCL accounts for the lack of CTA detection, although this has not been
shown. Further, the etiology and pathophysiological significance of the various
manifestations of contrast extravasation remain unknown. However, given the association
between risk of hematoma expansion and poor outcome with the number and density of
extravasation defects, it is likely that more rapid extravasation, such as that seen on
arterial phase CTA, may confirm the highest risk13.
CT perfusion (CTP)-derived permeability surface area product (PS) is a novel
method of measuring the rate of contrast extravasation from the intra- to extravascular
compartment16. Knowing the rate of contrast extravasation may provide insight into the
pathophysiology of hematoma expansion by identifying the contributing target
abnormality. A clinical technique that quantifies this rate provides objective assessment
of hematoma expansion risk rather than the qualitative approach currently used. Such
information may become increasingly important as novel ICH treatments, such as focused
ultrasound coagulation, are developed that will target specific defects17.
Using the CTP-PS parameter we sought to measure the rate of contrast
extravasation for CTA-Spot Sign defects and PCCT-PCL defects, respectively. PS values
from these two abnormalities will be compared to PS values from hematoma volumes
excluding any extravasation, hematoma volumes in patients without extravasation, and
contralateral normal tissue. We hypothesize that the rate of contrast extravasation will be
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highest in CTA Spot Sign defects compared to PCL defects and hematoma regions
without extravasation.

6.2 MATERIALS AND METHODS
6.2.1 Patient cohort
With approval by the local institutional ethics review board+, 16 consecutive patients with
ICH presenting over a 6-month period at a tertiary stroke centre underwent initial noncontrast CT (NCCT), and CTA upon admission. The imaging was reviewed acutely with
the patient on the CT table by an attending neuroradiologist with 5 years experience. If
ICH was identified, a PCCT scan and CT Perfusion (CTP) study was performed
regardless of the result of contrast extravasation in CTA. Spot Sign and PCL
extravasation were identified retrospectively by the presence of contrast extravasation on
the CTA or PCCT, respectively. Of 16 screened patients, 7 demonstrated contrast
extravasation. Nine foci of contrast extravasation were present on each of the CTA and
PCCT, respectively, for a total of 18 regions.

6.2.2 Image acquisition
CT scanning was performed on a 64-slice CT (Lightspeed plus and VCT; GE Healthcare,
Waukesha, Wis) scanner at admission and 24 hours after presentation in all patients. The
standard ICH protocol includes a NCCT head followed by a CTA and PCCT. Pre- and
post-contrast head imaging was acquired from the skull base to vertex with parameters:
____________________________________
+

Appendix G – Human Ethics Approval form
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120 kVp; 340 mA; 4 x 5 mm collimation; 1 second/rotation; and a table speed of 15
mm/rotation. CTA studies were acquired from C6 to the vertex in the helical HS mode
with parameters: 0.7 ml/kg contrast (to a maximum of 90 ml through an antecubital vein
via at least an 18 or 20 gauge angiocatheter); 5 to 10 second delay; 120 kVp; 270 mA; 1
second/rotation; 1.25 mm slice thickness at 0.625 mm intervals, table speed 3.75
mm/rotation. The CTP study was comprised of 2 phases. The first phase was a 45 seconds
continuous (cine) scan reconstructed at 0.5 second intervals to produce a series of 90
sequential images for each of the eight slices, covering a total of 40 mm from the basal
ganglia to the lateral ventricles. The second phase collected images covering the same 8
slices over an additional 90 seconds immediately after the first phase at intervals of 15
seconds. Scan parameters for both phases were: 80 kVp, 190 mA, 8 x 5 mm collimation
and 1 second/rotation. The dose-length products for NCCT, CTA (intracranial only) and
CTP components were 1073, 592 and 1804 mGy-cm, respectively. Assuming a
conversion factor of 0.0021 mSv per mGy-cm, the effective dose was 7.3 mSV.
Iodinated contrast agent at a dose of 0.5 ml/kg (maximum 50 ml) was injected 3-5
seconds prior to the start of the first phase at a rate of 4 ml•s-1. A 5 minute post processing
time is as previously reported15. The follow up consisted of an NCCT only. All images
were viewed on AGFA Impax 4.5 PACS workstation.

6.2.3 Image analysis
CT Perfusion 4 software (GE Healthcare) was used to calculate parametric maps of PS.
Arterial input and venous output functions were obtained from the ipsilateral anterior
cerebral artery and from the superior sagittal sinus, respectively (Figures 6.1 and
6.2). Partial volume averaging was corrected by multiplying the arterial input function by
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Figure 6.1 Example of patient with a spot sign and post-contrast leakage

(A) Baseline contrast enhanced source CTP image. (B) Corresponding time-density
curves (TDC) for the artery (red) and vein (blue; Hounsfield Unit scale: 0-600). (C) TDC
for Spot Sign (yellow), post contrast-leakage (PCL; green), and contralateral region of
interest (ROI; purple; Hounsfield Unit scale: 0-30). (D) CTA with Spot Sign visible
(yellow arrow). (E) Post-contrast enhanced CT (PCCT) showing PCL (green arrow) and
Spot Sign with extravasation (yellow arrow). (F) Perfusion weighted image and (G)
permeability surface area product (PS) map. ROIs encircle the contrast extravasation
(Spot Sign and PCL) on the perfusion weighted image, and entire hematoma excluding
extravasation and overlap with ventricles (intraventricular hemorrhage). ROIs are
superimposed onto PS map and reflected about the midline.
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Figure 6.2 Example of patient without contrast extravasation

(A) Baseline contrast enhanced source CTP image. (B) Corresponding time-density
curves (TDC) for the artery (red) and vein (blue; Hounsfield Unit scale: 0-400). (C) TDC
for region of interest (ROI) within hematoma (yellow), and contralateral ROI (green;
Hounsfield Unit scale: 0-16). (D,E) CTA and PCCT with no visible contrast extravasation
within hematoma. (F) Perfusion weighted image (PWI) and (G) permeability surface area
product (PS) map. An ROI encircles the hematoma on the PWI. Hematoma ROI is
superimposed onto PS map, excluding overlap with ventricles, and is reflected about the
midline.
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the ratio of the area of venous time attenuation curve to that of the arterial input
function18. Maps were calculated by deconvolution of the arterial input curve and tissue
curves from 2 x 2 pixel blocks of CT images using the adiabatic approximation to the
Johnson-Wilson (J-W) model19.
PS, by definition, is the unidirectional rate of contrast extravasation from the
intravascular to the extravascular space through a disrupted blood-brain barrier20.
Extravasation of contrast material leads to prolonged enhancement of the tissue beyond
the intravascular (first) phase which can only be properly characterized by a two-phase
CTP study as previously described21. Parametric maps were analyzed by one author with
4 years’ experience using custom software (IDL v6.1, RSI Inc, Boulder, Colo. USA).
Extravasation, observed on CTA and/or PCCT, was located on inherently co-registered
perfusion weighted images (PWI) from the CTP protocol. Four regions of interest (ROI)
were superimposed onto co-registered PS functional maps for extravasation positive
patients: areas of focal contrast extravasation on 1) location of CTA Spot Sign defect
and/or 2) location of PCL defect, 3) entire hematoma excluding both extravasation and
overlap with ventricles (IVH), and 4) mirror regions contralateral to extravasation regions
defined in (1) and (2), (Figure 6.1). For extravasation negative patients, ROIs were placed
on: 1) entire hematoma volume excluding overlap with ventricles, and 2) mirror regions
contralateral to region defined in (1) (Figure 6.2). ROIs were superimposed onto cerebral
blood flow (CBF), cerebral blood volume (CBV) and PS functional maps; pixels with
values of CBF >100 ml•min-1•(100g)-1 and CBV > 8 ml•(100g)-1 were excluded22.
Hematoma volumes at presentation and follow up study were calculated blinded to
extravasation status using Medical Image Processing, Analysis and Visualization (Center
for Information Technology, National Institutes of Health) Hematoma expansion was
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defined as an increased volume of > 6ml or 30%11, 23. Intraventricular hemorrhage (IVH)
was not considered in the definition of hematoma expansion.

6.2.4 Statistical Analysis
All analyses were performed with SPSS for windows (v. 16; SPSS Chicago, Ill), and all
data sets were checked for normality with the Shapiro-Wilk calculation to determine
whether a parametric or a non-parametric test should be used. The Wilcoxon rank-sum
test with bonferroni-correction was used to compare all PS values. Significance was
defined as p < 0.05. Average PS values were compared for: 1) Spot Sign defects only (9
foci), 2) PCL defects only (9 foci), 3) hematoma excluding extravasation, 4) regions
contralateral to extravasation, 5) hematoma in patients without extravasation and 6) an
area contralateral to (5). Unpaired t-tests were used to compare differences in age, time to
CTA, average arterial pressure, international normalized ratio, partial thrombosplatin
time, National institute of Health Stroke Scale Score and glucose score, respectively.
Using the Wilcoxon rank-sum test with bonferroni-correction, the average hematoma
volume at follow-up (24 hours) was compared with admission hematoma volume within
extravasation positive and negative groups, respectively.

6.3 RESULTS
Permeability surface area product (PS) data was acquired for 16 ICH patients (9 males
and 7 females). Their demographics are listed in Table 6.1. Of the 7 patients with
extravasation on the admission CTA and/or PCCT imaging, three patients had both Spot
Sign and PCL defects, three patients had only PCL defects, and one patient had only a
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Table 6.1 Demographics for extravasation positive and negative groups

Patients are dichotomized into contrast extravasation positive (n = 7) and negative (n = 9)
groups. MAP = average arterial pressure; INR = international normalized ratio; PTT =
partial thrombosplatin time; NIHSS = National institute of Health Stroke Scale Score.
Unpaired t-tests are used to compare the data.
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Spot Sign defect. Nine patients did not present with extravasation on CTA or PCCT. One
extravasation positive patient received rFVIIa as an off-label treatment. Average PS was
6.5 ± 1.60 ml•min-1•(100g)-1, 0.95 ± 0.39 ml•min-1•(100g)-1, 0.12 ± 0.39 ml•min-1•(100g)1

,0.26 ± 0.09 ml•min-1•(100g)- 1, 0.38 ± 0.26 ml•min-1•(100g)-1 and 0.09 ± 0.32 ml•min-

1

•(100g)-1 for 1) Spot Sign defects only (9 foci), 2) PCL defects only (9 foci), 3)

hematoma excluding extravasation, 4) regions contralateral to extravasation, 5) hematoma
in patients without extravasation and 6) an area contralateral to (5). PS values from Spot
Sign defects and PCL defects were significantly different from each other and all other
regions of interest (p < 0.05; Table 6.2). Average absolute or percent hematoma volume
increased from 34.1 ± 41.0 ml to 40.2 ± 46.1 ml or 27.8% in contrast extravasation
positive patients. In extravasation negative patients absolute or percent volume decreased
from 19.8 ± 31.8 ml to 17.4 ± 27.3 ml, or -1.5% (Table 6.3).
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Table 6.2 PS values for extravasation positive and negative patients

Permeability surface area product (PS) values (ml•min-1•(100g)-1 ) for patients with (n =
7) and without (n = 9) contrast extravasation. Sub-groups are based on region of interest
location. Wilcoxon rank-sum tests with bonferroni-correction were used to compare data.
*Denotes significantly different (p < 0.05) from all other sub-group mean PS values.
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Table 6.3 Hematoma expansion data for extravasation positive/negative patients

Patients are dichotomized into contrast extravasation positive (n = 7) and negative groups
(n = 9). Initial and final hematoma volumes were measured at admission and 24 hours,
respectively. Wilcoxon rank-sum tests, with a bonferroni-correction, were used to
compare initial and final hematoma volumes within both groups, respectively.
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6.4 DISCUSSION
Early CT contrast extravasation [CTA Spot Sign and post contrast-leakage (PCL)] is an
important predictor for ICH evolution10, 12, 14, 15. Size and density of contrast on admission
CTA reflect the rate of contrast accumulation and have recently been shown to be two of
three factors associated with hematoma expansion and patient outcome15. This study
utilizes CTP-derived PS measures to quantify the differential rates of contrast leakage in
contrast extravasation abnormalities observed on admission CTA or PCCT. A technique
such as CTP that quantifies contrast leakage rate may better define which patients with
extravasation are at highest risk for expansion. Hematoma volume expansion occurred
more frequently in patients with extravasation, who also tended to have worse clinical
outcome.
Although the pathophysiological significance of the CTA Spot Sign and PCCTPCL defect is uncertain, we have previously suggested that the former may represent the
primary causative abnormality, whereas the latter may represent secondary vessel injury
due to hematoma shearing24. Although PCL appears to be significant for hematoma
growth compared to patients with no extravasation, a recent study showed that 40% of
patients with only the PCL defect did not demonstrate hematoma expansion14. As such,
the clinical effect of PCL appears overshadowed by the presence of the CTA Spot Sign
where only 4% of Spot Sign positive patients did not undergo hematoma expansion13.
The rate of contrast extravasation is an important consideration when assessing
the sensitivity of modalities being used. Slower rates of contrast accumulation will be
more difficult to detect with early scan techniques if insufficient contrast density has
accumulated. Two recent studies reported higher rates of extravasation detection using a
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delayed CTA acquisition (median 113 seconds delay following initial CTA) or PCCT
(typically performed 3-5 minutes following contrast injection)14, 15. Herein, the detection
of 9 extravasation defects on PCCT, not present on early CTA, is consistent with these
accounts. Importantly, however, all PCL defects could be visualized as increased PS on
post processed CTP functional maps. By virtue of a dynamic acquisition lasting 2 minutes
after contrast injection, CTP appears more sensitive in assessing different contrast leakage
rates than either CTA or PCCT; however this remains to be confirmed in a larger clinical
study. CTP has the advantage of not requiring a pre-contrast decision between early and
late scanning. Further, the overall dose of CTP is similar to a NCCT and avoids
radiosensitive structures such as the thyroid and orbits.
Quantification of the rate of leakage provides a unique opportunity to objectively
study the effect of the rate of contrast extravasation on hematoma expansion for which the
CTA Spot Sign is currently a surrogate marker. The high PS values obtained in patients
with the CTA Spot Sign emphasize the rapid rate of contrast extravasation, reinforcing
the need for a rapid and efficient treatment. Herein, we calculated PS with the JohnsonWilson (J-W) distributed parameter model which accounts for: 1) the ‘gradual’ leakage of
contrast as it travels from the arterial input to the venous output and 2) the clearance
(backflux) of contrast from the interstitial space into the vascular space. Another tracer
kinetic model for the calculation of PS is the Patlak model which, unlike the J-W model,
uses compartments to represent the vascular and interstitial spaces25. Therefore, it is
required that both contrast arrival and leakage through the brain vasculature are
instantaneous, as opposed to gradual, finite transit. Thus, the Patlak model is not valid
under conditions when the arterial contrast concentration is changing rapidly, as seen
during the vascular (first) phase of our data acquisition. This is exemplified by the initial
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region of non-linearity observed in the Patlak plot, when the first pass data is included26.
Whereas the J-W model can be used to measure PS, CBV and CBF simultaneously, the
Patlak model provides estimates of PS and CBV but not CBF, which has to be estimated
separately by using another calculation/model25. The Patlak model also assumes that there
is no clearance (backflux) of contrast from the interstitial space into the vascular space.
As a result, PS measured with the J-W model, which accounts for backflux, will be higher
than that derived from the Patlak model.
Several limitations of this study need to be discussed. First, the case series is
limited by a small sample size. For practical reasons, patients were recruited by
supervising neuroradiologists during daytime admissions. Although difficult to achieve
given the relatively low incidence of ICH admissions and lower incidence of contrast
extravasation, these results will require validation from larger patient cohorts. The
influence of systemic and local features such as blood pressure, hematoma location, mass
effect and shift, respectively, on the rate of extravasation and hematoma growth is
currently unknown limiting the prediction of potential hematoma volume. Also, because
the CTA, PCCT and CTP imaging are separated by ~10-15 minutes, PS could
conceivably change between sequences. The effect of time to scan on presence of
extravasation is not yet fully understood. Patients with extravasation in this series
demonstrated a non- significant increased time to scan. Conceivably, increased duration
from ictus may result in greater opportunity for BBB disruption, re-bleeding and contrast
extravasation; however, a retrospective series evaluating a longer time to scan interval in
patients with ICH reported a non- significant trend to lower incidence for expansion
beyond 3 hours10. Similarly a prospective ICH study of 268 patients demonstrated no
difference in spot sign incidence within the first 3 hours (personal communication: Dr.
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Andrew Demchuck). Due to the concurrence of PCCT- PCL and CTA Spot Sign in some
patients, we were unable to compare hematoma expansion in patients possessing solely
PCL or Spot Sign; within the same hematoma, the interaction of different coexisting
patterns of extravasation is uncertain. Finally, PS may be underestimated in the presence
of higher BBB disruption where increased amounts of blood, with lower Hounsfield unit
than CT contrast, can leak into the extravascular space during the CTP acquisition.

6.5 CONCLUSION
In conclusion, the CTP-PS parameter measures different rates of CT contrast
extravasation for ICH patients with/without CTA-Spot Sign and/or PCL defects. This
information could be used to guide hemostatic treatment during the acute stroke stage.
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CHAPTER 7
Development and Implementation of a Rabbit Model of Middle
Cerebral Artery Embolic Occlusion: Pre-morbid Cerebrovascular
Conditioning with Dipyridamole

The contents of this chapter have been adapted from the paper entitled “Dipyridamole
treatment prior to stroke onset: examining post-stroke cerebral circulation and outcome in
rabbits”, published in Translational Stroke Research, 2011;2:186-194, by C.D. d’Esterre,
K.M. Tichauer, R.I. Aviv, L. Morrison, W. Eisert, T.Y.

7.1 INTRODUCTION
Clinical outcome following embolic stroke depends on a timely maintenance of the
ischemic penumbra through endogenous regulation and exogenous intervention. Primary
stroke treatment with intravenous tissue plasminogen activator is the most widespread
method of restoring blood flow to the ischemic defect; however, it is an aggressive
approach that can lead to undesirable complications, primarily hemorrhagic
transformation1. For this reason, there is much interest in uncovering novel methods for
cerebrovascular conditioning before stroke onset.
Clinical trials have suggested a combination of extended-release dipyridamole
(DIP) and low dose aspirin, both antithrombotic drugs which limit platelet activation, as a
cornerstone for reducing stroke incidence in high-risk patients2. In addition to its
antithrombotic ability, DIP offers many pleiotropic, neuroprotective properties and has a
lower propensity for bleeding when compared to aspirin3, 4. DIP conditioning may
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ameliorate the effects of stroke, if it were to occur; however, clinical observations are
conflicting regarding this issue5-7. Therefore a multi-modal experiment is warranted to
verify the possible neuroprotective benefit of pre-stroke DIP administration.
Pre-clinical animal models of focal ischemia are imperative to evaluate vascular
changes and outcome throughout the acute ischemic stroke (AIS) setting. Animal models
have notable advantages over clinical studies: 1) in animals, final infarct volume from
brain tissue staining can be delineated minutes after euthanasia, limiting infarct expansion
into penumbral tissue, as opposed to imaging based final infarct delineation in humans; 2)
when assessing drug efficacy in humans, inconsistent dosing and different baseline
characteristics (ie. other medications and underlying vascular pathologies) can skew
clinical results8. In comparison, controlled drug administration and baseline homogeneity
can be achieved non-clinically; 3) Serial imaging is feasible with animal models, as
radiation dose and/or potential toxicity from contrast is not an issue.
Large vessel mechanical- or filament-induced occlusions, thrombotic infusion and
endothelin-1 induced vasoconstriction have been used successfully to create focal
ischemic territories; however, these techniques do not completely simulate human AIS
pathophysiology, posing a problem when establishing neuroprotective treatment
efficacies. Thus, an AIS induction method which involves embolic occlusion of a large
vessel, usually the middle cerebral artery (MCA), by an autologous blood clot is an
appropriate model to investigate the pathophysiology related to thromboembolism. The
most common thromboembolic MCA occlusion technique, first described in canines,
involves injection of a fibrin rich autologous blood clot into the internal carotid artery
(ICA) via a ligated external carotid artery (ECA) in rats9, 10. This technique has since been
applied to rabbits who, unlike rats, have a complete Circle of Willis with anterior and
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middle cerebral arteries arising from the ICA, similar to that in humans11. The rabbit
embolic large/small clot stroke models were first developed to investigate the effects of
anticoagulants on cerebral perfusion and intracerebral hemorrhage12. Since then, these
model have been used reliably to examine the efficacy of several AIS treatment
strategies, including one of the first studies to show benefits of tissue plasminogen
activator (tPA) administration13-16. The models produce a homogeneous stroke, and clot
placement is easily confirmed with hemodynamic measurements from computed
tomography perfusion (CTP) or magnetic resonance imaging (MRI). Nonetheless, the
ligation of the ECA and its branches may cause damage to muscles involved in
mastication, causing accelerated weight loss and misinterpretation of neurological
outcome17.
The purpose of this work was to 1) develop an improved, reproducible rabbit large
clot embolic model (RLCEM) of focal cerebral ischemia, assessed with the CT perfusion
(CTP) imaging modality, while maintaining adequate perfusion to extra-cranial
structures, and 2) implement this modified RLCEM to examine the effect a common
secondary stroke anti-thrombotic treatment, dipyridamole, on stroke severity.
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7.2 MATERIALS & METHODS
7.2.1 Surgical procedures
Study procedures were approved by our institutional review board+. Twenty male New Zealand
white rabbits (2.7-3.6 kg) were randomized to either DIP treatment (n=10) or saline treatment
(n=10). Seven days before stroke onset anesthesia was induced with 5% isoflurane, with
subsequent ‘pedal reflex’ to test for deep pain response. Close monitoring of CO2 levels and
‘pedal reflex’ response throughout the entire experiment ensured the animal was properly
anesthetized. A cannula was inserted into a saphenous vein, and a single bolus of
ketamine/diazepam (3mg/kg, 0.3mg/kg) was administered to maintain anaesthesia during
intubation. Subsequently the rabbit was ventilated with 4% isoflurane. The right jugular vein
was exposed, tied off and catheterized at 2cm proximal to the heart. The opposite end of the
catheter was fed subcutaneously to a battery-powered infusion pump (Med-e-cell, Sandiego,
CA), fixed behind the head. Pumps were filled with either 5mg/ml pharmaceutical grade DIP
(Pharmaceutical Partners Canada, Richmond Hill, ON) or 9mg/ml sterile saline. The infusion
was continued for 7 days at 0.08ml•h-1. At 4 and 7 days after insertion of the infusion pump,
blood was collected from an ear-artery to determine the plasma concentration of DIP
spectrofluorometrically (F-7000, Hitachi High Technologies America, Inc., Santa Clara, CA).
Samples were excited with light at a wavelength of 420 nm and fluorescence spectra were
recorded in the range of wavelengths from 430-660 nm and compared to standard calibration
solutions. The calibration solution was made by dissolving 1 mg of DP into 20 ml of alcohol
with subsequent dilution to 100 ml with water18. Sodium hydroxide solution was added as
__________________________________
+

Appendix H – Animal Ethics Approval Form
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necessary to achieve a physiological pH (Microprocessor pH meter, Hanna Instruments, Ann
Arbour, MI).
On the last day of treatment, the left internal carotid artery (ICA) was exposed under
5% isoflurane and tied off at the common carotid bifurcation. An 18 gauge catheter was
advanced 1.5cm into the ICA, at which time a baseline CTP scan was acquired under 3%
isoflurane. Autologous arterial blood was used to fill 3 thrombin-coated capillary tubes
(Thrombostat; Sigma-Aldrich, St Louis, Mo). A 3 mm autologous arterial blood clot was then
injected into the left ICA with 2.5ml of saline

11

. The catheter was removed and ICA was

repaired with 8-0 suture. Microvascular clips were removed and reperfusion was observed in
within ICA, ECA and common carotid arteries (Figure 7.1).
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Figure 7.1 Methodology for blood clot induction with extracranial perfusion
preservation

Gross anatomy (A) and diagram of left common carotid artery (CCA), external carotid
artery (ECA), and internal carotid artery (ICA). (B) An 18-gauge catheter was placed into
the ICA via an incision in the CCA, for injection of an autologous blood clot into the
middle cerebral artery (MCA). After injection, the catheter was removed and the incision
was repaired to allow reperfusion of the CCA, ECA and ICA. A small stenosis (black
arrow) is observed on the contrast enhanced CT angiography 3D rendered image in (C),
which confirmed reperfusion of these major arteries. Coronal slices of perfusion weighted
image (D) describing anatomical regions, with corresponding CBF (E), and CBV (F)
functional maps. An ischemic defect (red arrow) with hypervolemia (yellow arrow), a
CBF/CBV mismatch, is present within the left hemisphere, while complete reperfusion of
extracranial vessels is observed. CTP images are coloured according to a rainbow colour
scale with red and purple representing high and low values, respectively: CBF, 0-180
ml·min-1·(100g)-1; CBV, 0-10 ml·(100g)-1.
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Additional CTP scans were acquired at 10 and 30 minutes after embolization under 3%
isoflurane. Animals were then recovered with fentanyl (12.5 mcg patch) and buprenorphine
(0.1ml/kg) and monitored until stable. CTP scans under 3% isoflurane were repeated at 1, 4, 7,
14, 21, and 28 days post-embolization if possible (some animals were sacrificed prior to the
end day due to severe neurological deficits). Neurological testing was done on each scanning
day blinded to the treatment of the animal

19

. During CTP scanning, rectal temperature was

maintained between 37ºC and 39ºC and arterial blood pH, partial pressures of O2 and CO2, and
mean arterial pressure were monitored. Animals were euthanized with potassium chloride
injection either on day 28 post or when the animal was assessed a neurological score greater
than 15 (see Neurological Testing section)19. Following sacrifice, the brain was removed to
locate the embolus, and sectioned for histology.

7.2.2 CT perfusion imaging
Each CTP scan was performed with a Lightspeed Plus 4 section CT scanner (GE
Healthcare, Waukesha, WI). A preliminary axial CT scan was used to localize four 5 mmthick slices in the supply territories of the middle cerebral arteries11. Next, a 5ml bolus of
300mg·ml-1 non-ionic, iodinated contrast (Omnipaque, GE Healthcare, Mississauga,
Ontario) was injected into a saphenous vein at 0.5 ml•s-1. The head was continuously
scanned for 50 seconds using 80kVp, 80mA and 1s rotation period. From the acquired
data, 512 x 512 images were reconstructed at 0.5 second intervals.
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7.2.3 CTP data analysis
Each CTP study was analyzed by one author for consistency using commercially
available CT perfusion software (version 4, GE Healthcare, Milwaukee, Wis; Figure 7.2).
For each CTP imaging data set, time density curves (TDC) for the arterial input function
(AIF) and venous output functions (VOF) were obtained from the anterior cerebral artery
and superior sagittal sinus, respectively. Partial volume averaging of the AIF was
corrected using the VOF-TDC. Perfusion weighted maps were created by averaging the
cine CT perfusion images over the duration of the first pass of contrast. Parametric maps
of cerebral blood flow (CBF; ml·min-1· 100g-1) and cerebral blood volume (CBV;
ml·100g-1) were calculated by deconvolution of tissue TDCs and the AIF. This
hemodynamic functional map calculation method has been described previously

20

.

Functional maps were further analysed by custom software developed in our lab using
IDL v6.2 (ITT Visual Information Solutions, Boulder, CO). For each slice, regions of
interest (ROIs) were manually traced around the ipsilateral and contralateral hemispheres
using the perfusion weighted functional map, and superimposed onto hemodynamic
maps. For each ROI, mean CBF and CBV were also determined within the ipsilateral and
contralateral hemispheres following exclusion of pixels with a CBF > 100 ml·min1

·(100g)-1 or CBV > 8 ml·(100g)-1 - a technique used to eliminate large vessel

hemodynamic values, focusing on parenchymal perfusion21.
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Figure 7.2 A typical CT perfusion study and corresponding excised brain slices.

Four contiguous, coronal CTP-derived functional maps acquired 30 minutes post stroke
for a saline-treated animal. Infarct region (white) on TTC stained excised brain slices,
analysed at 7 days post stroke, corresponds to the initial ischemic defect shown on the
CBF [ml·min-1·(100g-1)] and CBV [ml·(100g-1)] maps. Within tissue that is destined to
infarct, CBV in various regions is still within the normal physiological range. CTP
images are coloured according to a rainbow colour scale with red and blue representing
high and low values, respectively: CBF, 0-180 ml·min-1·(100g-1); CBV, 0-10 ml·(100g-1)
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7.2.4 Neurological testing
One blinded individual performed all neurological assessments. Spontaneous behaviour,
reaction to handling, posture, gait, limb hypertonia, righting reflexes, limb reflexes, and
feeding behaviour were scored separately: 0, normal; 1, mild; 2, moderate; and 3,
severely impaired, and all scores summed, and averaged for each group19.

7.2.5 Post-mortem analysis
Brain tissue from up to one week post stroke onset was analysed histopathologically
(Figure 7.3). Minutes after brain excision, brain tissue was cut into coronal sections
corresponding to the CT scan slice locations and stained with 2,3,5-tetrazolium chloride
(TTC) to quantify the extent of infarcted tissue – the entire brain was used for this
quantification. Additionally, presence, location, and length of emboli were noted. Brain
tissue was fixed in 10% buffered paraformaldehyde solution for 24 hours, then stored in
Dulbecco’s phosphate buffered saline (1X) for future histolopathological staining.
Regions of interest from three tissue types were selected from: i) within the TTC-defined
infarct, ii) 1.5 mm from the TTC-defined infarct volume (peri-infarct penumbral region),
and iii) normal tissue contralateral to the infarct. These tissue fragments were embedded
in paraffin, cut into 5μm thick sections and stained (H&E) to quantify hemorrhage; to
determine the extent of peri-infarct inflammation with leukocyte quantification; and to
quantify the extent of peri-infarct apoptosis with caspase-3 staining. All quantification
was performed by a single individual in a blinded manner. To quantify hemorrhage, each
section was analysed at a magnification of 100x for the number of visible areas of
extravascular red blood cells. One and two points were given for each localized and
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confluent area, respectively, to a maximum of 10 (most severe). Scored sections were
averaged and used to give an average hemorrhage score for each group. Apoptosis
quantification was done using an apoptotic index (AI). Sections at 400x magnification
were used to create digital images, on which apoptotic cells were manually counted, using
point counting. The AI was calculated, using the entire field of view, as: the total number
of apoptotic cells / the total number of nuclei. To quantify inflammation, 3 random 2mm2
areas were chosen for each tissue type, from each section. Each area was given a score
based on the following criteria: 0 = minimal leukocyte infiltration, 1 = mild, 2 =
moderate, and 3 = severe. An average leukocyte infiltration score was calculated from all
sections for each group.
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Figure 7.3 Examples of histology

1

2

3

4
i

ii

iii

Histopathological staining of healthy tissue (A-C), and infarcted tissue from DIP- (D-F)
and saline-treated (G-I) animals. Column 1, 2, and 3 show hemorrhage (100x
magnification), leukocyte infiltration (200x magnification), and caspase-3 staining (400x
magnification), respectively. Column 4 shows excised brain slices for i) normal brain (no
stroke), ii) saline- and iii) DIP-treated animals.
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7.2.6 Statistical Analysis
The statistical package, SPSS 15.0 (SPSS Inc., Chicago, IL), was used for all analyses.
Differences were considered significant at p < 0.05. Repeated measures analysis of
variance was used as an omnibus test to identify significant differences between the DIPand saline- treated groups for all physiological parameters, data collected from CTP
imaging, and neurological scoring. Differences in mortality were analysed using Fisher
exact test. Mann-Whitney, non-parametric comparison was used to analyse all
histopathological data. Linear regression was used to determine the relationship between
CTP-defined ischemic defects at time of sacrifice and excised brain infarct volumes for
each animal.

7.3 RESULTS
Twelve of the twenty animals studied were included in the results (6 DIP, 6 saline;
average weight: 3.1 ± 0.3 kg). Animals were excluded from the study if there were
problems in the embolization procedure, or if blood plasma DIP concentrations were not
therapeutic (< 1 µg/ml plasma)22. No differences were observed between the
physiological parameters of the treated and non-treated groups on any scan day. At 10
minutes post-embolization, mean arterial pressure (MAP) in both groups increased
significantly from their respective baseline values (p < 0.05); for the remainder of the
experiment, average MAP of both groups returned to baseline levels. At 28 days post
embolization, 66% of the DIP-treated animals survived compared to 0% of the salinetreated. All saline-treated animals had to be sacrificed on or before day 7 post-
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embolization due to severe neurological deficit. The survival times between the groups
were significantly different (p < 0.05).
Figure 7.4 compares mean neurological scores collected from DIP- and salinetreated animals before each CTP scan. On days 4 and 7, the average neurological score of
the DIP group was significantly lower than the saline-treated (p < 0.05). On days 14, 21,
and 28, the average neurological score of the DIP-treated group dropped to below 5 and
was significantly less than one day post stroke (p < 0.05).
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Figure 7.4 Neurological Scoring

Mean neurological scores (mean+SD) for dipyridamole- and saline-treated groups.
Significant differences were observed between groups on days 4 and 7 (*p < 0.05).
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Cerebral emboli were found in 3 of 6 DIP-treated animals and 4 of 6 saline-treated
animals. Average length of emboli in DIP and saline treated groups were 1.6 ± 0.5 and
2.3 ± 0.2 mm, respectively. The average percent volumes of infarcted tissue in the
hemisphere ipsilateral to the stroke were 31 ± 7% and 69 ± 10% for the DIP- and salinetreated groups, respectively (p < 0.05).
Average baseline CBF values for both DIP- and saline-treated groups were 72.9 ±
3.6 and 74.32 ± 4.9 ml·min-1·(100g)-1; these were within the normal CBF physiological
range of 45-75 ml·min-1·(100g)-1, and similar to values previously reported in our group
23, 24

. A significant decrease in average CBF was found at 10 and 30 minutes for both

DIP- and saline-treated animals compared to their respective baseline values (p < 0.05).
Comparing DIP- and saline-treated animals, average CBF was significantly different on
days 1 and 4 (p < 0.05). For the DIP-treated group, values on days 4 to 28 were
significantly higher than values at 10 and 30 minutes post embolus induction (p < 0.05).
Contralateral hemisphere CBF, averaged over the entire study, for DIP- and saline-treated
groups was 67 ± 5.2 and 69 ± 4.1 ml·min-1·(100g)-1 (p > 0.05). There were no significant
differences in average CBV within the ipsilateral hemisphere within or between groups
throughout the study (p > 0.05). For both groups, CBV was slightly elevated at 10 and 30
minutes post stroke. The mean CBV for DIP- and saline-treated, averaged over the entire
study was 2.5 ± 0.2 and 2.4 ± 0.2 ml·100g-1 within ipsilateral hemisphere, and 2.4 ± 0.7
and 2.3 ± 0.4 ml·100g-1 in the contralateral hemisphere, respectively. These values were
slightly higher than CBV values previously obtained from our group using a microsphere
technique25.
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Figure 7.5 CTP-defined ischemia versus TTC-defined infarction
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Figure 7.6 Ipsilateral CBF and CBV values
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(A) Ipsilateral hemisphere mean CBF (ml·min-1·100g-1). Significant differences (p <
0.05) were found at 10 and 30 minutes for both DIP treated (#) and saline treated (%)
animals compared to their respective baseline values. Significant differences (p < 0.05)
occurred between DIP- and saline-treated animals on days 1 and 4 (*). For the DIP-treated
group, values on days 4 to 28 were significantly higher (p < 0.05) than values at 10 and
30 minutes post embolus (ε). (B) Ipsilateral hemisphere mean CBV [ml·(100g)-1]. No
significant differences were observed within or between time points for both groups (p >
0.05). CBV was slightly elevated at 10 and 30 minutes post stroke. All values are mean ±
standard deviation.
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Figure 7.7 depicts the hemorrhage scores and apoptotic indices for infarct, periinfarct and contralateral hemisphere brain tissue. Hemorrhagic infarction was 5 fold
greater in saline-treated animals (p < 0.05). For both groups, hemorrhage was minimal in
peri-infarct and contralateral tissue regions. For both groups, apoptosis was significantly
higher in peri-infarct tissue, compared to infarct and contralateral regions (p < 0.05).
Within peri-infarct tissue, apoptosis was elevated in saline-treated animals (p < 0.05).
Comparing DIP- and saline-treated groups, respectively, inflammatory scores
(median [range]) for infarct, peri-infarct and contralateral tissue were: 2[1-3] and 2[2-3];
2[1-2] and 2[1-2]; 0[0-1] and 0[0-1]. Inflammation was significantly lower in
contralateral tissue for both groups (p < 0.05). Inflammation, within infarct and periinfarct regions, was not significantly different within or between groups.
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Figure 7.7 Hemorrhage and apoptosis indices

Hemorrhage scores and apoptotic indices for infarct, peri-infarct and contralateral
hemisphere brain tissue for DIP- and saline treated animals. Hemorrhagic infarction was
fivefold greater (p < 0.05) in saline-treated animals (asterisk). For both groups, apoptosis
was significantly higher (p < 0.05) in peri-infarct tissue (number sign). Within the periinfarct tissue, apoptosis was elevated (p < 0.05) in saline-treated animals (%). All values
are mean + standard deviation
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7.4 DISCUSSION
This study investigated how dipyridamole (DIP), an antithrombotic drug with antiplatelet
(AP) properties, improves cerebral circulation and long-term outcome in a modified
rabbit embolic stroke model. The model is an improvement on the RLCEM, allowing
reperfusion to the extracranial vasculature. Cerebral hemodynamics were investigated
using serial CTP imaging, neurological deficit was determined by repeated neurological
testing, and excised brains were analysed with histopathological staining. Animals fared
better when treated with a therapeutic dose of DIP before stroke onset: on average, they
scored better neurologically, had more favourable cerebral hemodynamics 1 day after
embolization, and smaller infarct volume as defined on TTC stained excised brains.
Additionally, the DIP-treated group had lower incidence of hemorrhage, and were more
likely to recanalize.
Activated platelets in the brain play a central role in accelerating the formation of
thrombi, instigating progressive tissue injury 26. AP agents are routinely used as a strokeprevention strategy for at-risk populations, especially post transient ischemic attack (TIA)
27

. Even with AP therapy, 4–20% of patients with TIA will have a stroke within 90 days

of the episode, half of those occurring within the first 48 hours 28. As such, exploring the
potential of AP agents to minimize stroke severity is necessary. DIP has been shown to
have numerous benefits, which could aid with vascular maintenance/recovery during an
ischemic episode

29

. DIP attenuates platelet aggregability through several mechanisms.

DIP inhibits thromboxane synthase, limiting the conversion of prostaglandin to
thromboxane, an inducer of platelet aggregation and vasoconstrictor30,

31

.

Also, by

limiting adenosine uptake into platelets, DIP initiates the buildup of intraplatelet cyclic
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adenosine monophosphate (cAMP), blocking the platelet response to ADP

22

. Adenosine

has also been shown to promote nitric oxide (NO) production by vascular endothelial
cells 32. NO is a potent vasodilator and inhibitor of platelet activation in its own right

33

.

The overall reduction in activated platelets limits both platelet/fibrinogen bridging and
platelet plugging. These mechanisms may help conserve collateral flow to the ischemic
tissue periphery, limiting infarct expansion into the penumbra. In this study, average
ipsilateral CBF in the DIP-treated group returned to pre-stroke levels 24 hours post
embolus induction. This hemodynamic recovery could be attributed to platelet effects, but
may also result from an increase in circulating plasmin - DIP has been shown to promote
plasminogen activator release by endothelial cells, which would encourage fibrinolysis of
the induced blood clot34. On that note, DIP-treated animals had a relative reduction in clot
size within excised brains compared to the saline-treated counterparts. Still, it is not
known whether portions of the clot broke off to create downstream microemboli, or the
fibrin mesh was disentangled by way of plasmin interaction.
Interestingly, an increased propensity to hemorrhage, which may be expected with
the use of antithrombotic therapy, was not observed in the DIP-treated animals. This
result is supported by the European Stroke Prevention Study (ESPS-2), which showed no
increases in bleeding with the addition of DIP to aspirin treatment compared to aspirin
alone2. In fact, we showed minimal hemorrhagic infarction in DIP-treated animals.
Although not measured in this study, DIP can decrease the expression of matrixmetalloproteinase-9 (MMP-9), an enzyme implicated in blood brain barrier (BBB)
breakdown and inflammation35. An increase in reactive oxygen species, especially during
ischemia, is also a major culprit of BBB dysfunction; when ROS concentrations get too
high, apoptosis is triggered36, 37. DIP can potentially minimize neuronal damage caused
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by reactive oxygen species (ROS) through prevention of membrane lipid peroxidation,
and by stimulating the vessel wall’s ROS scavenging capability38, 39. As such, the DIP
ROS scavenging ability could decrease ROS-induced apoptosis throughout the ischemic
defect. DIP-treated animals had slightly lower concentrations of cells undergoing
apoptosis within the peri-infarct regions. Overall, the neuroprotective benefits offered by
DIP could have important implications for BBB stability and the prevention of
hemorrhagic transformation, edema and cell death.
Innate inflammation, beginning at stroke onset, can exacerbate the ischemic defect
through the interaction of platelets, leukocytes and thrombotic moderators

26

. Initial

neutrophil infiltration can obstruct microvascular blood flow via capillary plugging, as
well as increase vascular permeabililty 40, 41. Additionally, ROS and cytokine release from
neutrophils can cause extravascular parenchymal damage42. An increase in adenosine
levels have been shown to inhibit neutrophil activation by reducing the expression of
neutrophil adhesion molecules43. Although DIP causes intravascular increases in
adenosine, as described herein, we did not observe a difference in leukocyte infiltration
between DIP- and saline-treated animals. Given that DIP was administered only prior to
stroke onset, we can speculate that DIP blood concentrations, around the time of
euthanasia, were too low to cause inter-group differences in adenosine concentrations,
and subsequent reductions in neutrophil deactivation.
There are study limitations which warrant discussion. First, it was difficult to
obtain accurate cerebral blood volume (CBV) measurements since isoflurane, a potent
vasodilator, was used as the anaesthetic during all CT perfusion scanning44. For both
groups, a slight increase in mean CBV at 30 minutes post stroke was observed; this could
be related to the autoregulatory vasodilation phenomenon that occurs during the hyper-
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acute stroke phase, causing a mismatch between CBF and CBV in the ischemic tissue11.
Nonetheless, we did not observe CBV differences within or between groups. Second,
neurological assessment may have been skewed due to variations in the extent of surgical
trauma between animals – internal carotid anatomical variability contributed to increased
surgery time. Third, our sample size was small relative to other studies using rodents;
however, our serial in-vivo imaging procedures and neurological testing allowed
comparisons in the same animal to be made over many days of survival eliminating the
need to use a larger number of animals to achieve the same statistical power. Lastly, it
was uncertain whether the emboli found within excised brains were originally injected or
endogenously produced. Even so, this model examines the animal’s ability to deal with
the injected embolus and its associated pathological manifestations (ie. microemboli,
inflammation).

7.5 CONCLUSION
Dipyridamole is given to patients at increased risk of stroke as it decreases the incidence
of cerebroembolism. Presumably, if stroke was to occur, the pathways involved in
secondary stroke prevention may be neuroprotective during an ischemic episode. We
used a novel animal stroke model to demonstrate that pre-morbid treatment with
therapeutic concentrations of DIP provides a neurovascular advantage post stroke onset.
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CHAPTER 8
Conclusion and Future Work

8.1 SUMMARY
The introduction of this thesis describes the importance of early treatment strategies to
promote tissue salvage and maintain neuronal function in the two most common stroke
sub-types, cerebral ischemia and intra-cerebral hemorrhage (ICH). As discussed in detail
in the previous chapters, the objective of this thesis was to help with the selection of
patients who will benefit from acute stroke treatment (thrombolytics, antihypertensive/coagulation drugs, surgical techniques), as well as determine if pre-stroke
neuroprotection can reduce stroke severity. Specifically, CTP thresholds of hemodynamic
parameters including CBF, CBV and PS for cerebral tissue and BBB status, as well as the
neuroprotective benefit of a common secondary ischemic stroke preventative drug,
dipyridamole, were explored. Patients with thromboembolic cerebral ischemia and
primary ICH were studied, along with the development and implementation of two
unique animal models of ischemic stroke.
In this final chapter, I will review the major findings of my research and discuss
the implications of the six studies. The discussion will encompass experimental and
clinical relevance of the methods and results, as well as important areas that require
further investigation. Although we were successful in demonstrating the ability of CTP
imaging to verify drug efficacy and monitor stroke progression, considerable work is still
required before the goal of an individualized stroke treatment is realized. Therefore, an
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outline of the possible investigations that should follow this work will be included.
Finally, the major conclusions obtained from this work will be summarized.

8.1.1 Prediction of acute tissue viability for ischemic stroke
Although much research has gone into the management of acute ischemic stroke (AIS),
treatment remains limited to revascularization with either intravenous tPA or
endovascular strategies (including intra-arterial tPA). The use of either treatment depends
on time since stroke onset, the amount of brain tissue involved, location and size of the
blood clot, and robust collateral circulation. In general, small and more distal clots which
are not amenable to mechanical removal, and present less than 4.5 hours from symptom
onset, are treated with intravenous tPA, while larger and more proximal clots are treated
up to 8 hours with endovascular techniques. For revascularization to proceed, whether the
benefit of tissue salvage outweighs the risk of reperfusion injury, particularly
intracerebral hemorrhage (ICH), is an important consideration. To address this concern,
we need to know if the infarct is too large such that benefits from tissue salvage may be
too small in light of possible hemorrhagic transformation, worsening clinical outcome.
Chapters 2, 3 and 4 address the importance of predicting infarct volume during the AIS
setting. Using both human and animal studies, we determined that the acute CBF/CBV
mismatch may, at times, represent tissue that is not salvageable, even upon reperfusion.
This goes against the central dogma which asserts that autoregulatory maintenance, as
observed by the increase in CBV, represents electrically silent yet viable tissue.
Subsequently, we showed that the CBF parameter was optimal for predicting final
infarction in a retrospective analysis, and also best delineated the hyper-acute infarct core,
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as defined by MR-diffusion weighted imaging and TTC-histology, in a novel porcine
model of ischemic stroke.

8.1.2 Role of the CTP-PS parameter in acute stroke
The CTP-blood brain barrier permeability surface area product (BBB-PS), which
quantifies the leakage rate of CT contrast dye from the intra- to extra-vascular space, has
the ability to predict clinical and radiological outcome for patients with intracerebral
hemorrhage (ICH) secondary to cerebral ischemia and for patients with primary ICH.
In the risk versus benefit assessment of revascularization in patients with ischemic
stroke, it is important to recognize that some patients with small infarct volumes may still
proceed to symptomatic hemorrhagic transformation. On the contrary, patients arriving
past the thrombolysis treatment window who still have salvageable tissue, irrespective of
infarct core size, may also be a candidate for tPA. Therefore, assessment of the acute
infarct core volume, penumbra volume and integrity of the BBB within infarct, penumbra
and contralateral normal tissue are necessary in the decision of revascularization. In
patients with secondary ICH from prolonged ischemia with or without reperfusion,
admission BBB-PS was higher within the ischemic and contralateral regions compared to
patients without hemorrhage at follow-up. The patients with secondary hemorrhage had a
significantly higher PS than did those without hemorrhage. A PS threshold of 0.23 ml 1

•min-1•(100g)-1 also enabled the differentiation of patients with HT from those without.
For patients with primary ICH, admission BBB-PS was the highest in patients

withthe CT angiography (CTA)-Spot Sign compared to those with Post-contrast CT
Leakage (PCL) and those without CT contrast extravasation. Moreover, increased BBB-
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PS was correlated with hematoma expansion. Measuring the rate of leakage provides a
quantitative method to study the degree of BBB derangement on hematoma expansion.
The high PS values obtained in patients with the CTA Spot Sign emphasize the rapid rate
of contrast extravasation, reinforcing the need for a rapid and efficient treatment in this
subgroup of patients.
These two acute stroke studies were the first to use quantitative CTP-BBB PS
parameter to predict clinical and radiological outcome in patients with primary and
secondary ICH. Using the admission BBB-PS parameter can inform treatment decisions
for both of these stroke sub-types.

8.1.3 Reducing stroke severity with secondary prevention drugs
Antiplatelet (AP) drugs are universally recognized for their effectiveness in reducing
recurrent stroke in high risk patients1, 2. If stroke does occur, extending the tPA
therapeutic window and minimizing long term morbidity may be an additional benefit of
this treatment. Dipyridamole (DIP) is prescribed clinically in extended-release form as a
secondary stroke treatment, and is primarily recognized as an antithrombotic agent with
AP properties3. DIP offers both platelet and non-platelet neuroprotective benefits and,
unlike aspirin, has a lower propensity for bleeding4. Using a novel rabbit large clot
embolic model (RLCEM), we found that administration of therapeutic concentrations of
DIP improved ipsilateral CBF at 24 hours after stroke induction. The RLCEM mimics the
clinical situation in which a patient would take DIP as a secondary treatment and still
suffer a stroke thereafter. The antithrombotic action of dipyridamole seems to be
mediated by two complementary mechanisms: i) an anti-platelet action, which reduces
thrombi formation, and ii) induced tPA release by endothelial cells, which breaks down
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established thrombi through plasmin activation, and subsequent fibrinolysis. As such, DIP
has implications for both primary and secondary stroke prevention.
Anti-platelet drugs are now emerging as potential treatments of the inflammatory
response of ischemic stroke. Adenosine level increases, initiated by DIP, have been
shown to inhibit neutrophil activation via reduction in expression of neutrophil adhesion
molecules5. There was an increase in H&E stained neutrophils throughout the ipsilateral
cerebral parenchyma of non-treated animals out to 7 days – DIP treated animals had
minimal neutrophil staining at that time. Neutrophils are generally associated with acute
inflammation; therefore their presence during the sub-acute stroke stage would suggest
acute inflammatory processes are continuing to occur and that DIP may reduce the
inflammatory processes initiated by neutrophils during the sub-acute stroke stages.
Dipyridamole (DIP) is given to patients at increased risk of stroke as it
decreases the incidence of cerebroembolism. Presumably, if stroke was to occur, the
neuroprotective pathways involved in secondary stroke prevention may be of benefit
during an ischemic episode. These neuroprotective pathways are linked to suppression of
inflammatory processes, which have direct and indirect effects on thrombus formation
and vascular endothelium. As such, acute stroke interventions should implement antiinflammatory mediators, which include anti-platelet drugs, into practice.

8.2 EXPERIMENTAL & CLINICAL RELEVANCE
The studies described in this thesis contribute important information for the advancement
of acute stroke diagnosis and treatment. The animal studies described in Chapters 4 and 7
employed two clinically relevant models of acute ischemic stroke that reproduces a
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number of important features of the human disease. These models allowed us to monitor
infarct expansion by making consecutive CTP measurements over the first few hours
following stroke; this information is not readily obtained in the clinical setting.
One of the current problems in acute ischemic stroke care is that the number of
patients that receive treatment remains very low. Thrombolysis and mechanical clot
removal are the only two treatments approved for clinical use. Treatment using
mechanical retrieval is very limited; thrombolysis is more widely available, but it is
restricted to a small percentage of patients. One of the major limiting factors for
reperfusion therapy is the narrow 4.5 to 8 hour time window that is mandated for
thrombolysis and mechanical clot removal, respectively. The use of the admission
NCCT/CTA can help clinicians make thrombolytic treatment decisions by providing
evidence of early ischemic changes and vessel occlusion status; however, without
perfusion data, information on the severity of hypoperfusion is lacking, a critical factor
when deciding to reperfuse - the rate of neuronal death differs for tissue with a CBF of 5
ml·min-1·100g-1 versus 12 ml·min-1·100g-1 between 1-3 hours; although both CBF values
will ultimately cause infarction sub-acutely. Moreover, we can observe an unremarkable
admission NCCT for a patient with infarct core perfusion values because hypoperfusion
has not been established long enough. Therefore, to improve the thrombolytic selection
criteria, it is important to include only those patients with a substantial volume of
penumbra to salvage, for which accurate infarct core delineation is critical. This approach
could be implemented using CTP imaging and applying the thresholds derived from this
thesis.
A number of important criteria must be satisfied if a technique for improving
patient selection will gain widespread clinical use. Among the most important
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requirements are: wide availability, minimal cost, rapid and accurate assessment of
penumbra and infarcted tissue. As we have shown in this thesis, CTP imaging is one
potential candidate that satisfies most of these requirements. CT scanners are widely
available around the clock in most hospitals and relatively inexpensive compared with
other imaging techniques. CTP imaging requires less than three minutes of scan time and
the functional maps can be calculated within 5-7 minutes.
Another important aspect of the work contained within this thesis was the
identification of specific thresholds for grey and white matter. Given the different
metabolic needs, specific thresholds for each tissue type have the ability to improve
classification of penumbra and infarct. Implications of these tissue-specific thresholds
extend beyond patient selection for revascularization procedures and may be important in
future studies of neuroprotection.

8.3 FUTURE WORK
This thesis addresses many important questions concerning the diagnosis, prognosis, and
treatment of acute stroke. However, as is customary in research, for every question
answered there are a number of new questions raised. The following section will outline
potential new directions of research.

8.3.1 Improved calculation of CTP functional maps
To improve the image quality of the functional maps, we will use a newer iterative CT
image reconstruction technique and advanced image processing techniques including: 1)
masked smoothing, where smoothing is guided by a tissue mask derived from the average
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image of the source CTP images and 2) principal component analysis where the main
features (components) of all time-density curves from the raw CTP images are extracted
using a statistical procedure and then individual pixel time-density curves are smoothed
by reconstituting them with these main components that are not dominated by noise6.
These improvements in processing will be applied to the future studies described below.

8.3.2 Multi-variate prospective study to determine secondary ICH
To further improve the selection of patients for thrombolytic therapy, a predictive model
based on the acute infarct volume and BBB-permeability will be established using the
CTP thresholds obtained in this thesis. Further, we will investigate whether a second
(higher) BBB-PS threshold would predict symptomatic versus non-symptomatic
hemorrhage – it is speculated that less severe forms of hemorrhage may not be clinical
relevant and represent different pathogenesis7.

8.3.3 Minor stroke and transient ischemic attack
Patients with transient ischemic attack (TIA) and minor strokes are often excluded from
revascularization treatment because their neurological deficits are transient or mild;
however, these patients can often have subsequent stroke8. TIA confers a 10% risk of
stroke within 30 days, one half of these occurring within 48 hours; a proportion of these
sub-acute episodes are simply due to worsening of initial minor stroke9. Further, long
term disability has been shown to occur in patients with mild symptoms at presentation
and without recurrent events8. In these patients, cerebral perfusion pressure (CPP) may
have fallen to a level that needs to be corrected promptly to prevent an impending stroke.
Knowledge of CPP, along with basic clinical parameters, may be used to guide treatment
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and predict clinical outcome. CPP is inversely related to the tissue mean transit time
(MTT) which measures the time required for blood/contrast to traverse the tissue
vasculature under prevailing CPP. A related parameter to MTT is Tmax which is the sum
of MTT and the time blood requires to reach the local tissue distal to an obstruction via
collaterals. Determination of the optimal MTT (Tmax) threshold may predict impending
disabling stroke in patients with TIA/minor stroke (NIHSS <4).

8.3.4 Voxel based classification
An inherent limitation of the studies described in this thesis is the region of interest
analysis that was used to derive the hemodynamic thresholds. The thresholds derived
from this method depend on the mean value of the regions; therefore, the true thresholds
for infarction and BBB permeability may be different than those identified in this study.
To more accurately determine the thresholds, independent of the mean regional values,
voxel or pixel based thresholds can be applied. These thresholds could be derived in a
similar manner to the region of interest thresholds by obtaining hemodynamic values
from all voxels within the ischemic region. Voxels could then be classified, based on
delayed imaging.

8.3.5 Comparing AIS therapeutics
Using the RLCEM developed in this thesis, anti-thrombotic therapeutics in the AIS
setting can be compared. One treatment regimen, Clopidogrel monotherapy, has been
shown to reduce recurrent stroke, but may not improve the functional severity post stroke
onset, and has a propensity to cause intracranial bleeding10. This secondary stroke
preventative agent is typically given as an alternative to Aspirin or Dipyridamole11, 12.
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Using a similar methodology as described in chapter 7, investigation and comparison of
the effect of pre-morbid administration of anti-thrombotic drugs, which have anti-platelet
and pleiotropic properties, in the setting of embolic ischemic stroke are possible.

8.3.6 18F-Flumazenil imaging in porcine AIS model
To determine the volume of acute infarct core the use of the 18F-flumazenil tracer, a
central benzodiazepine receptor antagonist, could be utilized in the porcine model of AIS
developed in this thesis13. Using a similar methodology as described in chapter 4, a
comparison of infarction volume, as defined by contemporaneous CTP imaging, MRDWI and PET imaging, is possible. Moreover, an attempt to determine hemodynamic
thresholds for penumbral tissue using the CTP-CBF/Tmax mismatch, while comparing
the predicted infarct core to final infarct volume, defined using TTC histology can be
achieved. Moreover, infarct core and penumbra volumes derived from CTP imaging
could be compared with MR-perfusion weighted imaging as well as MR-arterial spin
labeling sequences.
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8.4 CONCLUSION
In summary, the significant findings in this thesis include:

1. As shown in the clinical studies and study with a novel porcine model of ischemic
stroke, very low CBV is indicative of infarct core, while acute and sub-acute
hypervolemia may be nutritive or non-nutritive. Moreover, the CBF parameter
was optimal for prediction of infarct volume.

2. Blood brain barrier integrity within the first few hours of stroke onset can be
measured with the CTP-PS parameter. PS values can predict radiological and
clinical outcome in the primary and secondary ICH stroke sub-types.

3. Pre-morbid administration of dipyridamole, a common secondary preventative
drug, may extend the tPA treatment window and reduce stroke severity.
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Appendix D
Method to determine the optimal CT perfusion hemodynamic thresholds
for gray and white matter in the setting of acute stroke

Patients and Imaging
Twenty-one patients, from the analysis in Chapter 5, had CTA confirmed full
recanalization at 24 hours, confirmed with the modified TIMI score1. All imaging was as
described in Chapter 5. Briefly, the CTP study scanned eight 5 mm thick sections of the
brain in 2 phases together with contrast injection via an antecubital vein at a rate of 2-4
ml/s. The first phase was a 45-second continuous (cine) acquisition reconstructed at 0.5second intervals to produce a series of 89 sequential images for each section. The second
phase followed 15 seconds after the completion of the first phase and scanned the same
eight sections at 15-second intervals for an additional 90 seconds. CBF, CBV, Tmax, a
special ‘Time-density curve (TDC) truncation’ functional maps and a perfusion-weighted
map were calculated from the acquired 2-phase contrast enhanced dynamic images as
described previously2.

Image Analysis
CTP functional maps of CBF, CBV, Tmax, and perfusion weighted images (PWI) were
calculated with CT Perfusion 4D, delay insensitive software (GE Healthcare), as
described in Chapter 1. Using custom software (IDL v6.2, RSI Inc.), follow-up images
from 5-7 day post stroke were registered to baseline images to adjust for movement
between the scans. The PWIs of the CTP studies were used to segment gray and white
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matter based on Hounsfield Unit thresholds. The resulting gray and white matter masks
were applied to the admission CBF and CBV maps to obtain average gray and white
matter values for infarcted tissue - pixels with CBF > 100 ml∙(100g)-1∙min-1 or CBV > 8
ml∙(100g)-1 were excluded and not used in calculating average CBF and CBV values for
regions of interest (ROI) to remove contributions from large vessels. Final infarction was
outlined on the registered 5-7 day follow-up imaging. These infarct ROIs were
superimposed onto the admission CTP functional maps. The critically hypoperfused tissue
(relative Tmax > 2), if present, was outlined on the admission Tmax map, and the
gray/white matter mask was applied3. The area outside of the infarct ROI and within the
area of critical hypoperfusion was operationally defined as penumbra. Logistic regression
analysis was performed using all data points. Gray and white matter CBF, CBV, and an
interaction term CBF·CBV were included as potential predictors in the regression model.
Sensitivity and specificity for infarction were calculated from the resulting regression
model.

Statistical Analysis
Logistic regression analysis was performed on functional data of all infarct and
penumbra. Gray and white matter CBF, CBV, and an interaction term CBF·CBV were
included as potential predictors of infarct vs penumbra in the regression model.
Sensitivity and specificity for infarction were calculated from the resulting regression
model. All statistical analyses were performed using SPSS 13 for Windows (SPSS for
Windows, SPSS Inc.).
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Results
Gray matter thresholds
Average CBF and CBV gray matter tissue that was infarcted on the 5-7 day NCCT was
5.60 ± 2.63 ml∙(100g)-1∙min-1 and 1.68 ± 0.82 ml∙(100g)-1, respectively. Average CBF and
CBV values for ischemic regions on the admission CTP that were not infarcted on the 5-7
day NCCT (Penumbra) were 20.10 ± 4.41 ml∙(100g)-1∙min-1, and 1.68 ± 0.82 ml∙(100g)-1.
Contralateral CBF and CBV values were 29.64 ± 9.53 ml∙(100g)-1∙min-1 and 2.75 ± 0.63
ml∙(100g)-1. Univariate logistic regression using admission CBF, CBV or CBF*CBV as
predictor was performed. Optimal gray matter CBF, CBV and CBF•CBV product
thresholds to separate penumbra from infarct were 10.1 ml·min-1·(100g)-1, 1.9 ml·(100g)1

, and 26.0, respectively. The regression model using the CBF parameter resulted in the

highest sensitivity (95.2%, 20/21) and specificity (95.2%, 20/21) for infarction, with an
overall accuracy of (95.2%, 40/42) of tissue types classified correctly (Figure A1).

White matter thresholds
Average CBF and CBV gray matter tissue that was infarcted on the 5-7 day NCCT was
5.86 ± 1.32 ml∙(100g)-1∙min-1 and 1.04 ± 0.61 ml∙(100g)-1, respectively. Average CBF and
CBV values for ischemic regions on the admission CTP that were not infarcted on the 5-7
day NCCT (Penumbra) were 12.27 ± 3.26 ml∙(100g)-1∙min-1, and 1.70 ± 0.61 ml∙(100g)-1.
Contralateral CBF and CBV values were 21.18 ± 6.89 ml∙(100g)-1∙min-1 and 1.33 ± 0.50
ml∙(100g)-1. Univariate logistic regression using admission CBF, CBV or CBF*CBV as
predictor was performed. Optimal white matter CTP-CBF, CBV and CBF•CBV product
thresholds to separate penumbra from infarct were 7.4 ml·min-1·(100g)-1, 1.25 ml·(100g)-
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, and 9.9, respectively. The regression model using the CBF•CBV product resulted in the

highest sensitivity (93.8%, 15/16) and specificity (87.5%, 14/16) for infarction, with an
overall accuracy of (90.6%, 29/32) of tissue types classified correctly (Figure A1).

Figure A1 Thresholds for infarction for gray matter CBF, CBV and CBF·CBV

Gray matter values for all Infarct (n=21) and Penumbra (n=21) regions of interest with the
solid line representing the optimal threshold to separate infarct from penumbra, the upper
and lower dashed lines represent the 5% and 95% probability for infarction, derived from
univariate logistic regression with A) CBF, B) CBV, and C) CBF·CBV product as
predictor. CBF provided the best classification of penumbra and infarct regions with a
sensitivity of 95.2%, (20/21) regions), and specificity of 95.2%, (20/21 regions), and
overall accuracy of 95.2% (40/42).
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Figure A2 Thresholds for infarction for white matter CBF, CBV and CBF·CBV

White matter values for all Infarct (n=16) and Penumbra (n=16) regions of interest with
the solid line representing the optimal threshold to separate infarct from penumbra, the
upper and lower dashed lines represent the 5% and 95% probability for infarction, derived
from univariate logistic regression with A) CBF, B) CBV, and C) CBF·CBV product as
predictor. The CBF·CBV parameter provided the best classification of penumbra and
infarct regions with a sensitivity of 93.7%, (15/16 regions), specificity of 87.5%, (14/16
regions), and overall accuracy of 90.6% (29/32 regions).

244
1.

Tan IY, Demchuk AM, Hopyan J, Zhang L, Gladstone D, Wong K, et al. Ct
angiography clot burden score and collateral score: Correlation with clinical and
radiologic outcomes in acute middle cerebral artery infarct. AJNR. American
journal of neuroradiology. 2009;30:525-531

2.

d'Esterre CD, Aviv RI, Lee TY. The evolution of the cerebral blood volume
abnormality in patients with ischemic stroke: A ct perfusion study. Acta
radiologica. 2012;53:461-467

3.

Bivard A, Spratt N, Levi C, Parsons M. Perfusion computer tomography: Imaging
and clinical validation in acute ischaemic stroke. Brain : a journal of neurology.
2011;134:3408-3416

245

Appendix E – Human Ethics Approval Form

246

Appendix F
Tracer Kinetic Modeling

The Johnson and Wilson model used in this study is a refinement to compartmental
models which have previously been used to measure PS in the context of tumors1,2.
Because contrast agents are not metabolized in tissue and excluded from cell entry, the
modeling of contrast agent distribution calls for only two compartments, the plasma and
interstitial space, with bidirectional exchange via passive diffusion between the
compartments. Groothuis et al. were the first to apply compartmental models in CT
scanning to measure this parameter3,4. Compartmental models can only measure PS and
CBV, not CBF, because when PS is much smaller than CBF, contrast distribution in the
brain is only determined by diffusion. The Patlak approach simplifies the compartmental
model by assuming the absence of contrast agent backflux from the interstitial to the
intravascular space4,5. Under the Patlak assumption, the normalized tissue concentration is
linearly related to the normalized integral of the artery input function with the slope and
intercept of the linear regression equal to PS and CBV5. Notably, the Johnson and
Wilson model used in this study does not require us to invoke the Patlak assumption,
which is likely not valid for contrast agent behavior in the brain with a ‘leaky’ BBB.
Unlike compartmental models, it also allows CBF to be estimated together with CBV and
PS. Kinetics of contrast distribution in the brain using the Johnson and Wilson model
applies to the entire brain independent of whether the blood-brain barrier is intact.
The model divides the brain into two principal spaces: the intravascular space
(IVS) and the extra-vascular space (EVS), separated by a capillary endothelium of
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variable permeability and therefore applies to both leaky and non-leaky blood-brain
barrier. Three basic assumptions concerning contrast kinetics in the brain were made in
the model6. First, the permeable capillary endothelium allows bidirectional diffusion of
contrast between EVS and IVS. Second, there is an axial contrast concentration gradient
in the capillaries but the radial concentration gradient is assumed to be negligible. Third,
within the EVS, the tracer concentration is assumed to have a homogeneous spatial
distribution. St Lawrence and Lee had derived the adiabatic approximation solution which
simplifies the calculation of parametric maps with the Johnson and Wilson model7. The
adiabatic approximation assumes that the EVS contrast concentration is changing slowly
(i.e. in a quasi-steady state) relative to the rate of change of concentration in the IVS
(capillaries). Under this approximation, the impulse residue function, H(t), can be
represented simply as:
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[1]

where Tc is the capillary mean transit time (MTT) and F is cerebral blood flow (CBF), so
that cerebral blood volume (CBV) is F·Tc according to the Central Volume Principle8. E
is the contrast extraction fraction and Ve is the EVS contrast distribution volume. E
relates to the PS of brain capillaries (blood-brain barrier) via the following relationship:
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 F 

[2]

If Ca(t) is the arterial input function to the brain, then the measured brain tissue curve, Q
(t), can be calculated as the convolution of Ca(t) and H(t):
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Qt   F  C a t   H t  To 

[3]

where * is the convolution operator and To is the appearance time of brain contrast
relative to that in the input artery. The validity of Equation 3 assumes that brain blood
flow is constant and Q (t) is linear with respect to Ca(t). With Q(t) and Ca(t) measured in
a CT Perfusion study, CT Perfusion 4 (GE Healthcare) estimates the parameters: CBF,
CBV, MTT, PS and To by iteratively changing their values until an optimum fit to Q(t) is
achieved via Equations 1-3.
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